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All day, the same our postures were,
And wee said nothing, all the day.
But O alas, so long, so farre
Our bodies why do wee forbeare?
This Extasie doth unperplex
(We said) and tell us what we love.
Loves mysteries in soules doe grow,
But yet the body is his booke.
John Donne
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The administration to normal men of supraphysiological doses of testosterone causes a
profound inhibition of spermatogenesis and is currently being investigated as a method
of male contraception. Azoospermia, however, is achieved in only 50-70% of men, the
remaindermaintaining a very low rate of spermatogenesis. The object of these studies
was to investigate the biochemical basis for the maintenance of spermatogenesis in the
oligozoospermic group, and in particular to investigate the hypothesis that the activity
of the enzyme 5a-reductase, which converts testosterone to the more potent androgen
dihydrotestosterone (DHT), is increased in these men either constitutionally or as a
result of treatment
Thirty-three normal men were recruited to a clinical trial of hormonal male
contraception. After a baseline period, subjects were administered 200 mg testosterone
oenanthate i.m. weekly. Semen samples were analysed at 4 weekly intervals. When
the sperm density had fallen below 5 million/ml in 3 consecutive samples, the subjects
were required to discontinue all other forms of contraception for one year, during
which the weekly injections of testosterone were continued. 18 of the subjects became
azoospermic within 20 weeks of testosterone treatment, the other 15 remained severely
oligozoospermic with a mean sperm density of 2.0 ± 0.8 million/ml at that time.
Multiple blood sampling over the week following the first injection and after 16
weeks of testosterone treatment demonstrated that there were no differences in plasma
concentrations of total or bioavailable testosterone or of oestradiol between those men
becoming azoospermic and those remaining oligozoospermic. Similarly, the rate and
degree of suppression of gonadotrophin secretion was similar in the two groups.
Measurement of the metabolic clearance rate (MCR) of testosterone and of the
conversion rate (CR) of testosterone to DHT by infusion of radiolabeled testosterone
showed that MCR was similar in the two groups at baseline, and was increased in both
after 16 weeks of testosterone treatment. CR was also similar in the two groups at
baseline, but increased after 16 weeks of treatment in the oligozoospermic group only.
The concentrations of DHT and androstanediol glucuronide (AdiolG), products
of 5a-reduction of testosterone, were measured in blood plasma and seminal plasma.
After 16 weeks of testosterone treatment, blood plasma concentrations of both steroids
were increased, but the increase was greater in the oligozoospermic group. In seminal
plasma, there was an increase in testosterone and AdiolG in both groups. However,
the concentration of DHT was only increased in the oligozoospermic group. The
urinary excretion of steroid metabolites was measured to investigate the effect of
testosterone treatment on hepatic 5aR activity. There was no consistent effect on the
ratio of 5a/5p-reductase metabolites of either C19 or C21 steroids. These results
suggest that testosterone treatment causes an increase in peripheral but not hepatic 5aR
activity in those men who remain oligozoospermic, but not in those who become
azoospermic.
The concentration in plasma of the testicular steroid 170H-progesterone was
reduced by 50% in both groups. In contrast, the plasma concentration of
dehydroepiandrosterone sulphate, an adrenal steroid, was reduced in the azoospermic
group only. The urinary metabolites of these steroids showed parallel changes. These
results suggest that there may be an interaction between testicular and adrenal
steroidogenesis, and that adrenal steroids may be a source of androgen precursor when
testicular steroidogenesis is reduced.
The sebum excretion rate (SER) was investigated as a measure of end-organ
response to androgen. Testosterone treatment resulted in an increase in SER of both
forehead and back, but there were no differences between the two groups.
An increase in 5aR activity is suggested to be the basis for the maintenance of
spermatogenesis in those men who remain oligozoospermic on supraphysiological
doses of testosterone, and this suggests new approaches for the development of
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The importance of the testes in normal male development and fertility was known to
Aristotle. Confirmation that the testes are the source of a male factor was provided by
the experiments of Berthold, who in 1849 showed that castration of a cockerel was
followed by regression of the comb, and that this could be prevented by the
transplantation of the testis to a new site. The administration of testicular extracts to
men achieved prominence following the experiments of Brown-Sdquard in the last
century. In his publication of 1889, he described the effect of injection into himself of
an aqueous extract of dog and guinea-pig testis. At that time he was aged 72, and
reported that the injection gave enhanced strength, heightened intellectual capacity and
increased sexual potency, and took 30 years off his age. This dramatic description led
to an explosion of "organotherapy", and although this method of treatment became
synonymous with quackery, the scientific stimulus arising from Brown-Sdquard's
description resulted in the birth of modern endocrinology (Wilson, 1990).
Testosterone was purified in 1931 (Butenandt, 1931), and synthesised chemically
shortly thereafter. The studies in this Thesis concern the administration of testosterone
to normal adult men as a hormonal method of contraception, and in this Chapter
testicular function and its control are described.
1.1 Testicular steroidogenesis.
1.1.1 The pathways.
It has long been recognised that the principle intratesticular androgen is testosterone,
present in the testis in a concentration approximately 100 fold greater than in peripheral
plasma, and that steroidogenesis in the testis is largely localised to the Leydig cell
(Eik-Nes, 1970). Leydig cells differentiate and start to secrete androgens in the seventh
week of intrauterine life, which correlates with the onset of androgen-dependent sexual
differentiation (Bloch, 1964; Siiteri and Wilson, 1974). The plasma level of
testosterone in the male foetus approaches that of the adult at 12-16 weeks gestation,
with a subsequent fall as the Leydig cells involute until puberty (Tapainen,
Kellokompu-Lehtinen, Pelliniemi and Huhtaniemi, 1981). This is not dependent on
the secretion of gonadotrophins from the foetal pituitary, as it occurs in anencephalic
foetuses: however it may be dependent on chorionic gonadotrophin (CG), as CG levels
in foetal plasma correlate in time with Leydig cell development and foetal plasma
testosterone concentration (Clements, Reyes, Winter, and Faiman, 1976).
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Much of the early information regarding the presence of steroid pathways in the
testis was obtained from experiments in which testicular tissue (often not fractionated)
was incubated with radioactive substrates. From the relative rates of production of
steroid products, inferences were made as to the presence of those pathways. As the
rate of enzyme activity will be dependent on the presence of cofactors, the pH of the
medium etc, the quantification of the contributions of various pathways is difficult
using such techniques. Quantification requires the determination of the size of the
endogenous pools of the intermediates, and this has become possible with the
refinement of radioimmunoassay and mass spectrometric techniques, and, more
recently, the advent of techniques ofmolecular biology has allowed the sequencing and
detailed characterisation of some of the enzymes involved.
The testes are able to convert acetate to cholesterol, and most cholesterol is believed
to be synthesised de novo in the Leydig cells (Morris and Chaikoff, 1959). This step
takes place on the inner mitochondrial membrane rather than in the endoplasmic
reticulum, which is the site in most other tissues (Pignatoro, Radicella, Calvo and
Charreau, 1983). Subsequent conversion to pregnenolone by side-chain cleavage is the
most important step in the pathway (vide infra), and also takes place within the
mitochondria (Toren, Menon, Forchielli and Dorfman, 1964; van der Vusse, Kalkman,
and van der Molen, 1973). This and subsequent steps are catalysed by members of the
cytochrome P-450 superfamily. Pregnenolone can then be further converted by either
the A5 or A4 pathways in the endoplasmic reticulum. In man, the A5 pathway is
considered to be more important (Yanaihara and Troen, 1972; Weusten, Smals,
Hofman, Kloppenborg and Benraad, 1987), in contrast to the rat, in which the A4
pathway appears to be of greater importance (Samuels, Bussman, Matsumoto and
Huseby, 1975). The intermediates in the A5 pathway are 17a-hydroxypregnenolone
(170H-pregnenolone), dehydroepiandrosterone (DHA), and androstenediol. The
A4 intermediates are progesterone, 17a-hydroxyprogesterone (170H-progesterone),
and androstenedione. These pathways, with the enzymes responsible, are shown in
Figure 1.1.
It has been found that pregnenolone and progesterone are converted to DHA and
androstenedione respectively by the action of a single enzyme, 17a-hydroxylase/
Cl7,20"lyase (Nakajin, Shively, Yuan and Hall, 1981), although 170H-pregnenolone
and 170H-progesterone appear to be distinct intermediates. There is a single copy of
the gene for this enzyme on chromosome 10 in both testis and adrenal (Matteson,
Picardo-Leonard, Chung, Mohandas and Miller, 1986). It therefore appears that the
two catalytic functions can be separately regulated, with 17oc-hydroxylation being
preponderant in the adrenal, resulting in the production of Cortisol, a 17-hydroxylated
Figure 1.1
Steroidogenic pathway from cholesterol to testosterone, showing
further conversion to DHT, 17-ketosteroids and oestrogens.
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C21 steroid, while in the testis both activities are present, resulting in the synthesis of
testosterone.
The final step in the synthesis of testosterone is mediated by the enzyme
17(3-hydroxysteroid dehydrogenase, which reversibly converts androstenedione to
testosterone (Rivarola, Podesta, Chemes and Aguilar, 1973). This enzyme also
converts DHA to androstenediol and oestrone to oestradiol.
The further metabolism of testosterone to dihydrotestosterone (DHT) is catalysed
by the enzyme 5a-reductase (5ocR), and DHT can be converted to the androstanediols
by 3a-hydroxysteroid dehydrogenase (Dorrington and Fritz, 1975). The activity of
5aR in the testis is discussed further in Section 1.6.3. Testosterone can also be
converted to oestradiol by the enzyme aromatase, the activity of which is high in the
Sertoli cells of immature rats but decreases thereafter (Dorrington and Armstrong,
1975). The intratesticular functions of these potentially active steroid metabolites of
testosterone are unknown.
1.1.2 Regulation.
The importance of the pituitary in the control of testicular steroidogenesis was
demonstrated by the finding that hypophysectomy is followed by regression of the
testes and a decrease in testosterone synthesis (Smith, 1927; Woods and Simpson,
1961). This can be prevented by the administration of luteinizing hormone (LH) or
CG, and the synthesis of testosterone from Leydig cells in vitro can be stimulated by
LH (Hall, 1966; Janszen, Cooke, van Driel and van der Molen 1976). It is now
recognised that pituitary secretion of LH is the most important hormonal regulator of
testicular steroidogenesis.
Incubation of slices of rabbit testis with LH causes a stimulation of the conversion
of cholesterol to testosterone, but not of pregnenolone to testosterone (Hall, 1966).
The enzyme which cleaves the side chain of cholesterol is a cytochrome P-450 known
as P450scc> located on the inner mitochondrial membrane (Moyle, Jungas and Greep,
1973). This site contains only small amounts of cholesterol: the supply of cholesterol
may therefore be the rate-limiting step, and the site of control. This hypothesis is
supported by experiments in which mitochondria were isolated from Leydig cells and
incubated with LH, and the rate of pregnenolone synthesis determined (Hall, 1983).
LH had no effect under these circumstances, demonstrating that LH has no effect on
isolated mitochondria. In contrast, when Leydig cells are incubated with
aminoglutethimide, an inhibitor of P450scc> LH causes an increase in the amount of
cholesterol found in the inner mitochondrial membrane, and mitochondria isolated from
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treated cells and washed to remove the aminoglutethimide show an increased capacity to
produce pregnenolone. A labile "steroidogenesis activator peptide" has been described,
which promotes the passage of cholesterol from the outer to the inner mitochondrial
membrane (Mertz and Pederson, 1989).
The effect of LH is mediated by binding to specific receptors on the surface of
Leydig cells (Davies, Dufau and Catt, 1978; Loosfelt, Misrahi, Atger, Saless, Thi,
Jolivet, Guiochon-Mantel, Sar, Jallal, Gamier and Milgrom, 1989). The binding of
LH causes an increase in intracellular cyclic adenosine monophosphate (cAMP), by
activation of the enzyme adenylate cyclase via a guanyl nucleotide regulatory subunit
(Abramowitz, Iyengar and Bimbaumer, 1979). In turn, cAMP activates protein kinase,
although other intracellular transducing systems may also be involved, such as
lipoxygenase resulting in the formation of leukotrienes, and direct activation of
adenylate cyclase by calmodulin and protein kinase C (Hall, 1988; Cooke, 1990).
The immediate response to LH stimulation is mobilisation of cholesterol stores, as
described above, with increased supply of cholesterol to the inner mitochondrial
membrane as a substrate for P450scC- This results in increased production of
pregnenolone. With more prolonged stimulation, LH enhances transcription of genes
encoding steroidogenic enzymes, giving rise to de novo synthesis of enzyme
(Waterman and Simpson, 1989). If LH stimulation is more prolonged, an adaptive
v
response is seen, in which there is loss of LH receptors, a reduced effect on cAMP,
and also interference with steroidogenesis itself (Saez, Haour and Cathiard, 1978;
Dufau, 1988). While the pulsatile nature of LH secretion may result in this effect being
of little physiological importance (vide infra, Section 1.4), it may alternatively be
involved in the feedback of testosterone on LH secretion, and enhance LH pulsatility.
Leydig cells also have receptors for prolactin, which potentiates the response to LH
(Hafiez, Bartke and Lloyd, 1972; Aragona and Friesen, 1975). Gonadotrophin
releasing hormone (GnRH) has also been reported to have direct effects on the testis
(Hsueh and Erikson, 1979), and thus the precise regulation of Leydig cell function and
testicular steroidogenesis may be controlled by the interaction of several hormones.
The intratesticular control of steroidogenesis is largely unexplored in humans, although
the condition of "testicular toxicosis", in which there is precocious puberty associated
with adult plasma levels of testosterone in the absence of gonadotrophin secretion
(Rosenthal, Grumbach, and Kaplan, 1983), may demonstrate the potential importance
of local control. There are reports of stimulatory substances secreted by human
seminiferous tubules in vitro (Verhoeven and Cailleau, 1987). Indeed, many
substances have been proposed to be paracrine factors within the testis, but evidence as
to a physiological role for any of these factors is lacking (Sharpe, 1990). One such
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possible substance is oxytocin: this is present in the testis (Nicholson, Swann,
Burford, Wathes, Porter and Pickering, 1984), and may have a role in the paracrine
regulation of steroidogenesis (Adashi, Tucker and Hseuh, 1984) or of seminiferous
tubule contractility (Worley, Nicholson and Pickering, 1985).
1.2 Spermatogenesis.
1.2.1 The Sertoli cell.
Primordial germ cells migrate from the endoderm of the yolk sac to the genital ridges at
5 to 6 weeks post conception (Witschi, 1951). Sertoli cell precursors then surround the
germ cells, forming the sex cords (Jost, Magre, Cressant and Perlman, 1974) and thus
the beginnings of the seminiferous tubules of the differentiated testis. This process is
controlled by a product of the putative testis-determining "TDF' gene, located on the
short arm of the Y chromosome. The product of this gene was held to be the male-
specific histocompatibility antigen H-Y, until male mice were found which lack this
antigen (McLaren, Simpson, Tomanari, Chandler and Hogg, 1984). An alternative
candidate is a recently-cloned gene termed SRY (Sinclair, Berta, Palmer, Hawkins,
Griffiths, Smith, Foster, Frischauf, Lovell-Badge and Goodfellow, 1990). This
process clearly predate the development of Leydig cells and the onset of androgen
synthesis (vide supra, Section 1.1.1).
The Sertoli cells are thus in a position to have full influence over the germ cells, and
they further influence embryological development by the secretion of the peptide
Miillerian inhibitory hormone (Josso, Picard and Tran, 1977; Cate, Mattaliano,
Hession, Tizard, Farber, Cheung, Ninfa, Frey, Gash, Chow, Fisher, Bertoni, Torres,
Wallner, Ramuchandra, Ragin, Manzanaro, MacLaughlin and Donahoe, 1986) which
suppresses the development of the Miillerian system, the precursor of the female
internal genitalia. A further indicator of the influence of Sertoli cells is the development
of tight intercellular junctions between adjacent Sertoli cells, which develops at puberty
(Nicander, 1967; Dym and Fawcett, 1970). This blood-testis barrier limits the passage
of ions as well as larger molecules, and results in the effective production of two
compartments: the basal compartment adjacent to the basal membrane containing the
spermatogonia, and the adluminal compartment, the location of the spermatocytes and
spermatids. The fluid of the seminiferous tubule has a high concentration of potassium
and bicarbonate, with low concentrations of sodium and chloride: it thus resembles
intracellular rather than extracellular fluid (Waites and Gladwell, 1982). The
importance of this ionic environment in the development of spermatozoa is unknown.
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The nature of the tight junctions is such that all nutrients and hormonal signals
reaching the adluminal germ cells have to pass through the cytoplasm of the Sertoli
cells. This also provides an immunological barrier. The nature of the substances
regulating this passage is largely unknown, although a number of secretory products of
the Sertoli cell have been identified, including androgen binding protein (APB),
inhibin, transferrin and the protease inhibitor plasminogen activator which appear to be
controlled by FSH (vide infra, Section 1.3.2; Syed, Karpe, Ploen and Ritzdn, 1986;
Lacroix, Smith and Fritz, 1977).
1.2.2 Organisation.
After the high activity of foetal life, the testis is quiescent during childhood. An
increase in testicular volume is the first clinical sign of puberty (Marshall and Tanner,
1970), and reflects the increasing mass of the seminiferous tubules. This can be
detected biochemically by measuring the increasing nocturnal pulsatile secretion of LH
and an overnight rise in plasma testosterone level (Boyar, Finkelstein, Roffwarg,
Kapen, Weitzman and Hellman, 1972; Wu, Butler, Kelnar, Stirling and Huhtaniemi,
1991).
Unlike the situation in the female, male germ cells do not enter meiosis until puberty
and the initiation of spermatogenesis. At that stage, the spermatogonia enter a series of
mitotic divisions to form primary spermatocytes, which then enter meiosis to produce
haploid secondary spermatocytes and, after a second division, spermatids. The
anatomical organisation of this sequence was described by Clermont (1963), who
found that activity in the human seminiferous epithelium could be divided into 6 stages,
each containing a specific constellation of cell types at particular stages ofmaturation.
In cross-section, there are usually several stages visible in each tubule, in an apparently
irregular fashion, but reinvestigation of the topographic arrangement by Schulze (1982)
has demonstrated that the stages are arranged in a helical pattern. This contrasts with
the organisation in many other species, eg the rat and most primates, in which the
stages are arranged radially in a longitudinal sequence.
Spermatids undergo the differentiation process of spermiogenesis to become
spermatozoa. This involves formation and maturation of the acrosome cap,
condensation of the nuclear chromatin and reshaping of the nucleus with loss of
residual cytoplasm, and development of the spermatid midpiece containing the
mitochondria and tail containing an axial filament complex (the axoneme) flanked by
nine pairs of microtubules (Clermont, 1963; de Kretser, 1969). The spermatozoa are
then released from the Sertoli cell into the lumen of the tubule (the process of
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spermiation), whence they pass through the rete testis to the epididymis and so to the
vas deferens. The process of spermatogenesis is estimated to take 74 days in man
(Heller and Clermont, 1964).
1.3 The hormonal control of spermatogenesis.
The involvement of the pituitary gland in the control of spermatogenesis was first
described by Smith (1927). Using the classic endocrine technique of gland removal
followed by replacement of the postulated active substances, he demonstrated the
importance of pituitary factors in the stimulation of testicular growth and
spermatogenesis in the rat by observing the effect of hypophysectomy and subsequent
administration of pituitary extracts. It was subsequently recognised that two pituitary
hormones are involved, with separate effects on the Leydig cells and on
spermatogenesis (Greep, Fevold and Hishaw, 1936). This finding provides the basis
for current understanding of the dual control of the endocrine and spermatogenic
functions of the testes, by the glycoproteins LH and follicle-stimulating hormone
(FSH) respectively. The control of testicular steroidogenesis has been discussed
above, and in this section experimental findings relating to the hormonal control of
spermatogenesis are reviewed.
1.3.1 The influence of testosterone.
The precise relative contributions of LH-controlled androgens and of FSH in the
control of the onset and maintenance of spermatogenesis remain the subject of debate.
After hypophysectomy in rats, elongated spermatids are progressively lost, followed by
a reduction in round spermatids and spermatocytes (Bocabella, 1963; Clermont and
Morgantheler, 1955), but this could be prevented (in qualitative terms) by the
administration of testosterone at or soon after surgery (Walsh, Cuyler and McCullagh,
1934; Steinberger, 1971; Ahmad, Haltmeyer and Eik-Nes, 1975). This effect was also
apparent following the administration of other steroids, including DHT and
androstenediol (Ahmad et al., 1975; Chowdhury and Steinberger, 1975; Dube, Pelletier
and Labrie, 1988), as well as other precursors of testosterone (Harris and Bartke,
1975). LH itself, or CG, maintained spermatogenesis (Clermont and Harvey, 1965;
Russell and Clermont, 1977; Vernon, Go and Fritz, 1975), but the interpretation of
these experiments is difficult because of the presence of FSH-like activity in the
preparations used. The use of the Leydig cell toxin dimethanesulphonate (EDS) to
completely destroy Leydig cells has allowed the demonstration that testosterone alone,
if given in sufficient dose to maintain intratesticular testosterone concentrations, will
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maintain spermatogenesis quantitatively without loss of fertility (Sharpe, Fraser and
Ratnasooriya, 1988).
In man, the administration of testosterone in sufficient dose to inhibit
gonadotrophin secretion causes profound inhibition of spermatogenesis, but a low rate
of spermatogenesis was maintained in some subjects (Swerdloff, Campfield, Palacios
and McClure, 1979; Nieschlag, Behre and Weinbauer, 1989; vide infra, Section 1.7).
This partial maintenance of spermatogenesis was also found when a progestogen was
used to inhibit gonadotrophin secretion, combined with replacement doses of
testosterone (Wu and Aitken, 1989).
Similar results have been obtained using gonadotrophin-releasing hormone (GnRH)
analogues to inhibit the secretion of LH and FSH. Treatment with a GnRH antagonist
inhibited spermatogenesis in rats (Rivier, Rivier and Vale, 1980). The simultaneous
administration of testosterone, however, was reported to maintain spermatogenesis
quantitatively (Rea, Marshall, Weinbauer and Nieschlag, 1986), but under those
conditions, the administration of testosterone was found to stimulate FSH secretion
(Rea et al.,1986; Bhasin Fielder and Swerdloff, 1988), thus making interpretation
difficult. Others have used the anti-androgen flutamide in combination with a GnRH
antagonist (Chandolia, Weinbauer, Fingscheidt, Bartlett and Nieschlag, 1991). These
studies demonstrated that flutamide accelerated testicular involution, and reduced the
stimulatory effect of subsequent administration of FSH on spermatogenesis.
The administration of gonadotrophins (either as partially "purified" FSH or as
human menopausal gonadotrophin) was shown to partially restore spermatogenesis in
men following hypophysectomy (Genzell and Kjessler, 1964; MacLeod, Pazianos and
Ray, 1964), and administration of human FSH following suppression of
spermatogenesis by supraphysiological doses of testosterone caused some restoration
of spermatogenesis (Matsumoto, Karpas, Paulsen and Bremner, 1983). In a non-
human primate, daily injection of a GnRH antagonist caused azoospermia, but the
addition of androgen replacement (using the long-acting androgen 20-Aet-l) at
physiological or supraphysiological doses caused progressive restoration of
spermatogenesis (Weinbauer, Gockeler and Nieschlag, 1988). Others have shown
more reproducible azoospermia using a GnRH antagonist with testosterone replacement
(Bremner, Bagatell and Steiner, 1991). The difference may lie in the use of mini-
pumps to administer more constant and effective levels of the antagonist in the latter
study, so the influence of the replacement androgen is inconclusive.
In addition to studies using GnRH antagonists, the effect of administration of the
GnRH agonist buserelin (as a subcutaneous implant) during treatment with the
androgen 19-nortestosterone hexyloxyphenylpropionate has recently been studied in
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man (Behre, Nashan, Hubert and Nieschlag, 1992). Those authors found that
treatment with the GnRH agonist partially reversed the inhibition of spermatogenesis
caused by the androgen, and this was associated with a restoration of FSH secretion to
almost normal levels. LH secretion remained suppressed.
It therefore appears that, in rats, testosterone can maintain spermatogenesis in a
quantitative manner in the complete absence of gonadotrophins, and that the presence of
FSH is not essential. The crucial factor appears to be the maintenance of a sufficient
intratesticular concentration of testosterone by exogenous administration after
destruction of endogenous synthesis, which is not possible in human experiments.
However, the results of both human and animal experiments suggest that the presence
of FSH in some way "facilitates" the effect of testosterone, supporting spermatogenesis
at lower testosterone concentrations. Many aspects of the mechanisms of initiation and
control of spermatogenesis by testosterone and FSH remain unexplored.
1.3.2 The effects of FSH.
The intratesticular injection of FSH was found to specifically stimulate Sertoli cells
(Murphy, 1965), and receptors for FSH are found on Sertoli cells (but not on germ
cells) (Castro, Alonso and Mancini, 1972). The mechanism of action of FSH is
believed to be by a similar method to that of LH (and indeed to most peptide
hormones), as discussed above. This involves a guanyl nucleotide regulatory subunit,
linked to adenylate cyclase, with subsequent activation of protein kinases (Abramowitz
et al„ 1979; Jahnsen, Purvis, Birnbaumer and Hansson, 1980).
Several proteins have been identified as Sertoli cell products, most particularly
androgen binding protein (ABP) (Hagenas, Ritzdn, Ploen, Hansson, French and
Nayfeh, 1975). This substance is very similar to SHBG, differing only in the
carbohydrate moieties (Joseph, Hall and French, 1987; Reventos, Hammond, Crozat,
Brooks, Gunsalus, Bardin and Musto, 1988). ABP is secreted into tubular fluid and is
transported to the epididymis, and in rats (a species without SHBG) is also found in
plasma where it has been used as a marker of Sertoli cell activity (Gunsalus, Musto and
Bardin, 1978); this has not been possible so far in the human because of the similarities
between ABP and SHBG. The production of ABP is stimulated by both FSH and
testosterone (Hansson, Reusch, Trygstad, Torgersen, Ritzdn and French, 1973;
Rommerts, Kriiger-Sewnarain, van Woerkom-Blik, Grootegoed and van der Molen,
1978), and although a role as a tubular store and buffer of androgen appears likely, its
precise role remains obscure.
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Other proteins identified as Sertoli cell products whose production is stimulated by
FSH and which may be involved in spermatogenesis include transferrin and
plasminogen activator (Syed et al., 1986; Lacroix et al., 1977). Again, the precise role
of these and other proteins remains to be established. The secretion and function of
inhibin by Sertoli cells is discussed below (Section 1.4.2).
1.3.3 Androgen action within the testis.
It is apparent from the findings discussed above that, at least in the rat, testosterone
alone can maintain spermatogenesis after hypophysectomy if given in sufficient dose.
For this to occur, it must be given before the seminiferous epithelium has regressed.
This suggests a facilitatory interaction between testosterone and FSH within the testis,
and there is also biochemical evidence for this.
Androgen receptors are found in the testis, and have been localised to both Sertoli
and Leydig cells, peritubular cells and testicular arteriole muscle cells (Hansson,
McLean, Smith, Tindall, Weddington and Nayfeh, 1974; Mulder , Peters, de Vries and
van der Molen, 1975; Bergh and Damber, 1992). Both testosterone and FSH stimulate
ABP, acting synergistically (Hansson et al., 1973), and a similar additive effect of
testosterone and FSH has been demonstrated on the enhancement of androgen receptor
binding by both hormones (Verhoeven and Cailleau, 1988). This also provides a basis
for the results of Chandolia et al. (1991) (vide supra, Section 1.3.1).
It is not known whether germ cells are androgen target cells, but an essential role
for androgens in their development appears unlikely from the work of Lyon (Lyon,
Flenister, and Lamoreux, 1975). Those authors fused normal and androgen-insensitive
(i.e. lacking androgen receptors) Tfm mouse blastocysts, making chimaerae. Some
resulting males were fertile, and mating with normal females produced female offspring
carrying the Tfm gene. This gene is carried on the X chromosome and thus the
spermatozoon bearing it had matured despite the absence of androgen receptors. This
assumes that androgen effects are always mediated via the androgen receptor, but there
is increasing evidence that cell surface actions may be important (Rommerts, 1992)
Testosterone can be metabolised within the Sertoli cell. The activity of the
aromatase enzyme is high in the Sertoli cell of young rats and is FSH-dependent, but
declines to low levels with maturity, whereas aromatase activity in the Leydig cells
increases (Dorrington and Armstrong, 1975; Tsai-Morris, Aquilano and Dufau, 1985).
The potential importance of 5aR in the testis is discussed further in Section 1.6.3.
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1.4 The control of gonadotrophin secretion.
The gonadotropins LH and FSH are secreted by the gonadotrophes of the anterior
pituitary gland in response to stimulation by GnRH. This decapeptide is secreted into
hypophyseal portal blood from the terminals of neurones projecting from the medial
preoptic area of the hypothalamus to the median eminence (Davidson and Bloch, 1978;
Elde and Hokfelt, 1978; Silverman, Krey and Zimmerman, 1979). The pattern of both
LH and FSH secretion in the peripheral circulation is pulsatile (Santen and Bardin,
1973; Veldhuis, King, Urban, Rogol, Evans, Kolp and Johnson, 1987), and in
experimental animals pulsatile secretion of LH has been demonstrated to directly
parallel secretion of GnRH into portal blood (Levine, Pau, Ramirez, and Jackson,
1982; Clarke and Cummins, 1982), The pulsatile secretion of gonadotrophins in man
is assumed to have a similar basis, and in many studies the pulse frequency of LH
secretion is taken to reflect that ofGnRH. In investigations of the feedback control of
gonadotrophin secretion, both frequency and amplitude of this pulsatile secretion can
therefore be assessed, but interpretation is complicated by the possibility of both
hypothalamic and pituitary sites of action of regulatory hormones. The discussion here
will concentrate on human data, with evidence from animal studies included to provide
details of some effects not subject to investigation in humans because of the limitations
of clinical experimental design. In addition, as the secretion of GnRH in humans
cannot be detected in vivo, this discussion will refer only to feedback control by
testicular hormones.
1.4.1 Sex steroids.
The testes secrete DHT and oestradiol in addition to testosterone (Kelch, Jenner,
Weinstein, Kaplan and Grumbach, 1971; Baird, Galbraith, Fraser and Newsam, 1973;
Pazzagli, Borrelli, Forti, and Serio, 1974), although most of these two hormones in
peripheral plasma is derived from peripheral conversion (Longcope, Kato and Horton,
1969; Ito and Horton, 1971). Aromatisation of testosterone also occurs in nervous
tissue (Naftolin, Ryan, Davies, Reddy, Flores, Petro, Kuhn, White, Takaoki and
Wolin 1975), but DHT is not subject to this. Thus there are (at least) three
interconverting steroid hormones to be considered in the investigation of feedback
control.
The administration of testosterone or DHT inhibits gonadotrophin secretion
(Sherins and Loriaux, 1973; Santen, 1975), and several studies have reported that this
is by a reduction in pulse frequency with no effect on pulse amplitude (Winters, Janick,
Loriaux and Sherins, 1979; Santen, 1975; Matsumoto and Bremner, 1984). This was
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interpreted to imply a site of action at the hypothalamus, by reducing the frequency of
GnRH secretion. Oestradiol also caused an inhibition of gonadotrophin secretion, but
this was by a reduction in pulse amplitude with no effect on pulse frequency (Kulin and
Reiter, 1972; Sherins and Loriaux, 1973; Santen 1975; Winters et al., 1979; Gooren,
1989).
The non-steroidal anti-oestrogen clomiphene and the anti-androgen flutamide have
been used to investigate the effect of endogenous steroids. Clomiphene increased basal
LH secretion and prevented the inhibitory effect of testosterone (Winters et al., 1979;
Veldhuis and Dufau, 1987), and flutamide increased LH pulse frequency (Balzano,
Migliari, Sica, Scarpa, Pintus, Loviselli, Usai and Balestrieri, 1987; Urban, Davis,
Rogol, Johnson and Veldhuis, 1988) and the mass of bioactive LH released per pulse
(Veldhuis, Urban and Dufau, 1992), although in that study LH pulse frequency was
unaffected. Reduction of endogenous DHT concentrations by administration of the
5aR inhibitor finasteride had no effect on basal or GnRH-stimulated gonadotrophin
concentrations, although there was a slight but significant increase in plasma
testosterone concentrations (Rittmaster, Lemay, Zwicker, Capazzi, Winch, Moore and
Gormley, 1992). These studies demonstrate the importance of differentiating between
the effects of steroids in physiological and supraphysiological concentrations.
Urban, Dahl, Padmanabhan, Beitins and Veldhuis (1991) have also recently
reported that DHT or oestradiol infusion did not affect FSH pulse frequency, which
finding they interpret in terms of dissociation between LH and FSH secretion.
Similarly, earlier studies showed that pulsatile GnRH administration is required for the
stimulation of LH but not FSH secretion (Fauser, Dony, Doesberg and Rolland, 1983),
and increasing frequency of administered GnRH pulses increased LH but not FSH
secretion (Spratt, Finkelstein, Butler, Badger and Crowley, 1987; Sauder, Frager,
Case, Kelch and Marshall, 1988).
It therefore appears that androgens reduce gonadotrophin pulse frequency without
affecting amplitude, while oestrogens reduce pulse amplitude. Furthermore, it has been
concluded that the effect of androgens is mediated at the level of the hypothalamus.
Animal experiments have provided clear evidence of an inhibitory effect of androgens
on gonadotrophin secretion at the level of the pituitary. This effect is evident both in
vivo (Debeljuk, Arimura and Schally, 1972) and in vitro (Kao and Weisz, 1975;
Drouin and Labrie, 1976; Speight and Fink, 1981), although stimulatory effects have
been reported on FSH secretion in rats in vivo (Rea et al., 1986; Bhasin et al., 1988),
and at the level of FSH P mRNA (Wierman and Wang, 1990) after GnRH antagonist
treatment. The human data thus requires reinterpretation, especially in the light of
recent reports of the effects of sex steroids on gonadotrophin secretion in men with
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idiopathic hypogonadotrophic hypogonadism (IHH, Kallmann's syndrome)
(Finkelstein, Whitcomb, O'Dea, Longcope, Schoenfeld and Crowley, 1991;
Finkelstein, O'Dea, Whitcomb and Crowley, 1991). These authors used the model of
men with IHH receiving intravenous pulsatile GnRH therapy to circumvent the
possibility of hypothalamic site of action of steroids in the negative feedback control of
gonadotrophin secretion, as the GnRH pulse frequency and amplitude is controlled.
Under these conditions, testosterone markedly suppresses LH pulse amplitude,
demonstrating a direct effect on the pituitary of testosterone, or of a metabolite of
testosterone. This effect was greater in normal men, which is compatible with an
additional effect on the hypothalamus. Administration of testolactone, an aromatase
inhibitor, caused an increase in LH secretion when given alone to men with IHH, and
prevented the effect of testosterone when given in combination. The inhibitory effect of
testosterone on the pituitary is therefore largely due to aromatisation to oestradiol. This
was supported by similar experiments in which oestradiol was infused (Finkelstein et
al., 1991a): the degree of inhibition of LH and FSH secretion was similar in men with
IHH and normal men, indicating that the pituitary is the major site of action of
oestradiol in the negative feedback inhibition of gonadotrophin secretion.
In conclusion, it appears that both androgens and oestrogens are involved in the
control of gonadotrophin secretion in men, with multiple sites of action and interaction,
with a greater control of LH secretion by testosterone than of FSH. A hypothalamic
site of action appears most important for the effect of androgens, but the pituitary may
be a more important site of action of oestradiol, either from the peripheral circulation or
produced by local aromatisation of testosterone.
1.4.2 Inhibin.
Further control of FSH secretion is mediated by the peptide hormone, inhibin. The
existence of a protein hormone secreted by the testes and involved in the feedback
inhibitory control of FSH secretion was originally proposed by McCullagh (1932).
This hormone, which he termed inhibin, has now been extensively characterised,
including description of the primary amino acid sequence in the pig and cow (Mason,
Hayflick, Ling, Esch, Ueno, Ying, Guillimin, Niall and Seeberg, 1985; Forage, Ring,
Brown, Mclnerney, Cobon, Gregson, Robertson, Morgan, Hearn, Findlay,
Wettenhall, Burger and de Kretser, 1986). This established that it is composed of a
and (3 subunits, with two forms of the p subunit (PA and PB), either of which could
combine with the common a subunit. The structure of human inhibin has also been
described (Mason, Niall and Seeberg, 1986), and shows 85% homology of the a chain
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sequence with bovine and porcine inhibin, and an even greater homology of both P
chains.
Castration results in a rapid fall in plasma inhibin levels in man (Ishida, Tashiro,
Watanabe, Fujii, Yoshida, Imamura, Minowada, Shinohara, Fukutani, Aso and de
Kretser, 1990) as in the rat (Robertson, Hayward, Irby, Jacobsen, Clarke, McLachlan
and de Kretser, 1988), confirming a gonadal source. In the rat testicular inhibin levels
are reduced after hypophysectomy and restored by FSH administration but not by
testosterone (Au, Robertson and de Kretser, 1985). In a non-human primate, GnRH
antagonist treatment caused a decrease in serum inhibin levels (Weinbauer, Khurshid,
Fingscheidt and Nieschlag, 1989), which was restored by FSH administration
(Weinbauer, Behre, Fingscheidt and Nieschlag, 1991). The physiological importance
of an inhibin-like hormone is suggested by the selective elevation of FSH but not LH in
men with severe impairment of spermatogenesis (de Kretser, Burger, Fortune,
Hudson, Long, Paulsen and Taft, 1972), although decreases in plasma inhibin are not
always found (Tsatsoulis, Shalet, Morris and de Kretser, 1990). These results suggest
that inhibin may be involved in the control of FSH secretion by a classical negative
feedback loop.
Cultured monkey Sertoli cells secrete inhibin (Noguchi, Keeping, Winters, Saito,
Oshima and Troen, 1987), and are thought to be the main or only site of inhibin
secretion in the testis. Secretion of inhibin is reduced in Sertoli cell preparations from
animals after hypophysectomy, and can be restored by gonadotrophin administration
(Steinberger, 1981): it thus follows the same pattern as other Sertoli cell products. In
man, pulsatile secretion of inhibin into spermatic venous blood has been reported, and
the pulses of inhibin secretion coincided with pulses of testosterone secretion (Winters,
1990). This may imply a common mechanism of control involving LH and Leydig
cells.
Inhibin was originally characterised on the basis of its ability to inhibit FSH
secretion, in in vivo and in vitro bioassays: the secretion of both basal and GnRH
stimulated release is inhibited, as is cellular FSH content (de Jong, 1988) and there is a
rapid reduction in cellular FSH P mRNA levels (Attardi, Keeping, Winters, Kotsuji,
Maurer and Troen, 1989). These results support direct studies in which inhibin
preparations suppressed FSH secretion in vivo (Hermans, van Leeuwen, Debets and de
Jong, 1980; Lorenzen, Dworkin and Schwartz, 1981). A synergistic effect between
inhibin and testosterone on FSH secretion has been suggested based on the inhibition
of FSH secretion in response to GnRH stimulation of cultured pituitary cells (Kitahara,
Kotsuji, Keeping, Oshima, Troen and Winters, 1991). A local, paracrine role for
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inhibin has been also been proposed in the ovary, in the regulation of preovulatory
oestrogen synthesis (Hillier, 1991): a similar role in the testis awaits description.
Direct evidence for a role for inhibin in the control of FSH secretion in man is
lacking, but several animal studies support this. The administration of the Leydig cell
toxicant EDS to rats, which results in a decline in plasma testosterone concentration,
caused a rise in LH comparable to that following castration but a lesser rise in FSH
(Jackson and Morris, 1977). Cryptorchidism cause a similar rise in FSH secretion
with no change in testosterone concentration, but subsequent administration of EDS
caused a further rise in FSH secretion, to concentrations found after castration
(O'Leary, Jackson, Averill and de Kretser, 1986). These studies suggest that both
inhibin and testosterone have a role in the normal control of FSH secretion.
Serum inhibin levels rise during puberty in both boys and girls (Burger,
McLachlan, Bangah, Quigg, Findlay, Robertson, de Kretser, Warne, Werther,
Hudson, Cook, Fielder, Greco, Yong and Smith, 1988), and fall with advancing age in
men (Tenover, McLachlan, de Kretser, Burger and Bremner, 1988). Testosterone-
induced suppression of gonadotrophin secretion caused a fall of 60% in inhibin levels,
which was only partially restored by gonadotrophin treatment (McLachlan, Matsumoto,
Burger, de Kretser and Bremner, 1988). Others have reported that 19-nortestosterone
also suppressed inhibin levels in normal men, but subsequent administration of a
human FSH preparation had no effect (Jockenhovel, Fingscheidt, Khan, Behre and
Nieschlag, 1990).
Although, as mentioned above, FSH is often elevated in infertile men with damaged
seminiferous tubules, the expected decrease in inhibin concentrations is not consistently
seen in these men. Thus inhibin levels were normal or slightly elevated in men with
spontaneous or chemotherapy-induced damage to the seminiferous tubule (de Kretser,
McLachlan, Robertson and Burger, 1988; Tsatsoulis et al., 1990), and there was a
positive correlation between FSH and inhibin in the men studied following
chemotherapy. More recently, a close negative correlation has been reported between
serum concentrations of inhibin and FSH or sperm density in normal men, but these
relationships were not found in men with varicoceles, whether or not they were fertile
(Plymate, Paulsen and McLachlan, 1992).
It therefore appears that inhibin may have a role in the control of FSH secretion,
albeit subsidiary to that of testosterone, although further studies are required to define
its importance in physiological and pathological states. The existence of the (3A:pA
dimer, activin, with stimulatory effects on FSH secretion has been described (Ling,
Ying, Ueno, Esch, Denoroy, Guillimin, 1985; Vale, Rivier, Vaughan, McClintock,
Corrigan, Woo, Karr and Speiss, 1986), and a paracrine role for both these peptides
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within the testis is currently being explored. The highly vectorial secretion of inhibin
towards the lumen of the seminiferous tubule in vivo and by cultured primate Sertoli
cells (Maddocks and Sharpe, 1990; Handelsman, Spaliviero and Phippard, 1990)
suggests a negative paracrine role in the control of spermatogenesis. In contrast,
activin has been shown to have stimulatory effects on spermatogonial proliferation
in vitro (Mather, Attie, Woodruff, Rice and Phillips, 1990).
1.5 Action of Androgens.
1.5.1 The androgen receptor.
Androgens are believed to exert their biological effects after binding to an intracellular
protein receptor. This was first demonstrated by Bruchovsky and Wilson (1968) and
Anderson and Liao (1968). Bruchovsky and Wilson showed that [3H]testosterone and
[3H]DHT are present in rat prostatic cytoplasm within one minute after administration
of [3H] testosterone to rats, and that both were found in prostatic nuclei as much as 2
hrs after the injection. Anderson and Liao showed that nuclear chromatin from
prostate, but not from liver, retained [3H]DHT with high affinity after incubation of
homogenate with [3H]testosterone. Both studies thus demonstrated the rapid
conversion of testosterone to DHT within the cytoplasm of the prostatic cell, and
nuclear binding of both steroids. The importance ofDHT in the action of androgens is
discussed further below, and in Section 1.6.
Complementary DNA encoding the androgen receptor has now been cloned, and
the gene localised to the X chromasome (Chang, Katoris and Liao, 1988; Lubahn,
Joseph, Sullivan, Willard, French and Wilson, 1988). This has confirmed that it
belongs to the steroid receptor superfamily, a family of proteins which bind steroids
(including glucocorticoids, mineralocorticoids, oestrogens, progestogens, vitamin D
derivatives and thyroxine) and subsequently interact with the genome. The structure of
the receptor has many characteristics in common with other members of the family,
having 4 domains; a hormone binding region, a hinge region, a DNA-binding domain
and an N-terminal domain (Wilson, 1992).
Androgen resistance syndromes result when the physiological response to
testosterone is reduced or absent. The two most important are disorders of the
androgen receptor and of conversion of testosterone to DHT. These result in very
different clinical syndromes, respectively testicular feminisation and pseudovaginal
perineoscrotal hypospadias or 5a-reductase (5aR) deficiency. These syndromes
illustrate the effect of androgens on the development of the normal male phenotype, and
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in particular the importance of the conversion of testosterone to DHT in the
development of the external genitalia.
1.5.2 Male sexual development.
There are three stages in normal intra-uterine sexual development
1. The determination of chromosomal sex, which is completed on fusion of the germ
cells.
2. Translation of genetic sex into gonadal sex. The testis develops at 6 weeks of life
after migration of the primordial germ cells to the genital ridges, and after 7 weeks
Leydig cells appear. As discussed in Section 1.2, the mechanism of translation of
genetic into gonadal sex is incompletely understood, but it appears that the development
of the testis is dependent on a product of the testis-determining gene, located on the Y
chromasome (Simpson, Chandler, Goulmy, Disteche, Ferguson-Smith and Page,
1987; Wartenberg, 1989; vide supra, Section 1.2.1), and the absence of this factor
results in the development of an ovary.
3. Gonadal sex is translated into somatic or phenotypic sex. This involves
differentiation of the internal and external genital "anlage" into male or female forms.
The internal genitalia in both sexes are derived from a dual duct system, theWolffian
(mesonephric) and Miillerian (paramesonephric) ducts. In males, the Wolffian system
develops into the epididymis, vas deferens and seminal vesicles, and the Miillerian duct
degenerates. The external genitalia and the urethra develop from a common anlagen in
both sexes, with the genital tubercle, genital folds and genital swellings forming the
glans penis, the scrotum and the shaft of the penis respectively, and the urogenital sinus
forming the prostate and prostatic urethra.
The first two of these stages of sexual differentiation occur before the development
of the ability of the foetus to produce androgens (Siiteri and Wilson, 1974), but the
third stage is critically dependent on the secretion of hormones from the testis. This
was demonstrated by Jost (1953), who showed that foetal rabbits castrated in utero at a
sufficiently early stage of gestation developed a female phenotype regardless of gonadal
sex. Androgens were able to replace the masculinising effect of the testis, but failed to
inhibit Mullerian duct development. Miillerian inhibiting hormone is secreted by the
Sertoli cells and has a local effect on the ipsilateral Mullerian duct (Josso et al., 1977),
and the stimulatory effect of testosterone on the internal ducts is also a local effect (Jost,
Vigier, Prepin and Perchelet, 1973). The tissues of the urogenital sinus and external
genitalia have been shown to have 5aR activity, and it appears that the development of
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these structures is dependent on the conversion of testosterone to DHT (Siiteri and
Wilson, 1974). The effect of deficiency of 5aR activity is described in Section 1.6.
1.5.3 Testicular feminisation.
Complete testicular feminisation is at the extreme of a range of conditions of defective
virilisation, a spectrum varying from XY individuals with female phenotype to mild
undervirilisation in phenotypically normal men, but all have similar X-linked
inheritance and hormonal profiles (Griffin, 1992). Testicular feminisation is
characterised by a normal male 46,XY karyotype, bilateral testes, absent Mullerian
structures and a female phenotype but usually diminished axillary and pubic hair
(Morris, 1953). The plasma levels of testosterone and LH are normal or elevated
(Wilson and MacDonald, 1978).
It had previously been suggested that the condition was due to unresponsiveness of
the target tissues to testosterone. This was confirmed by studies of the testicular
feminised mouse, which demonstrated a defect in the binding of androgens to the
androgen receptor (Bardin, Bullow, Sherins, Mowszowicz and Blackburn, 1973).
Subsequently Keenan, Meyer, Hadjian, Jones and Migeon (1974) reported very low
levels of high affinity binding of DHT to skin fibroblasts from patients with this
condition.
The androgen receptor has now been extensively characterised in many families
with testicular feminisation (Griffin and Durrant, 1982), and the genetic mutation
responsible for the condition characterised in several. This approach has allowed the
demonstration of a deletion at the carboxy terminal steroid binding domain (Brown,
Lubahn, Wilson, Joseph, French and Migeon, 1988), or more often single base
deletions (Marcelli, Tilley, Wilson, Wilson, Griffin and McPhaul, 1990) or
substitutions (Tincello, Hargreave, Wu, Padayachi and Saunders, 1992). Complete
deletion of the androgen receptor gene has also been described (Quigley, Friedman,
Johnson, Lafreniere, Silverman, Lubahn, Brown, Wilson, Willard and French, 1992).
The wide variations in the underlying genetic basis for the condition may provide an
explanation for the spectrum of clinical manifestation of testicular feminisation, and for
the finding that in vitro androgen binding is normal in some patients with complete
androgen insensitivity (Griffin, 1992). The clinical manifestations of testicular
feminisation thus reveal the effect of defective androgen stimulus throughout the body.
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1.6 Dihydrotestosterone and 5oc-Reductase.
Testosterone is converted to DHT by the enzyme 5a-reductase (5aR). This conversion
is regarded as a key reaction in androgen action, essential for the development of the
male phenotype during embryogenesis and subsequently for androgen-mediated growth
of tissues such as the prostate. The conversion of testosterone to DHT was first
demonstrated by Farnsworth and Brown (1963) using prostatic tissue in vitro, and this
conversion was subsequently confirmed in vitro and in vivo following injection of
[3H]testosterone and the subsequent isolation of [3H]DHT (Bruchovsky and Wilson,
1968). These authors also reported that 5aR activity was absent from rat skeletal
muscle, a finding that has been confirmed in the adult human (Gloyna and Wilson,
1969), although there may be some activity in fetal skeletal muscle (Kelch, Lindholm
and Jaffe, 1971). DHT has a greater biological activity than testosterone (Dorfman and
Shipley, 1956), binding to the androgen receptor (Anderson and Liao, 1968;
Bruchovsky and Wilson, 1968), but with a greater affinity than testosterone (Keenan et
al., 1974; Grino, Griffin and Wilson, 1990). It has also been suggested that the DHT-
receptor complex has a higher affinity for acceptor sites in the nuclear chromatin than
does the testosterone-receptor complex (Kovacs, Griffin, Weaver, Carlson and Wilson,
1984). Both these effects will therefore act as an amplifier of androgen action, and this
appears to be required for some but not all androgen-mediated functions.
1.6.1 The effects of 5a-Reductase deficiency and inhibition.
The importance of 5aR and of DHT as essential components of androgen action is
demonstrated by the effect of its deficiency (Imperato-McGinley, Guerrero, Gautier and
Peterson, 1974; Walsh, Madden, Harrod, Goldstein, MacDonald and Wilson, 1974;
Peterson, Imperato-McGinley, Gautier and Sturla, 1977). The condition of male
pseudohermaphroditism (previously described as pseudovaginal perineoscrotal
hypospadias by Nowakowski and Lenz (1961)), due to autosomal recessive inheritance
of 5aR deficiency has been described in the Dominican Republic (Imperato-McGinley
et al., 1974), Papua New Guinea (Imperato-McGinley, Miller, Wilson, Peterson,
Shackleton and Gajdusek, 1991) and Great Britain (Ng, Taylor, Hughes, Ransley and
Grant, 1990). Affected males have ambiguous external genitalia at birth, often
resulting in rearing as girls (although rearing in a specific intersex, prepubertal male,
role has been described in some tribes in Papua New Guinea), but they have male
internal urogenital tracts. At puberty, a male muscular habitus develops, with growth
of the phallus and scrotum and some descent of the testes, and most assume the male
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gender role (Imperato-McGinley, Peterson, Gautier and Sturla, 1979). These subjects
have been extensively investigated, and as many of the results are of relevance to the
studies carried out in this Thesis, they will be discussed here, as described by Peterson
et al. (1977).
The plasma concentration of testosterone is slightly higher than normal, but the
concentration of DHT is markedly reduced, and there is no increase in plasma DHT
after injection of hCG despite a normal increase in testosterone. LH and FSH
concentrations are higher than normal, despite the mildly elevated concentration of
testosterone, suggesting reduced negative feedback at the hypothalamo-pituitary axis.
The metabolic clearance rate of both testosterone and DHT is normal, but conversion of
testosterone to DHT is reduced. Urinary excretion of androgens is abnormal, with an
aetiocholanolonerandrosterone ratio between 6 and 22 (normal 1.0 - 2.1).
Androsterone is the major 5a-reduced metabolite of testosterone in urine, whereas
aetiocholanolone is the major 5p-reduced metabolite. The ratio of the two is therefore
taken as an index of 5aR activity. Testicular biopsy has been reported as showing
reduced spermatogenesis at less than 10% of normal (Johnson, George, Neaves,
Rosenthal, Christensen, Decristoforo, Schweikert, Sauer, Leshin, Griffen and Wilson,
1986), although this result must be interpreted in the light of the concurrent presence of
partial maldescent, as the testes are found in the inguinal canal or labio-scrotal folds.
These subjects show reduced body hair, female pubic hair distribution, and little acne.
The prostate is small.
The urinary excretion of steroids has also been used to diagnose 5aR deficiency in
children (Imperato-McGinley, Gautier, Pichardo and Shackleton, 1986). In addition to
the androgen [3/a pair aetiocholanolone/androsterone, the equivalent Cortisol
metabolites can be quantified as the same enzyme is responsible for 5a-reduction of
C21 and C19 steroids (Fisher, Kogut, Moore, Goebelsmann, Weitzman, Isaacs, Griffin
and Wilson, 1978). The C21 metabolites are tetrahydrocortisol (THF) and allo-
tetrahydrocortisol (aTHF). In children as in adults with 5aR deficiency, the
THF/aTHF ratio is greatly increased, allowing diagnosis at an age when urinary
excretion of androgens is too low for accurate quantification.
The isolation of complementary DNA to 5aR from the prostate has recently been
described (Andersson and Russell, 1990; Andersson, Berman, Jenkins and Russell,
1991), suggesting the presence of two types of 5aR. One type was absent in two
males with 5aR deficiency, and that enzyme was demonstrated to have many of the
characteristics of the major isoenzyme in genital tissue, including acidic pH optimum
and sensitivity to inhibition by the 4-azasteroid derivative, finasteride. This enzyme has
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been designated 5aR 2, in contrast to 5aR 1, which was also cloned from human
prostate and has an alkaline pH optimum, is relatively insensitive to finasteride and is
present in subjects with 5aR deficiency. The significance of the two isoenzymes is
unknown, but it appears that 5aR 1, which is expressed at only a low level, may be
sufficient (in the presence of increased concentrations of testosterone) for the partial
virilisation that occurs at puberty in boys with 5aR deficiency (Imperato-McGinley et
al., 1979), but is not sufficient for the in utero masculinisation of the external genitalia.
The gene encoding 5aR 1 (SRD5A1) has now been localised to chromasome 5, with a
pseudogene mapped to the X chromasome (Jenkins, Hsieh, Milatovich, Normington,
Berman, Francke and Russell, 1991).
The abnormalities described in males with 5ocR deficiency illustrate the profound
influence ofDHT on the development of the male phenotype, with the demonstration of
those androgen-mediated effects which are dependent on DHT, despite the elevated
level of testosterone. The partial virilisation that occurs in these males at puberty is
compatible with the demonstration that there is only one molecular species of androgen
receptor (Quarmby et al., 1990), with the relative binding of testosterone and DHT
according to the law of mass action (Grino et al.,1990). The study of these subjects
does not, however, shed much light on the influence of DHT on spermatogenesis,
because of the complicating effect of often-coexisting cryptorchidism (Johnson et al.,
1986).
The development of compounds with inhibitory effects on 5aR activity has
heralded a new stimulus into the study of the importance of 5aR in human
pathophysiology, with particular emphasis on the condition of benign prostatic
hyperplasia (Horton, 1992). Inhibitors of 5aR cause regression of the hyperplastic
canine prostate, with a reduction in prostatic DHT levels (Brooks, Berman, Glitzer,
Gordon, Primka, Reynolds and Rasmusson, 1982), and prevent testosterone-induced
growth of the prostate in castrated dogs (Wenderoth, George and Wilson, 1983).
These parent drugs, however, are also weak inhibitors of androgen binding to the
androgen receptor, and thus part of the effect could be due to a direct antagonistic
effect This is not the case for finasteride, which has very low affinity for the androgen
receptor (Liang, Heiss, Cheung, Reynolds and Rasmusson, 1984). When given to
new-born male rats, finasteride prevents development of some but not all androgen-
dependent organs: thus growth of the penis, prostate,and seminal vesicles was inhibited
despite elevated plasma levels of testosterone, but the perineal muscles and preputial
glands were not affected (George, Johnson and Wilson, 1989). Exposure in utero was
without effect in female rats, but caused abnormal development of the mesenchymal
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wedge between the urogenital sinus and rectum in male rats, which resulted in the
opening of the urethra as a groove on the ventral surface of the penis, i.e. hypospadias
(Anderson and Clark, 1990). These experiments provide valuable evidence as to the
importance of 5aR in various organs in animals, but the administration of finasteride to
humans is of necessity limited to adults. Several studies have now been described.
Finasteride is a very potent inhibitor of 5aR in men, a single dose of 0.04 mg
having effects for several days (Gormley, Stoner, Rittmaster, Gregg, Thompson,
Lasseter, Vlasses and Stein, 1990). Plasma DHT and AdiolG levels were reduced by
approximately 65% and 40% respectively, testosterone levels were unchanged or
increased, and LH and FSH levels were unchanged (Vermuelen, Giagulli, De
Schepper, Buntinx and Stoner, 1989; Rittmaster, Stoner, Thomson, Nance and
Lasseter, 1989; Gormley et al., 1990). The urinary excretion of the 5aR metabolite of
Cortisol, aTHF, was also reduced, indicating an inhibition of the hepatic as well as the
peripheral enzyme (Vermuelen et al., 1989). Comparison of men with congenital 5ocR
deficiency with normal men treated with finasteride demonstrated many similarities
between the two groups in both plasma and urinary steroid metabolism (Imperato-
McGinley, Shackleton, Orlic and Stoner, 1991). Prostatic concentrations of DHT were
reduced by finasteride to a greater extent than in plasma, to approximately 10% of
controls despite prostatic tissue testosterone concentrations being increased 10-fold
(Geller, 1990; McConnell, Wilson, George, Geller, Pappas and Stoner, 1992).
Shrinkage of prostatic volume has also been reported (Stoner, 1992).
1.6.2 The control of 5c*-Reductase activity.
An important characteristic of 5ocR is that its activity is dependent on androgen levels in
many tissues, with both stimulatory and inhibitory effects described. In pubic skin,
5aR activity increases at puberty (Mauvais-Jarvis, 1977), and enzyme activity is
therefore thought to be androgen-dependent, as it is in the prostate (Moore and Wilson,
1973). Pubic skin fibroblast 5aR activity is increased by DHT (Mowszowicz,
Melanitou, Doukani, Wright, Kuttenn and Mauvais-Jarvis, 1983), and in the prostate a
similar effect has been demonstrated at the level of both enzyme activity and mRNA
(Andersson, Bishop and Russell, 1989; George, Russell and Wilson, 1991). These
results suggest that in these two tissues, there is a positive feedback effect of DHT on
its rate of production, and this effect may be the basis for the profound inhibition of
prostatic DHT levels seen after finasteride administration despite elevated tissue
testosterone levels (McConnell et al., 1992).
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Further evidence for a positive influence of the androgen receptor on 5aR is
provided by studies on patients with testicular feminisation, in whom the androgen
receptor is absent (Keenan et al., 1974; Griffin, Punyasthiti and Wilson, 1976). These
subjects have normal, high 5aR activity in perineal skin, but it is very low or absent in
pubic skin (Northcutt, Island and Liddle, 1969; Kuttenn, Mowszowicz, Wright,
Baudot, Jaffiol, Robin and Mauvais-Jarvis, 1979; Quigley et al., 1992). 5ocR activity
is also present in foetal urogenital tissue before the onset of testosterone secretion by
the testis, and is similar in males and females (Siiteri and Wilson, 1974). 5aR activity
in these tissues in the adult is also much higher than in pubic skin (Kuttenn et al.,
1979). This suggests that the low 5aR activity in pubic skin is secondary to the
absence of the androgen receptor (Imperato-McGinley, Peterson, Gautier, Cooper,
Danner, Arthur, Morris, Sweeney and Shackleton, 1982).
It therefore appears that 5aR in tissues exhibiting secondary sexual characteristics
is androgen dependent, whereas in urogenital tissue the activity of the enzyme is much
greater, but is not androgen-dependent. Thus in the tissues exhibiting secondary sexual
characteristics the effect of the increase in testosterone secretion at puberty will be
amplified. This is in contrast with 5aR activity in rat adrenal cortex, which is greatly
increased after hypophysectomy or castration and is reduced by androgen
administration (Trzeciak and Malendowicz, 1981; And6, Canonaco, Valenti, Aquila,
Tavolaro, Maggiolini, Panno and Dessi-Fulgheri, 1989; Lephart, Simpson and
Trzeciak, 1991), and in the rat liver, which is increased after orchidectomy (Andersson
et al., 1989). This has been demonstrated at the mRNA level in both organs
(Andersson et al., 1989; Lephart et al., 1991). In the rat adrenal cortex, Lephart et al.
(1991) found that DHT administration reduced 5aR activity to almost undetectable
levels.
A further difference between liver and prostatic 5otR lies in its subcellular location:
in the liver, 5aR activity was equally distributed between mitochondria and
microsomes with negligible amounts in the nuclear fraction, whereas in the prostate the
nuclear fraction contained the most activity (Roy, 1971).
1.6.3 5a-Reductase in the testis.
Much of the information available in this field is from work carried out on species other
than man for reasons of limitations of availability of tissue. Extrapolation to the human
must therefore be cautious. The problem of scarcity of tissue is compounded by the
fact that much of the human tissue that has been studied may not be normal.
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The role of testosterone in the maintenance of spermatogenesis has been discussed
above. Thus testosterone has been shown to maintain spermatogenesis in
hypophysectomised rats (Walsh et al., 1934; Steinberger, 1971). The ability of rat
interstitial tissue and seminiferous tubules to convert testosterone to DHT and
androstanediol (Adiol) in vitro has been demonstrated (Nayfeh, Barefoot and Baggett,
1966; Rivarola and Podesta, 1972), and the activity of 5aR in the rat testis was found
to be dependent on the maturity of the animal. Thus the immature rat testis rapidly
converted [3H]progesterone to [3H]Adiol, with little accumulation of [3H]testosterone,
but in the adult [3H]testosterone became the major product (Nayfeh et al., 1966;
Coffey, French and Nayfeh, 1971). Others have confirmed a higher 5aR activity in
immature than mature rat testis (Folman, Ahmad, Sowell and Eik-Nes, 1973;
Matsumoto and Yamada, 1973; Dorrington and Fritz, 1975). Maximal formation of
[3H]Adiol from [3H]testosterone was found in 20-26 day old rats, the time of the first
meiotic division, at which time endogenous levels of Adiol are elevated (Rivarola,
Podesta and Chemes, 1972; Rivarola, Podestd, Chemes and Calandra, 1975). 5aR
activity in the rat testis is also differentially distributed between seminiferous tubules
and interstitial cells, with greater activity in the tubules (Rivarola and Podesta, 1972;
Nayfeh, Coffey, Hansson and French, 1975), which are also the site of 3a-
hydroxysteroid dehydrogenase activity, the enzyme which reversibly converts DHT to
the androstanediols (Dorrington and Fritz, 1975). Spermatocytes also appear to have
5aR activity but not 3a-hydroxysteroid dehydrogenase activity (Dorrington and Fritz,
1975).
Following hypophysectomy of immature rats, 5aR activity declined rapidly in both
tubules and interstitial tissue (Nayfeh et al., 1975), and this decline was partly restored
by either LH or FSH, but not by testosterone. In mature hypophysectomised rats, 5aR
activity in seminiferous tubules but not interstitial tissue was increased by LH (Nayfeh
et al., 1975). 3a-hydroxysteroid dehydrogenase activity in seminiferous tubules from
adult rats, however, was greatly increased following hypophysectomy, to a rate similar
to that found in immature rats (Dorrington and Fritz, 1975). These authors also
speculated that ABP, secreted by the Sertoli cells in response to FSH stimulation
(Hansson et al., 1973), might influence androgen metabolism in the Sertoli cell, by
competing with 3a-hydroxysteroid dehydrogenase for DHT, and thus reducing the
metabolism ofDHT. This is compatible with the finding that the concentration of Adiol
is low relative to that of testosterone and DHT in the seminiferous tubules of mature
rats (Podestd and Rivarola, 1974).
In important studies, Ahmad, Haltmeyer and Eik-Nes (1973 and 1975) showed that
DHT capsules implanted into the testis of hypophysectomised rats maintained
Chapter 1 25
spermatogenesis in the ipsilateral but not the contralateral testis: 5a-reduction of
testosterone is not reversible, therefore the maintenance of spermatogenesis in that
study cannot be attributed to the effect of testosterone. The development of inhibitors
of 5aR have enabled further investigation into the role of DHT in the testis. The
administration of one such inhibitor, 4-MA, did not impair fertility in male rats (Brooks
et al., 1982), nor did finasteride affect spermatogenesis (George et al., 1989). The
testicular concentration of testosterone was 250% of normal in the finasteride-treated
rats, however, which complicates interpretation.
Data from the human is scanty. Payne, Kawano and Jaffe (1973) demonstrated the
ability of testicular tissue from a 17-year old to reduce testosterone to DHT in vitro,
and this has been confirmed by others (Rivarola et al., 1973). As in the rat, there is a
differential anatomical distribution, and changes in activity at different stages of
maturity: activity was higher in the seminiferous tubule preparation than in interstitial
tissue, and there appeared to be an increase in activity with increasing maturity, with a
maximum in tissue from a 15 year old (Rivarola et al., 1975). A single adult in that
study had low activity, but also had reduced spermatogenesis, making interpretation
difficult. 5aR activity was undetectable in human foetal testis (Kelch et al., 1971).
The level of 5aR in the human testis may therefore show a similar pattern of
development to that in the rat, with an increase at puberty and fall subsequently.
Testicular 5ocR may also be androgen-controlled, in common with the activity of the
enzyme in other tissues, as it is decreased after hypophysectomy in the rat (Nayfeh et
al., 1975). No data are available for the human. However, 5aR activity in the rat
testis was not restored by testosterone administration, although gonadotrophin
administration partially restored activity (Nayfeh et al., 1975). An increase in activity at
the time of development of the seminiferous epithelium would be expected, and has
been reported in both human and rat (Rivarola et al., 1973, 1975; Matsumoto and
Yamada, 1973; Nayfeh et al., 1975). In both species, there appears to be a decrease in
5aR with full maturity. The presence of high intratesticular levels of testosterone may
also interfere with the enzyme assays by competing with the [3H] testosterone added as
the enzyme substrate, and differences in the level of endogenous testosterone between
tissue preparations and experimental models will complicate interpretation. Firm
conclusions as to the androgen-dependence of testicular 5aR therefore cannot be
drawn, but it is possible that 5aR in the seminiferous tubules, as elsewhere in the
body, acts as an amplifier of androgen action,. This may be particularly important at
puberty, when testosterone production is not at its adult level. The resulting increased
androgen stimulus may be important in the initiation of spermatogenesis.
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5aR is also present in the rat epididymis, and was decreased after orchiectomy
(Robaire, Ewing, Zirkin and Irby, 1977). This effect was partially restored by
testosterone administration. It has subsequently been shown in experiments measuring
5aR mRNA that concentrations of testosterone 5-8 fold higher than in peripheral
plasma are necessary to restore 5aR mRNA in the caput, where activity is highest, but
even then mRNA levels were only 50% of control (Viger and Robaire 1991).
Replacement of testosterone in amounts sufficient to restore normal peripheral
concentrations restored 5aR mRNA in the corpus and cauda epididymis. These results
were interpreted as suggesting that 5aR in the caput is regulated by a factor in addition
to testosterone, but as epididymal concentrations of testosterone are 10-12 fold higher
than in peripheral plasma (Turner, Ewing, Jones, Howards and Zegeye, 1985),
replacement may have been inadequate. Nevertheless, it appears that the epididymis of
the rat contains a high level of 5aR, which is to a large extent androgen-dependent.
Similar studies at the mRNA level on 5aR in the testis would be of value.
1.6.4 The origin of plasma DHT.
DHT in the plasma could be the result of direct glandular secretion, or the product of
peripheral or splanchic conversion of testosterone. The classical method for
investigating glandular secretion of a hormone is to determine the difference in
concentration between the venous blood draining the gland under investigation and that
in mixed peripheral venous blood. Thus for testosterone, it is accepted that testicular
secretion accounts for almost all the circulating hormone. Using this methodology, it
has been found that the testes in the adult male secrete DHT (Pazzagli et al., 1974;
Hammond, Ruokonen, Kontturi, Koskela and Vihko, 1977), and it has been estimated
that the daily testicular production is approximately lOOiig per day (Horton, 1978),
compared to 6 mg/day for testosterone. The metabolic clearance rate of DHT is
760 1/day, and the blood production rate is therefore 300fig/day (Ito and Horton,
1971). Testicular production therefore accounts for approximately one third of
circulating DHT.
Measurement of the conversion rate of testosterone to DHT allows calculation of the
contribution of circulating testosterone to DHT, and a value of 75% in men has been
suggested (Ito and Horton, 1971). In women, the contribution of testosterone is less
than 20%, and androstenedione is the major precursor (Ito and Horton, 1971). The
conversion of testosterone to DHT may occur in the splanchnic or the peripheral
circulations. This has been investigated in men by infusion of [3H] testosterone with
selective cannulation of the splanchnic circulation: the concentration of DHT did not
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differ across the splanchnic circulation, nor was [3H]testosterone converted to
detectable concentrations of [3H]DHT in the hepatic vein (Ishimaru, Edmiston, Pages
and Horton, 1978), despite the presence of 5aR in the liver. It therefore appears that in
men the majority of the conversion of testosterone to DHT which is subsequently
released into the circulation occurs peripherally, in tissues such as the skin and prostate
and that DHT is therefore a paracrine hormone. Experiments to measure the conversion
rate do not, however, allow for the subsequent conversion ofDHT to metabolites such
as Adiol before being released into the circulation, and may thus underestimate this
value. This further metabolism has been suggested to be of importance in androgen
metabolism in the skin, and to account for the poor discrimination between groups of
women with clinical hyperandrogenism by comparison of DHT concentrations in
plasma. This is discussed further in Chapter 5.
The effects of finasteride confirms the importance of 5a-reduction of testosterone in
determining the concentration of DHT in both plasma and tissues (vide supra, Section
1.6.1), but does not provide information as to the site of reduction of testosterone, as
both hepatic and peripheral 5aR are inhibited by this drug.
1.7 The development of hormonal male contraception.
The choice of contraception currently available to men is between the condom and
vasectomy. Both have considerable drawbacks, particularly the reliability and
acceptability of condoms and the irreversible nature of vasectomy, although the advent
of the human immunodeficiency virus has resulted in an increase in the advantages
offered by condoms. This paucity of choice of method contrasts with the wide range of
methods available for the control of female fertility, most notably in the use of
hormonal methods.
Hormonal methods of contraception in the male have been investigated for over 50
years, following the demonstration that administration of testosterone (as the propionate
ester) to normal men caused a reversible reduction in spermatogenesis without affecting
libido or potency (McCullagh and McGurl, 1939; Heller, Nelson, Hill, Henderson,
Maddock and Jungck, 1950). This has subsequently been confirmed and enlarged
upon in many other studies using a variety of testosterone derivatives, alone or in
combination with oestrogens or progestogens (de Kretser, 1974), but the goal of
complete suppression of spermatogenesis to provide the required degree of
contraceptive efficacy with the maintenance of libido, without side effects, and in an
acceptable method of delivery, remains elusive. This combination of effects is thought
to require:
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1. Complete suppression of LH and FSH secretion.
2. Consequent complete (but fully reversible) arrest of spermatogenesis.
3. Normal circulating concentrations of sex steroids, in particular testosterone and
oestradiol.
4. Pharmaceutical convenience.
Several approaches have been used to achieve this end, each with different advantages
and disadvantages.
1. Androgens alone.
Several studies have shown a profound inhibition of spermatogenesis when androgen
is given alone (vide supra, Section 1.3.1; Mauss, Borsch, Richter and Bormacher,
1974; Steinberger and Smith, 1977; Swerdloff, Palacios, McClure, Campfield and
Brosman, 1978), and most recently in a multicentre trial organised by the World Health
Organisation (World Health Organisation, 1990). In that study, 200mg testosterone
oenanthate was given weekly i.m. to 271 men in a protocol very similar to that of the
study described in this Thesis. Those men who became azoospermic continued on the
testosterone treatment and used it as their only method of contraception for one year.
Plasma levels of gonadotrophins were undetectable in all men, but only 65% became
azoospermic within 6 months of testosterone treatment. Side-effects largely reflected
the supraphysiological dose of testosterone, and included acne, hypertension and
polycythaemia. Behavioural disturbances were noted in 3 men. Only one pregnancy
was reported in a total of 1486 months of exposure, giving a Pearl Index of 0.8.
While this large trial provides much important information, a major finding is the
confirmation of incomplete suppression of spermatogenesis in a large proportion of
men, as reported in the earlier studies referred to above. Incomplete suppression of
spermatogenesis has been a consistent finding in all studies of hormonal male
contraception, whether using androgens alone or in combination with progestogens or
GnRH analogues (vide infra), with azoospermia being achieved in 50-70% of men in
most studies. The proportion of men achieving azoospermia varied greatly between
centres in the WHO study, with those with a predominantly Caucasian population
reporting much lower rates of azoospermia than those with Chinese populations, in
which azoospermia was achieved in over 90% of men studied. The basis for this
difference is unknown, and is discussed further in Chapter 5.
Whether androgens are used alone or in combination, the ideal is replacement of
physiological concentrations of testosterone or equivalent, and elimination of the high
peak concentrations which are the result of administration of currently used
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preparations. To this end, various compounds with longer half-lives have been tested.
They include 19-nortestosterone (Schiirmeyer, Knuth, Belkien and Nieschlag, 1984)
and testosterone buciclate (20-Aet-l). The latter maintained effective plasma
concentrations of testosterone for up to 4 months following single injection in monkeys
(Weinbauer, Marshall and Nieschlag, 1986) and is currently undergoing clinical
testing. Different pharmaceutical preparations of testosterone such as incorporation into
pellets (Handelsman, Conway and Boylan, 1990) or microspheres (Bhasin, Swerdloff,
Steiner, Peterson, Meridores, Galmirini, Pandian, Goldberg and Berman, 1992), also
cause constant concentrations of testosterone over several months but have only been
used as replacement therapy in hypogonadal men.
Potential fertilising capacity of residual spermatozoa ofmen on testosterone alone or
in combination with MPA has been found to be severely impaired but still present as
determined by the in vitro hamster oocyte penetration test (Matsumoto, 1988; Wu and
Aitken, 1989; Wallace, Aitken and Wu, 1992), emphasising the need for azoospermia
to ensure complete contraceptive efficacy.
2. Androgen-Progestogen combinations.
Progestogens inhibit gonadotrophin secretion in man, with subsequent suppression of
spermatogenesis (Bremner and de Kretser, 1976). This also causes a suppression of
testicular testosterone synthesis and secretion, and replacement androgen therapy is
therefore required for the maintenance of libido and potency in particular.
The most widely studied combination has been depot medroxyprogesterone acetate
(MPA) with testosterone oenanthate (Brenner, Mishell, Bernstein and Ortiz, 1977; Melo
and Coutinho,1977), but as with testosterone administration alone, azoospermia was
not uniformly achieved. Pregnancies have been reported in the partners of men who
had become oligozoospermic on this regime (Barfield, Melo, Coutinho, Alvarez-
Sanchez, Faundes, Braehe, Leon, Frich, Bartsch, Weiske, Brenner, Mishell, Bernstein
and Oritz, 1979). The combination of 19-nortestosterone with MPA caused
azoospermia in 9 out of 12 men (Knuth, Yeung and Nieschlag, 1989).
3. Analogues of GnRH.
Analogues of GnRH with both agonist and more recently antagonist properties have
been developed, and investigated as male contraceptive agents alone or in combination
with androgens. GnRH agonists initially stimulate then inhibit gonadotrophin secretion
through a complex process involving depletion of cell surface receptors and uncoupling
of signal transduction, a process known as "downregulation" (Bhasin and Swerdloff,
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1986). The decline in gonadotropin secretion results in a fall in testosterone secretion
and spermatogenesis (Schiirmeyer, Knuth, Freischem, Sandow, Akhtar and Nieschlag,
1984), but again azoospermia was not consistently achieved. This finding is perhaps
related to the incomplete suppression of FSH secretion in that study. Similar findings
have been reported using an implant of the long-acting GnRH agonist (buserelin), in
which the combination of buserelin with a long-acting androgen caused less consistent
suppression of spermatogenesis than when the androgen was given alone. Treatment
with buserelin resulted in FSH concentrations returning towards baseline after 9-15
weeks treatment despite continuing inhibition of LH secretion (Behre et al., 1992).
The more recent development of GnRH antagonists, which competitively inhibit the
action of endogenous GnRH at the pituitary gland (Perrin, Haas, Rivier and Vale,
1983; Wierman, Rivier and Wang, 1989), has led to a resurgence in interest in this
method of male fertility regulation (Jockenhovel, Bhasin, Steiner, Rivier, Vale and
Swerdloff, 1988; Pavlou, Wakefield, Schlechter, Linder, Souza, Kamilaris, Konidaris,
Rivier, Vale and Toglia, 1989) despite initial problems with histamine-like side-effects
(Pavlou, Interlandi, Wakefield, Island, Rivier, Vale and Kovacs, 1987). As with other
non-androgen methods, replacement androgen is required. This has the theoretical
advantage of having an inhibitory effect on GnRH secretion, which would otherwise
increase and thus tend to overcome the effect of the antagonist.
As with the GnRH agonists, FSH secretion is relatively resistant to suppression
(Jockenhovel et al., 1988; Pavlou et al., 1989) but azoospermia was achieved in 7 out
of 8 subjects using a protocol in which the antagonist was administered followed by a
low dose of testosterone oenanthate after 2 weeks (Pavlou, Brewer, Farley, Lindner,
Bastias, Rogers, Swift, Rivier, Vale, Conn and Herbert, 1991). The plasma
concentration of testosterone was only approximately 20% of baseline with the
replacement dose used, but this appeared sufficient to prevent complaints of reduced
f
libido or sexual activity. This finding has recently been confimed with a further 7 out
of 8 subjects achieving azoospermia following treatment with the same GnRH
antagonist but a more physiological replacement dose of testosterone (Tom, Bhasin,
Salameh, Steiner, Peterson, Sokol, Rivier, Vale and Swerdloff, 1992).
It therefore appears that inhibition of gonadotrophin secretion by progestogen or GnRH
antagonists with replacement testosterone administration results in azoospermia in the
majority of men, and the use of these agents rather than androgen alone avoids or
reduces the incidence of side-effects related to the supraphysiological doses of
androgen required. This is associated with a reduction in risk (Bardin, Swerdloff and
Santen, 1991). The use of GnRH antagonists may result in a greater rate of
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azoospermia with presumably increased contraceptive efficacy, but this has yet to be
established in a large trial. There also remains the possibility of allergic reaction, and
the current necessity for daily injection of the antagonist. A hormonal method of male
contraception for widespread use therefore remains elusive for the present, although the
most recent results outlined above provide some grounds for continuing development
1.8 Aims of this Thesis.
One major factor which remains to be established is the degree of fertility of those men
who become oligozoospermic as a result of one of the treatment regimes discussed
above. There is in vitro evidence that the fertilising capacity of such residual
spermatozoa is reduced, but there are no estimates available for the clinical risk of
pregnancy based on large-scale prospective trials. The results reported in this Thesis
are part of such a trial, the background, protocol, and preliminary results of which are
presented in Chapter 2.
The other studies in this Thesis were carried out to investigate the basis for the
maintenance of spermatogenesis in those men who remain oligozoospermic on this
regime by comparison with those who become azoospermia The hypothesis tested is
that the maintenance of spermatogenesis in the oligozoospermic group of men is related
to an increased activity of the enzyme 5aR. This will result in increased conversion of
testosterone to the more potent androgen DHT in the testis as elsewhere in the body,
and such amplification of the androgen stimulus may be sufficient to maintain a low rate
of spermatogenesis in the presence of low concentrations of testosterone. The possible
contribution of continuing endogenous production of androgens in the testis and
adrenal cortex was also investigated.
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Outline of Contraceptive Trial.
2.1 Introduction.
The studies reported in this Thesis are based on a trial conducted by the World Health
Organisation Task Force on Methods for the Regulation of Male Fertility, entitled
"Evaluation of the requirement for severe oligospermia (< 5 x 106/ml) in an antifertility
method based on the suppression of sperm production with testosterone enanthate in
normal men: multicentre study". The Medical Research Council Reproductive Biology
Unit in Edinburgh is one of the participating centres, and the men described here form
the Edinburgh cohort of the trial.
The background to this trial was described in Chapter 1, in which previous studies
in the development of a hormonal method of male contraception were discussed. The
rationale for this trial is that while administration of supraphysiological doses of
testosterone, in the form of testosterone oenanthate, is known to induce reversible
azoospermia and infertility in about 2/3 of normal men for a period of one year (World
Health Organisation, 1990), the fertility of the remaining third of men who maintain
non-zero sperm counts despite continuing to receive testosterone is unknown. The
major object of this trial is to determine the fertility of this group ofmen.
In this Chapter, an outline of the Protocol of the trial is described as a background
to the results presented in subsequent Chapters. The results presented here are the
demographic characteristics of the men and their partners recruited to the trial, and the
results of semen analyses. The semen analysis results are the part of the main trial most
relevant to the studies described in subsequent Chapters of this Thesis, as they form the
basis for the discrimination of the azoospermic and oligozoospermic groups of men.
2.2 Protocol of Trial.
2.2.1 Outline of design.
This was a prospective study to evaluate the contraceptive efficacy of severe
oligozoospermia (sperm density < 5 x lOfyml) and azoospermia. There were 4 phases
in the trial:
1. Pretreatment phase. Duration of 1 month, in which pretreatment semen analyses
and blood tests were carried out.
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2. Suppression phase. Variable duration of up to a maximum of 6 months from the
date of first injection. Couples entered the Efficacy phase when they had submitted
three consecutive semen samples with sperm densities of < 5 x 106/ml.
3. Efficacy phase. One year duration, throughout which no other form of
contraception is used. Sperm density was required to remain < 5 x 106/ml.
4. Recovery phase. Variable duration, from the date of last injection, to when mean
pretreatment sperm density was regained.
2.2.2 Requirement characteristics of subjects.
Couples recruited were in a stable relationship, requiring contraception, and with no
history of infertility. The male partner was aged 21 to 45, in good health without
cardiac, renal, prostatic or hepatic disease or active genitourinary infection. Two
pretreatment semen samples both had sperm density of > 20 x 106/ml, with > 50%
normal morphology and > 50% forward motility. Two pretreatment blood samples
gave normal values for full blood count, clinical chemistry (including cholesterol, high
density lipoprotein and low density lipoprotein) and hormone concentrations (LH,
FSH, testosterone). The female partner was not be older than 35 years, with a regular
menstrual cycle and no pelvic inflammatory disease in the last year. Before testosterone
treatment was started and before entering the Efficacy phase of the trial, she had a
negative pregnancy test.
Full informed consent was obtained from both partners, in writing and witnessed.
Ethical approval was given by the Lothian Region Division of Reproductive Medicine
Ethical Committee. Subjects had the right to withdraw at any stage and for any reason.
2.2.2 Drugs administered.
Suppression of spermatogenesis was achieved by weekly administration of 200 mg
Testosterone Oenanthate ("Testoviron Depot", Schering AG, Germany) by deep
intramuscular (i.m.) injection, in a volume of 0.8 ml.
2.2.3 Semen analyses.
Two semen samples were submitted during the Pretreatment Phase at an interval of at
least 2 weeks. During the Suppression Phase, samples were submitted after 4 and 8
weeks treatment, and then at fortnightly intervals until 3 consecutive samples with
sperm densities of < 5 x 106/ml had been submitted thus enabling the subject to enter
the Efficacy Phase. Samples were then submitted every 4 weeks, during both the
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Efficacy and Recovery Phases. Analysis was according to the World Health
Organisation Manual for the examination ofhuman semen and sperm-cervical mucus
interaction (1987). Azoospermia was confirmed by examination of the pellet after
centrifugation of the semen sample at 2000 g for 5 min.
2.2.4 Other procedures.
Subjects had a general Medical examination during the Pretreatment Phase, and at 4
week intervals during testosterone treatment and during the Recovery Phase. The
blood tests performed during the Pretreatment Phase were repeated at 12 week
intervals.
2.2.5 Statistical analysis.
Data was analysed using Students "t" test, for paired samples where appropriate, or by
Analysis of Variance with Neuman-Keuls test for post-hoc analysis for multiple results.
2.3 Results.
2.3.1 Recruitment.
Couples were recruited following articles in the newspapers and features on radio and
television. All General Practitioner practices in Lothian Region received a letter
informing them of the trial, and a poster for display. Posters were also displayed in
Family Planning Clinics and Public Libraries.
A total of 33 couples were recruited to the trial and started testosterone treatment.
Their ages, marital status, contraceptive method at the time of recruitment, and fertility
are shown in Table 2.1, together with source of recruitment and stated reason for
involvement in the trial. These results show that approximately 75% of the subjects
were of proven fertility, as were 60% of their partners. Approximately 2/3 of couples
were married. Problems with oral contraception accounted for 55% of couple's
primary reasons for interest in the trial, and 33% gave interest in the development of a
hormonal method of male contraception as their primary reason for involvement in the
trial.
The age, weight, and height of the men in the trial are given in Table 2.1. Further
analysis demonstrated that there were no differences in these parameters between those
becoming azoospermic and those remaining oligozoospermic: mean ages were 29 ± 1
and 32 ± 1 years, weights were 73.1 ± 2.3 and 80.3 ± 3.7 kg, and heights were 173 ±
2 and 177 ± 2 cm in the two groups respectively.
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Table 2.1.
Demographic characteristics of couples at recruitment, and age, height and weight of
the male partners.
Marital Status 59% married*
Fertility: Proven (as couple) 58% (19)
Male only 15% (5)
Female only 3% (1)
Neither partner 24% (8)
Current contraception: Condom 42% (14)
Oral 39% (13)
Diaphragm 3% (1)
Depo Provera 3% (1)
Withdrawal 3% (1)
Current pregnancy 9% (3)
Reason for involvement:
Problems with oral contraception 55% (18)
General interest in development of male method 33% (11)
Other contraceptive problems 12% (4)
Male Partner Age mean 31 years (range 21 - 42)
Height 175 ± 8 cm
Weight 76.4 ± 12.4 kg
* 3 couples got married during the course of the trial, increasing this value to 67%.
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2.3.2 Suppression of spermatogenesis.
Testosterone treatment caused a profound inhibition of spermatogenesis in all men,
with 18 becoming azoospermic by 20 weeks of treatment. The rate of suppression of
spermatogenesis was very variable, with one man becoming azoospermic after 4 weeks
of treatment while others showed no change in sperm density at that time although
subsequently achieving azoospermia. The cumulative number of men becoming
azoospermic is shown in Figure 2.1. From this it can be seen that there was a rapidly
rising incidence of azoospermia up to 20 weeks of testosterone treatment, but no men
became azoospermic between 20 and 40 weeks of treatment This group of men, who
rapidly achieved azoospermia which was confirmed on centrifugation of the semen
sample, are referred to as the "azoospermic" group throughout this Thesis, and the
remaining group ofmen are referred to as the "oligozoospermic" group.
Division into these two groups revealed that there was no difference in baseline
sperm density (mean of two pretreatment samples, 62 ± 8 x 106/ml in the azoospermic
group, 76 ± 13 x 106/ml in the oligozoospermic group), but that a difference was
apparent in the first treatment sample, submitted after 4 weeks. At this time the
azoospermic group had a mean sperm density of 15 ± 8 x 106/ml, compared to 39 ± 11
x 106/ml in the oligozoospermic group (p<0.05). The mean sperm density of the two
groups at up to 24 weeks of treatment is shown in Figure 2.2, using a log scale for
clarity.
The oligozoospermic group had a mean sperm density of 2.0 ± 0.8 x 106/ml after
20 weeks testosterone treatment, and this continued to decline. In a subgroup of
oligozoospermic men (n=6), sperm density of < 0.1 x 106/ml was achieved at 16
weeks, with sperm usually only detectable in the pellet after centrifugation of the
sample. 5 of these men became azoospermic after prolonged testosterone treatment, as
indicated by the gradual secondary rise in the incidence of azoospermia after 40 weeks
of testosterone treatment shown in Figure 2.1. This subdivision of the
oligozoospermic group is discussed further in Chapter 5.
2.3.3 Discontinuation from the trial.
Five men discontinued the trial before completing one year in the Efficacy Phase. One
man found the injections too painful, and left the trial after 4 weeks of the Suppression
Phase. Results from this man are not included in any analyses in this Thesis. One man
discontinued after 8 months of testosterone treatment as he emigrated, and two men
discontinued because of separation from their partners, in both cases after more than a
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Figure 2.1
Cumulative percentage ofmen achieving azoospermia
during testosterone treatment.
0 4 8 12 16 20 24
Weeks of testosterone treatment
Figure 2.2
The effect of testosterone treatment on sperm density in the
ejaculate in those men becoming azoospermic and those
remaining oligozoospermic.
Sperm density at week 0 is the mean of two baseline samples.
Open symbols, Azoospermic group, n=18
Filled symbols, Oligozoospermic group, n=15
Note the logarithmic ordinate
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year of testosterone treatment. There was one pregnancy during the Efficacy Phase,
2.3.4 Contraceptive Efficacy
There was one pregnancy during the Efficacy Phase. Semen analysis carried out within
7 days of the estimated date of conception showed a sperm density of 4.1 x 106/ml with
25% forward motility and 35% normal morphology. This pregnancy resulted in
spontaneous abortion at 6 weeks gestation. This outcome may be related to a functional
deficit of the spermatozoa, but previous studies using similar regimes have reported
successful pregnancy outcomes (Wallace et al., 1992). It therefore appears unlikely
that the outcome was related to TE treatment,
a mean and median age of 31 years. A little over half of the couples were married, and
a similar proportion were of proven fertility. While the combined oral contraceptive pill
was used by 39% of couples at recruitment, problems with that method were the single
most common reason given for interest in this study. This small population thus
illustrates the main reasons for requirement for a hormonal method of male
contraception and the breadth of interest in such a method.
The results shown in Figures 2.1 and 2.2 illustrate the effect of testosterone
treatment on sperm density in the ejaculate in these men. There was a pronounced fall
in sperm density in all men, but there was a clear separation of response into those men
who rapidly became azoospermic and those who remained oligozoospermic. This
difference was apparent in the rate of inhibition of sperm density, with the group who
were to become azoospermic having a significantly lower sperm density after only 4
weeks of testosterone treatment, i.e. the first treatment sample submitted. The
resistance of spermatogenesis to suppression in those men who remained
oligozoospermic was therefore evident in the rate of decline of sperm density as well as
in the degree of inhibition achieved.
Figure 2.1 shows the percentage of men achieving azoospermia during testosterone
treatment One man was azoospermic by 4 weeks, and the number of azoospermic men
increased rapidly over the first 20 weeks of testosterone treatment. At that time, 18
men (55%) were azoospermic, a similar proportion to that previously reported (World
Health Organisation, 1990). No further men became azoospermic up to 40 weeks of
treatment, although there was then a gradual secondary increase. The shape of the
curve thus obtained suggests that the two groups form distinct populations, and
illustrates the validity of the definition of the oligozoospermic group used in subsequent
studies in this Thesis.
Testosterone administration therefore causes profound inhibition of
spermatogenesis in all men investigated, but there appear to be two clearly distinct
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patterns of response. This cannot be simply explained on the basis of the age, height or
weight of the subjects, which did not differ between the two groups. The object of the
further studies in this Thesis was to investigate the biochemical basis for this
difference, and in particular to investigate the involvement of the enzyme 5aR in the
maintenance of spermatogenesis under these conditions.
Chapter 3
Pharmacokinetics and Pharmacodynamics of Testosterone
3.1 Introduction.
The evidence that testosterone is required for spermatogenesis was discussed in
Chapter 1. The concentration of testosterone in the testis is estimated to be
approximately 100-fold higher than that in peripheral plasma, but is the subject of
continuing debate (Sharpe, 1987; Rommerts, 1988). By administering testosterone to
hypophysectomised rats or stalk-sectioned monkeys to give conditions in which the
intratesticular concentration of testosterone is estimated to be 10%-20% of normal,
spermatogenesis is maintained qualitatively but not quantitatively (Bocabella, 1963;
Buhl, Cornette, Kirkton and Yuan, 1982; Marshall, Wickings and Nieschlag, 1984),
and replacement of physiological intratesticular concentrations of testosterone following
the administration of EDS results in normal spermatogenesis (Sharpe et al., 1988).
The administration of supraphysiological doses of testosterone to normal men
reduces intratesticular testosterone concentrations to approximately 5% of normal, at
which time the intratesticular testosterone concentrations were only 2 fold higher than in
plasma (Morse, Horike, Rowley and Heller, 1973): whether this alone (ie in the
absence of gonadotrophins) is sufficient to maintain a degree of spermatogenesis is
unclear. Indirect evidence as to the intratesticular concentration of testosterone in the
current study is provided by studies involving the administration of GnRH antagonist
with replacement testosterone to non-human primates. This caused a reduction in
intratesticular testosterone to 38% of pretreatment concentrations (Weinbauer et al.,
1988), under which conditions there was some maintenance of spermatogenesis.
However, the administration of GnRH antagonist with replacement testosterone to
normal men results in a high rate of azoospermia (vide supra, Chapter 1.7), which
suggests that there may be a significant species difference.
Thus the simplest explanation for some men remaining oligozoospermic on
supraphysiological doses of testosterone is that the intratesticular concentrations of
testosterone remain sufficient to support a very low rate of spermatogenesis, whereas in
the men becoming azoospermic, that concentration is below a threshold for
spermatogenesis. Previous trials using this experimental design have reported that the
concentration of testosterone in plasma does not differ between the two groups ofmen,
although the data were not presented (World Health Organisation, 1990).
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Following administration of testosterone oenanthate, plasma concentrations of
testosterone increase rapidly (Schulte-Beerbiihl and Nieschlag, 1980), with peak
concentrations approximately 3 times baseline within 24 hours, followed by a decline
over 10 days. With repeated administration, trough concentrations will increase to a
steady state, when an equilibrium is established between absorption and metabolism.
Similarly, peak concentrations after the first injection are likely to be lower than peak
concentrations achieved after the new equilibrium is established, but the precise
pharmacokinetics and pharmacodynamics with repeated testosterone injections in
normal men are unknown. It is thus possible that there are differences between men
becoming azoospermic and those remaining oligozoospermic that are apparent only on
close examination of the profile of testosterone absorption which are not seen when
trough concentrations alone are measured. With the suppression of endogenous
secretion of testosterone by the testes, the germinal epithelium may be exposed to
concentrations of testosterone similar to that those present in the peripheral circulation.
Thus the measurement of that circulating testosterone profile may provide information
relevant to the maintenance of spermatogenesis in some men under these conditions.
Testosterone is converted to oestradiol by the action of the enzyme aromatase both
within the testis and in the periphery (Longcope et al.,1969; Baird, Horton, Longcope
and Tait, 1969; Dorrington and Armstrong, 1975), and the administration of the dose
of testosterone oenanthate used in these studies causes an elevation of plasma oestradiol
concentration of approximately 90% (Swerdloff et al., 1979; Nieschlag, Waites and
Farley, 1991). A difference in plasma oestradiol concentrations between men
becoming azoospermic and those remaining oligozoospermic has been reported
(Wallace, Seth and Wu, 1993), but this difference was only detected at one time point
during the 12 month course of testosterone treatment. Changes in plasma concentration
of oestradiol have therefore been investigated in greater detail here, as such a difference
between azoospermic and oligospermic responders may reflect differences in androgen
metabolism both within the testis and in the periphery.
The concurrent presence of FSH appears to be of great importance in determining
the spermatogenic response to the presence of subphysiological intratesticular
concentrations of testosterone. In the experiments quoted above in which
hypophysectomised rats were used and there was therefore no FSH secretion,
spermatogenesis was greatly reduced. In an experimental protocol in which a GnRH
antagonist was used to inhibit gonadotrophin secretion in rats with a subcutaneous
testosterone implant, resulting in intratesticular testosterone concentrations of 15% of
normal, spermatogenesis was maintained at a normal rate (Rea et al., 1986). In that
model there was detectable FSH secretion. Similar results have been obtained in
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humans: following the suppression of gonadotropin secretion by testosterone, the
subsequent administration of FSH partially restored spermatogenesis (Matsumoto et
al., 1983).
The administration of a GnRH antagonist to men resulted in azoospermia in 7 out of
8 men (Pavlou et al., 1991). This treatment, in which androgen replacement was
delayed, resulted in a very rapid decline in gonadotrophin secretion which may be
related to the high rate of azoospermia. Furthermore, men who became azoospermic
during testosterone treatment show a rebound enhanced secretion of gonadotropins at
the beginning of the recovery period compared to those who became oligozoospermic,
despite levels being undetectable in both groups during treatment (Wallace et al., 1993).
In this Chapter, the possible importance of the rate of suppression of gonadotrophin
secretion in determining whether spermatogenesis is maintained has been investigated,
and whether the apparent difference in responsiveness of the hypothalamo-pituitary axis
is detectable at the beginning of testosterone treatment by closely monitoring the rate of
decline of LH and FSH in plasma. Previous studies of the importance of FSH in
determining the rate of spermatogenesis have been hampered by the relative
insensitivity of RIAs for FSH, with levels of sensitivity at approximately 20% of
normal male concentrations. Thus FSH secretion at a rate of 10% of normal would be
undetectable, making interpretation of experiments relying on complete suppression of
FSH (eg by supraphysiological doses of testosterone) difficult A novel method for the
measurement of hormones (including the gonadotrophins) has recently been developed
(DELFIA, Pharmacia Ltd), using antibodies labelled with a fluorescent marker,
europium. This method has greatly enhanced sensitivity, and has been used to detect
the nocturnal secretion of gonadotrophins in early puberty (Wu et al., 1991).
Testosterone binds to proteins in plasma, in particular SHBG and albumin, such that
only approximately 2% is free in solution, with approximately 60% being bound to
SHBG. The SHBG molecule has a single steroid binding site (Rosner and Smith,
1975). The function of this high-affinity binding to SHBG is generally believed to be
to reduce the hepatic clearance of the hormone, so acting as a reservoir of testosterone
(Mendel, 1989; Rosner, 1990), and it has been shown that infusion of SHBG in
monkeys reduces the metabolic clearance rate of testosterone (MCRT) (Pdtra,
Stanczyk, Namkung, Fritz and Novy, 1985). A better correlation between MCRT and
free + non-SHBG bound testosterone than with the free fraction alone has been found
(Siiteri, Murai, Hammond, Nisker, Raymoure and Kuhn, 1982). The free fraction of
plasma testosterone is regarded as being bio-available while that bound to SHBG is not
("the free hormone hypothesis"): whether that fraction bound to albumin is bio-
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available or not is the subject of active debate. Pardridge has proposed that the
dissociation of testosterone from albumin is sufficiently rapid that an equilibrium will
develop within the timespan of capillary blood flow, ie approximately 1 second
(Pardridge, 1981). This has been supported by direct measurement of the rate of
dissociation of testosterone from SHBG and albumin (Mendel, 1990; Mendel, Miller,
Siiteri and Murai, 1990). These experiments showed that testosterone dissociated from
SHBG with a half-life of 12 sec, compared to 0.5 sec from albumin. Further evidence
is provided by experiments in which [3H]testosterone in albumin-containing buffer or
in plasma is injected into the rat carotid artery, followed by measurement [3H] in brain
tissue 15 seconds later (the Oldendorf technique). Uptake of [3H]testosterone is
presumed to reflect the bioavailability of testosterone, and these experiments showed a
good correlation between "bioactive" and albumin-bound testosterone (Manni,
Pardridge, Cefalu, Nisula, Bardin, Santner and Santen, 1985).
The presence of high affinity binding of SHBG to prostate membrane preparations
has been reported (Hryb, Khan and Rosner, 1985), with a Kd=0.15 nM. Binding of
[3H]SHBG is reduced in the presence of steroids in proportion to their affinity for
SHBG (Hryb, Khan, Romas and Rosner, 1990). It therefore appears that SHBG is an
allosteric protein, with binding sites for both steroids and membranes arranged in such
a way that steroid binding masks the membrane binding site. Membrane bound
SHBG, however, retained the ability to bind steroids (Hryb et al., 1990), and the
membrane-SHBG complex was found to enhance the stimulation of cAMP
accumulation caused by steroids (Rosner, 1990). The function of SHBG may
therefore be more complex than the regulation of steady state circulating concentrations
of steroids, and may be involved in the transfer of steroids across cell membranes.
Such a function may underlie the finding that the presence of SHBG appears to affect
the uptake of testosterone by the prostate, as testosterone was taken up equally by
epithelium and stroma when perfused in buffer, but was preferentially sequestered by
the stroma in the presence of SHBG (Ellison and Pardridge, 1990). Indeed, SHBG-
like immunoreactivity has been demonstrated in a variety of tissues including the testis
and prostate (Bordin and Petra, 1980). These results suggests parallels with the
receptor-mediated uptake of cholesterol bound to low density lipoprotein (Goldstein
and Brown, 1977).
The concentration of SHBG is altered in a variety of hormonal states. The plasma
concentration of SHBG falls at puberty in boys (Blank, Attanasio, Rager and Gupta,
1978) and is reduced in hyperandrogenie states (Plymate, Leonard, Paulson, Fariss and
Karpas, 1983). However plasma SHBG concentrations also fell in two boys with
complete androgen insensitivity at the time of puberty (Cunningham, Loughlin,
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Culliton and McKenna, 1985). Conversely, oestrogen administration to men causes a
increase in SHBG concentrations (Anderson, 1974), and changes in plasma SHBG
concentration have been detected during the menstrual cycle, with a 20% rise during the
luteal phase (Plymate, Moore, Cheng, Bardin, Southworth and Levinsky, 1985).
SHBG concentrations are also elevated in thyrotoxicosis, with an associated increase in
total testosterone concentration and fall in MCRT (Gordon, Southren, Tochimoto, Rand
and Olivo, 1969). In that condition however, evidence of hyperandrogenicity is not
usually found although there may be abnormalities of the hypothalamo-pituitary-
testicular axis (Kidd, Glass and Vigersky, 1979; Hudson and Edwards, 1992). This
may be explained by a small fall in non-SHBG bound testosterone, and concentrations
of free testosterone may be normal or reduced (Chopra and Tulchinsky, 1974; Loric,
Duron, Guechot, Aubert and Giboudeau, 1989; Ford, Cook, Keightley and Feek,
1992; Hudson and Edwards, 1992). SHBG is reduced in obese men in proportion to
the degree of obesity, and there is also a reduced total testosterone concentration: from
this some have predicted that the two changes compensate for each other resulting in a
eugonadal state (Schneider, Kirschner, Berkowitz and Ertel, 1989), but others have
found that free and non-SHBG bound testosterone are also reduced, indicating a
hypogonadal state (Zumoff, Strain, Miller, Rosner, Senie, Seres and Rosenfield,
1990).
Determination of total testosterone alone therefore provides a very incomplete
analysis of the biologically relevant concentration of testosterone in plasma, and
changes in SHBG and the free and non-SHBG bound components should also be
considered. The examples of thyrotoxicosis and obesity demonstrate that measurement
of SHBG and total testosterone do not always allow accurate prediction of
"bioavailable" testosterone, and the free and non-SHBG bound components require to
be measured directly. In the experiments described in this Chapter, free and non-
SHBG bound testosterone were measured in addition to total testosterone and SHBG
itself, to further characterise the pharmacokinetics of testosterone administered using
this regime, and to investigate whether there might be differences between men
becoming azoospermic and those remaining oligozoospermic.
3.2 Materials and Methods.
The methods of radioimmunoassay, immunoradiometric assay and fluoroimmunoassay
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Figure 3.1
Schematic drawing illustrating the differences between the
three immunoassay methods used in this Chapter.
(a) Radioimmunoassay (testosterone, oestradiol)
(b) Immunoradiometric assay (SHBG)
(c) Fluoroimmunoassay (LH and FSH).
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To investigate the pharmacokinetics of absorption of testosterone, total, free, and
non-SHBG bound testosterone were measured in samples taken before the first
injection, and 1, 2, 4, and 7 days later, the last being immediately before the next
injection was given. This schedule was repeated after 16 weeks. Additional samples
were assayed for total testosterone at 2-4 week intervals between these two injections to
demonstrate that the steady state had been reached with weekly administration.
3.2.1 Testosterone RIA
Testosterone in plasma was measured by RIA using the method of Corker and
Davidson, (1978).
Plasma aliquots (50|il in duplicate) were extracted with 3ml hexane:ether (4:1) by
vortexing for 7 min. The organic phase was separated after freezing the plasma in
methylated spirit/solid CO2, dried down under nitrogen and reconstituted in 200|il of
phosphate buffered gelatine-saline (PBGS) buffer. IOOjj.1 of this was taken for assay.
Recoveries were determined by adding 50pl of PGBS containing 2500cpm
[3H]testosterone to the plasma sample before extraction, and measuring [3H] by liquid
scintillation counting (LSC) in 50|il of the reconstituted sample.
Standards over the range 5 to 640 pg/tube were used. 100|il of buffer containing
12000 cpm 125I-Testosterone and lOOpl of anti-testosterone antibody at a dilution of
1:350000 were added to each tube. The assay was incubated at room temperature for 3
hrs, then lOOpl of normal sheep serum (1:1000 dilution) and lOOpl of donkey anti-
-goat/sheep serum (1:25 dilution) were added. After incubation overnight at 4°C, 1ml
of 0.9% NaCl containing 0.2% Triton X-100 was added, and the tubes centrifuged at
2500 rpm for 30 min. The supernatant was decanted, and 125I in the pellet was
counted using a Wallac 1261 "Multigamma" counter. Results were calculated for this
and other immunoassays (DELFIA assays for LH and FSH, oestradiol, DHT and
AdiolG RIAs and SHBG IRMA) using the "AssayZap" computer program (Biosoft
Ltd, Cambridge). Quality control samples were included in all assays, allowing
calculation of an intraassay coefficient of variation (CV) of 6.4%, and an interassay CV
of 9.4%. Recovery values were 70-82%.
3.2.2 Free testosterone assay.
Testosterone is bound to SHBG and albumin in plasma, with only about 2% free in
men, and 1% in women. The method used in this Thesis involves the incubation of
plasma with a tracer concentration of [^Hjtestosterone,which equilibrates with the
various fractions of endogenous hormone. This is followed by ultrafiltration, which is
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carried out by centrifugation across a protein-retaining membrane. The concentration of
free hormone is unaffected by this and is therefore the same in the ultrafiltrate as in
plasma (Ekins, 1990). The membranes used here have a molecular weight cut-off of
10,000 (molecular weight of albumin is 67,000).
A 12.5cm column of hydroxyalkoxypropyl-dextran (H83586, Sigma) was prepared
in a glass pipette, and equilibrated with hexane:chloroform (95:5). 20|il
[3H]testosterone ([l,2,6,7-3H]-testosterone, 70pCi/mmol, Amersham) was dried
down under nitrogen, and redissolved in 1ml hexane:chloroform. This was added to
the column, which was eluted with the same solvent. The first 15ml was discarded,
and the next 6 aliquots of 5ml collected. The purified tracer eluted in fractions 2 and 3,
which were then combined and used in the assay.
100000 cpm of purified [3H] testosterone was dried down in each glass assay tube.
500|il of plasma was added, the sample vortexed, and incubated at 37°C for 30 min.
200p.l aliquots in duplicate were then added to prewarmed Centrifree ultrafiltration
devices (Amicon Ltd), with YMT membranes, and incubated for a further 10 min. The
devices were then centrifuged at 1000g/4000rpm at 37° for 5 min in a fixed angle head
rotor (angle 23°), and [3H] in a 50|il aliquot of the ultrafiltrate counted by LSC. [3H]
in a 50JJ.1 aliquot of the incubate was also counted. Results were calculated according to
the formula:
„
^ cpm in ultrafiltrate - background x 100% Free = — - —r-^ —
cpm in incubate - background
This gives a result as percentage free testosterone, which can be converted to
concentration of free testosterone by multiplying by the total testosterone concentration
as determined by RIA (vide supra, Section 3.2.1). Quality control plasma samples
were routinely included in all assays; intraassay CV was 7.1% and interassay CV was
11.0% at 2.1% free testosterone.
3.2.3 Non-SHBG bound testosterone assay.
The method used in this Thesis is derived from that of O'Connor, Baker, Dulmanis and
Hudson (1973), as modified by Tremblay and Dube (1974). The principle is similar to
that of the free testosterone assay described above, but instead of ultrafiltration to
separate free from protein-bound tracer [3H]testosterone, ammonium sulphate is used
to precipitate the SHBG. At the concentration of ammonium sulphate used, albumin is
not affected and the concentration of [3H]testosterone remaining in the supernatant
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represents that bound to albumin (as well as a small fraction bound to other globulins)
with that free in solution.
[3H]testosterone was purified as described above. 15000 cpm of [3H]testosterone
was added to each assay tube, and evaporated to dryness. 200|il of 0.9% NaCl was
added to each tube, followed by 200|il of plasma in duplicate, or 200|il of 1% BSA to
total counts tubes. The tubes were vortexed, and incubated at 37°C for 60 min. The
tubes were then cooled in ice water for 10 min, and 400(il of saturated ammonium
sulphate added, giving a final concentration of 50%. Tubes were immediately
vortexed, and after a further 10 min in the ice water, were centrifuged at 2000g for 20
min at 4°C. 200(il aliquots of the supernatant in duplicate were then taken for
determination of [3H] by LSC. Results were calculated using the formula
^ , , cpm in sample - background x 100% non-SHBG bound = — — —
cpm in total counts - background
Multiplication of this value by total testosterone determined by RIA gives non-SHBG
bound testosterone, in nmol/1. Quality control plasma samples were routinely included
in all assays; intraassay CV was 7.7% and interassay CV was 9.2% at 21% non-SHBG
bound testosterone.
3.2.4 Oestradiol RIA.
Oestradiol concentrations in plasma was measured by RIA (Glasier, Irvine, Wickins,
Hillier and Baird, 1989). 200pl aliquots in duplicate were extracted into 1ml of ethyl
ether by vortexing for 1 min. After freezing the aqueous layer, the organic layer was
decanted into glass tubes and dried down under nitrogen. The residue was
reconstituted in 100pl PBS buffer, and used directly for assay. Extraction efficiency
was determined in representative tubes using [3H]oestradiol, and was found to be
greater than 92%. Results were therefore not corrected for extraction.
Standards were used over the range 30-10000 pmol/ml. 200pl 125I-oestradiol
(approximately lOOOOcpm) and lOOpl of primary antiserum at a dilution of 1:1500000
were added to each tube, mixed, and incubated at room temperature for 3 hrs. Non¬
specific binding was determined by omitting the primary antiserum, and B0 by using
buffer in place of standard.
Donkey anti-sheep/goat antiserum (1:8 dilution) and 100|il of non-immune sheep
serum (1:400 dilution) were then added to all tubes. After incubation overnight at 4°C,
lml of 0.9% NaCl containing 0.4% Triton X-100 and 4% polyethylene glycol was
added, tubes were centrifuged at 3000g for 30 min, the supernatant decanted and 125I
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in the pellet counted. Results were calculated using "AssayZap". Quality control
samples were included in all assays, the interassay CV was 14.3%, and interassay CV
was 7.1% at 120 pmol/1. The limit of detection of the assay was 50 pmol/1. Samples
giving values below the limit of detection were assigned this value. This occurred in
30% of baseline samples, but no others.
3.2.5 SHBG assay.
SHBG concentration in serum was measured using an immunoradiometric assay
(IRMA) system supplied by Farmos Diagnostica Ltd, Finland. This circumvents the
instability of pure SHBG which reduces the accuracy of 125I-SHBG
radioimmunoassays by the use of a monoclonal anti-SHBG antibody which recognises
a specific determinant on the SHBG molecule. 125I-labelling of this antibody with
subsequent use in a "sandwich"-type IRMA allows very high specificity and reduces
variation in tracer quality.
Reagents were reconstituted as instructed. Standards, serum samples and quality
control samples were diluted 1 in 100 in assay buffer. lOOp.1 of diluted standard or
sample was then assayed. Equal volumes of anti-SHBG antiserum and
125I-anti-SHBG antibody were mixed, and 200|il of this was then added to all tubes.
Total counts tubes contained only label, non-specific binding tubes contained the label
and 100pl of buffer. Tubes were vortexed and incubated at room temperature for 60
min. 500|ll of solid-phase separation agent was then added, and after a further 15 min
incubation, tubes were centrifuged at 2000g for 15 min. The supernatant was
discarded, and radioactivity in the pellet was counted. Results were calculated using
"Assayzap", and expressed as nmol/1. Quality control sera were provided in the kit by
the manufacturer, and gave values within the expected range.
3.2.6 LH and FSH assays.
The gonadotrophins were measured using a time-resolved fluoroimmunoassay
(DELFIA, Pharmacia, Finland). This is a solid-phase, two site assay based on the
sandwich principle, in which two monoclonal antibodies are directed against antigenic
determinants on the a and gonadotrophin-specific (3 subunits. Standards and samples
bind to the first antibody, immobilised on the microtitre plate well, and a second
antibody labelled with europium is added. After washing off unbound second
antibody, the europium is dissociated by an enhancement solution. This forms highly
fluorescent chelates, and the level of fluorescence is proportional to the concentration of
hormone.
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Both hormones were measured using an identical technique, the only difference
being in the specificity of the antibodies to the (3-subunit of LH or FSH. The plates
were rinsed, then 25[il of standard (0 - 256 IU/1) or plasma sample was added in
duplicate followed by 200pl of buffer. Plates were mixed by rotatory shaking, then
incubated overnight at 4°C. Plates were then washed, 200|il of tracer-antibody added,
and incubated at room temperature for 30 min. Plates were again washed, and 200(ll of
enhancement solution added. Time-resolved fluorescence was then measured (Wallac
model 1234 fluorimeter), and results calculated using Assayzap. A time lapse between
excitation and counting allows nonspecific fluorescence to decay, giving increased
signal to noise ratio and thus low background values, and the excitation pulse length
allows 1000 cycles to be counted per sample well in 1 second. All samples were
assayed in one assay, and quality control samples were consistent with results
previously obtained in the laboratory. Assay sensitivity was 0.05 IU/1 for LH, and
0.06 IU/1 for FSH. Samples which gave results below the limit of sensitivity were
assigned that value.
3.2.7 Statistical analysis.
For repeated measures, Analysis of Variance with Neuman-Keuls test for post-hoc
analysis was used to determine levels of significance. For single results (eg SHBG
results), Students t test was used, on paired data where appropriate.
Pharmacokinetic modelling of plasma testosterone results was carried out using the
"RSTRIP" computer program (MicroMath Scientific Software, Salt Lake City, Utah,
USA), which uses least squares analysis of polyexponential functions (Behre,
Oberpenning and Nieschlag, 1990). A biexponential model was used in this analysis.
3.3 Results.
3.3.1 Testosterone results.
Following the first injection, plasma concentrations of total testosterone rose from
baseline values of 15.6 ± 1.2 nmol/1 to 45.0 ±4.1 nmol/1 on day 1 in the azoospermic
group, and from 15.8 ± 2.0 nmol/1 to 56.0 ± 2.0 nmol/1 in the oligozoospermic group.
These concentrations then declined to 21.6 ±2.2 nmol/1 in the azoospermic group on
day 7, and to 26.7 ± 2.4 nmol/1 in the oligozoospermic group. These results, with
those of the intervening time points, are shown in Figure 3.2a. The concentrations on

























Figure3.2 Plasmaconcentrationsftestostero eih semb coming azoospermicndth seremainingolig zoospermicfol w n injectionof200mgt stosteroneoenanthat . (a)Following1stinjection. (b)Following16thinjection. * p<0.01vsday0 Opensymbols,Azoospermicgroupn=18 Filledsymbols,Oligozoospermicgroupn=15 Mean±sem.
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(pcO.Ol), but on day 7 the concentrations were not significantly different from
baseline. At no time point were the values for the two groups significantly different
The profiles of concentrations of plasma testosterone after 16 weeks of testosterone
treatment are shown in Figure 3.2b. At this time, day zero concentrations are trough
testosterone concentrations, taken immediately before the next injection is given. In the
azoospermic group, the trough testosterone concentration was 35.2 ± 4.2 nmol/1, and
was 36.8 ± 3.4 nmol/1 in the oligozoospermic group. These concentrations rose to
67.0 ± 5.5 nmol/1 and 65.6 ± 8.0 nmol/1 respectively on day 1 after that injection. As
after the first injection, the concentrations on days 1, 2, and 4 were significantly
different from baseline values in both groups (pcO.Ol), but on day 7 the concentrations
were not significantly different from trough testosterone concentrations. At no time
point were the values for the two groups significantly different
There therefore appeared to have been an accumulation of testosterone in the plasma
of the subjects, as concentrations 7 days after the first injection were significantly lower
than trough concentrations taken after 16 weeks of testosterone treatment (pcO.Ol in
both groups). Determinations of plasma concentrations of testosterone at intermediate
time points are shown in Table 3.1, illustrating this accumulation. All samples were
taken immediately before the next injection was given, 7 days after the previous one.
Trough testosterone concentrations were significantly greater than pretreatment baseline
concentrations after 2 weeks of treatment (p<0.05) and at the time of subsequent
injections (pcO.Ol) in both groups, but were not significantly elevated after only one
week. Samples taken after 8, 12 and 16 weeks of testosterone treatment also had
significantly greater testosterone concentrations than those taken after 2 weeks of
treatment. There was therefore a significant rise in trough concentrations of
testosterone after 2 weeks of testosterone treatment, with further significant increases
following repeated administration but appearing to plateau after 8-12 weeks suggesting
that steady state had been reached by 8 weeks of treatment.
Computer pharmacokinetic modelling allowed calculation of area under the curve
(AUC), terminal half-life (fi/2), maximum concentration of testosterone (Cmax), and
time after injection of maximum concentration (tmax), for the two weeks analysed in
detail. Results are shown in Table 3.2. There were no differences between the
azoospermic and oligozoospermic groups in any of these parameters, but in both
groups there were significant increases in AUC and Cjnax after 16 weeks of treatment
as expected, as the baseline after 16 weeks is a trough concentration and as shown in
Table 3.1, is considerably higher than the pre-treatment baseline concentration. There
were no changes in the apparent half life of the administered testosterone (Cmax) or the
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treatment Baseline 1 2 4 8 12 16
Azoospermic 15.6 21.6 27.7* 31.3** 34.4** 34.8** 35.2**
(1.2) (2.2) (3.2) (3.2) (3.0) (3.6) (4.2)
Oligozoospermic 15.8 26.7 29.9* 30.8** 34.0** 40.2** 36.8**
(2.0) (2.4) (2.9) (3.0) (3.0) (3.1) (3.4)
Plasma concentrations of total testosterone at baseline and following repeated
administration of 200 mg testosterone oenanthate in men becoming azoospermic and
those remaining oligozoospermic. Values are mean (sem)
* p<0.05 vs baseline, ** p<0.01 vs baseline.
Table 3.2 Computer-modelled analysis of testosterone concentrations
First injection AUC (nmol.hrs/1) ti/2 (hrs) Cmax (nmol/1) tmax (hrs)
Azoospermic 6160 ±440 145 ± 24 55.2 + 4.9 15.2 ± 2.0
Oligozoospermic 8720 ± 590 177 ± 27 64.2 ±6.9 11.7 ± 4.6
After 16 weeks
Azoospermic 8720 ± 590(a) 163 ± 18 74.1 ± 5.5(c) 12.8 ± 3.7
Oligozoospermic 9580 ± 670(b) 155 ±60 77.5 ±6.5(4) 8.4 ± 2.2
(a) p<0.002, (b) p<0.005, (c) p<0.02, (d) p<0.05, all vs first injection.
3.3.2 Free and non-SHBG bound testosterone.
The results obtained for these two parameters were similar in many respects, and are
described here together. The first injection of testosterone caused an increase in free
testosterone concentrations from 270 ± 20 pmol/1 to 1120 ± 150 pmol/1 in the
azoospermic group on day 1, and from 260 ± 30 pmol/1 to 1370 ±180 pmol/1 in the
oligozoospermic group (p<0.01 in both groups, Figure 3.3a). This then declined to
470 ± 50 pmol/1 in the azoospermic group on day 7, and to 560 ± 50 pmol/1 in the
oligozoospermic group. In the oligozoospermic group, the concentration on day 7 was
significantly greater than the baseline concentration (p<0.05), but the concentrations
(b)
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were not significantly different in the azoospermia group. There were, however, no
significant differences between the two groups.
Plasma concentrations of non-SHBG bound testosterone showed a similar profile
after the first injection, rising from 5.5 ± 0.3 nmol/1 to 24.6 ± 3.5 nmol/1 in the
azoospermic group on day 1, and from 4.8 ± 0.5 nmol/1 to 30.0 ± 4.4 nmol/1 in the
oligozoospermic group (p<0.01 in both groups, Figure 3.4a). The concentrations then
declined to 9.8 ± 1.1 nmol/1 and 11.3 ± 1.1 nmol/1 in the two groups respectively.
These concentrations were not significantly different from baseline concentrations in
either group, and there were no significant differences between the two groups.
Profiles of free and non-SHBG bound testosterone after 16 weeks treatment are
shown in Figure 3.3b and 3.4b. At this time, the distribution of testosterone between
the bound and free fractions had altered considerably. Thus trough concentrations of
free testosterone were 1080 ±130 pmol/1 in the azoospermic group and 1150 ± 160
pmol/1 in the oligozoospermic group, similar to the peak concentrations after the first
injection and nearly 5 fold greater than baseline concentrations. Trough concentrations
of non-SHBG bound testosterone were increased to 17.5 ± 1.7 nmol/1 in the
azoospermic group, and to 19.3 ± 2.6 nmol/1 in the oligozoospermic group (p<0.001
vs day 7 concentration after first injection in both groups). There was still a marked
increase in concentrations of both free and non-SHBG bound testosterone after 16
weeks of testosterone treatment, and although the magnitude of the increase was not as
great as after the first injection, concentrations of both parameters were more than
doubled on day one after that injection. Again, there were no differences between the
two groups.
The changes in plasma concentrations of free and non-SHBG bound testosterone
expressed as a percentage of total testosterone are shown in Figures 3.5 and 3.6
respectively. Comparison of the values before testosterone treatment started, and over
the weeks following the first injection and after 16 weeks of testosterone treatment
illustrate the changes in distribution of testosterone between its binding proteins and
that free in solution with continuing administration of testosterone at supraphysiological
doses. These results differed from those expressed as concentrations, in that both the
percentage free and non-SHBG bound testosterone on day 7 following the 1st injection
were significantly greater than at baseline in both groups.
3.3.3 Oestradiol results.
The plasma concentration of oestradiol was measured in the same samples as
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testosterone treatment. In the azoospermic group, oestradiol rose from a baseline of
96.6 ± 9.9 pmol/1 to 184 ± 20 pmol/1 on day 1 (p< 0.01), and then fell to 110.6 ± 10.8
pmol/1 on day 7. In the oligozoospermic group, oestradiol rose from 76.9 ± 7.5 pmol/1
to 155 ± 20 pmol/1 (p<0.01), then fell to 82.4 ± 15.3 pmol/1 at the same time points.
Values on days 2 and 4 were also significantly greater than baseline in both groups
(p<0.01). After 16 weeks of testosterone treatment, oestradiol rose from a trough
concentration of 194 ± 27 pmol/1 (p<0.001 vs baseline) to 252 ± 20 pmol/1 on day 1
(p<0.01 vs trough concentration) in the azoospermic group, and from 173 ± 23 pmol/1
(p<0.002 vs baseline) to 220 ± 23 pmol/1 (p<0.05 vs trough concentration) in the
oligozoospermic group. The concentrations on days 2, 4 and 7 after 16 weeks of
testosterone treatment were not significantly different to trough concentrations in either
group. These results, and those of the other time points analysed, are shown in Figure
3.7. At no point were there significant differences in plasma concentration of oestradiol
between those men who became azoospermic and those remaining oligozoospermic.
3.3.4 SHBG results.
Plasma concentrations of SHBG were determined at baseline before treatment started,
and after 16 weeks (Figure 3.8). Baseline concentrations were 31.8 ± 3.6 nmol/1 in the
azoospermic group, and 34.5 ± 3.6 nmol/1 in the oligozoospermic group. After 16
weeks of testosterone treatment, these concentrations had fallen to 19.2 ± 2.3 nmol/1 in
the azoospermic group (p<0.001), and to 24.0 ± 2.6 in the oligozoospermic group
(p<0.01). There were no significant differences between the groups.
3.3.5 Gonadotrophin concentrations.
Plasma concentrations of both LH and FSH showed a rapid decline following the first
injection of testosterone (Figures 3.9 and 3.10). Plasma concentrations of LH were
significantly inhibited on day 1 following injection compared to baseline concentrations
in both groups. In the azoospermic group, LH concentration at the time of first injection
was 3.57 ± 0.20 IU/1., and 2.63 ± 0.31 IU/1 on day 1; in the oligozoospermic group,
LH concentrations were 4.24 ± 0.46 IU/1 at baseline and 2.78 ± 0.38 IU/1 on day 1
(p<0.01 in both groups). In contrast, the inhibition of FSH secretion was slightly
delayed: thus concentrations of FSH on day 1 were not significantly different from
those at the time of first injection (3.05 ± 0.39 IU/1, baseline; 2.86 ± 0.35 IU/1, day 1
in the azoospermic group and 3.19 ± 0.24 IU/1, baseline; 2.96 ± 0.28 IU/1, day 1 in
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Figure 3.8
Effect of testosterone treatment on plasma SHBG concentration
in those men becoming azoospermic and those remaining
oligozoospermic.
Open columns, baseline.
Hatched columns, after 16 weeks testosterone treatment.
* p<0.01 vs baseline
** pcO.OOl vs baseline.
Mean ± sem, n=18, azoospermic group
n=15, oligozoospermic group.
Days after 1 st injection
Figure 3.9
Plasma concentration of LH following injection of 200 mg
testosterone oenanthate in those men becoming azoospermic
and those remaining oligozoospermic.
B1 and B2 are baseline samples, B2 being taken at the time of
the first injection of testosterone.
Open symbols, Azoospermic group, n=18
Filled symbols, Oligozoospermicgroup, n=15
Note non-linear abscissa
Mean ± sem.
o*j —i 1 1 1 1 1 1 1
B1 B2 1 2 4 7 14 28 56 84
Days after 1 st injection
Figure 3.10
Plasma concentration of FSH following injection of 200 mg
testosterone oenanthate in those men becoming azoospermic
and those remaining oligozoospermic.
B1 and B2 are baseline samples, B2 being taken at the time of
the first injection of testosterone.
Note non-linear abscissa
Open symbols, Azoospermic group n=18
Filled symbols, Oligozoospermicgroup n=15
Mean ± sem.
Figure 3.11
Decline in plasma concentration of LH (open symbols)
and FSH (filled symbols) following injection of 200 mg
testosterone oenanthate.
Data are means of results of all subjects, expressed as
percentage of baseline concentration.
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inhibited in both groups (2.08 ± 0.21 IU/1 in the azoospermic group, and 2.09 ± 0.22
IU/1 in the oligozoospermic group, p<0.01 in both groups).
Figures 3.9 and 3.10 show that plasma concentrations of both gonadotrophins
declined rapidly to the limit of detection in both groups, with no significant differences
between groups at any of the time points investigated. None of the azoospermic group
and only one of the oligozoospermic group had detectable immunoreactive FSH after
12 weeks of TE treatment (the FSH concentration in that subject was 0.3 IU/1).
Immunoreactive LH was not detectable in any subjects after 12 weeks of TE treatment
To investigate the rate of decline of secretion of the gonadotrophins, results were
recalculated as percentages of baseline concentration for each man over the week
following the first injection. By 14 days concentrations were less than 10% of
baseline. The means of these results, for all subjects, are shown in Figure 3.11, with
computer-fitted logarithmic curves. Correlation coefficients were 0.99 for both
gonadotrophins. Substitution into the formulae for the curves allows calculation of the
apparent half-lives of the gonadotrophins: values of 50.0 hrs for LH and 78.2 hrs for
FSH were obtained.
3.4 Discussion.
The results presented here show the changes in plasma concentrations of testosterone
following injection of 200mg of testosterone oenanthate in normal men, and the
accompanying changes in free and non-SHBG bound testosterone. This profile was
determined at the time of the first injection, and repeated after 16 weeks of treatment.
The main purpose of these experiments was to investigate whether the maintenance of
spermatogenesis in some men under these conditions of supraphysiological
concentrations of testosterone could be explained by differences in pharmacokinetics or
pharmacodynamics of the administered testosterone.
The administration of testosterone caused a rapid increase in the plasma
concentration of testosterone, with concentrations after 24 hours which were 3 fold
higher than pre-injection levels (Figure 3.2). The plasma concentration then fell over
the following 6 days, and had returned to near baseline at the time of the second
injection. This trough concentration of testosterone was measured at intervals over the
following 16 weeks, demonstrating a rise in trough concentration up to 8 weeks of
treatment, with steady state achieved thereafter (Table 3.1). This indicates a degree of
accumulation of testosterone over that period.
The profile of testosterone following injection after 16 weeks of treatment showed a
similar pattern to that after the first injection (Figure 3.2). At no time point studied
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were there differences between the azoospermic group and those men remaining
oligozoospermic, either in measured concentration or calculated pharmacokinetic
parameters.
The pharmacokinetic analysis shown in Table 3.2 demonstrates that the peak
testosterone concentration achieved following the injection of 200 mg testosterone
oenanthate was 55-64 nmol/1 following the first injection, and 74-78 nmol/1 after 16
weeks of testosterone treatment. The terminal half-life was 145-177 hrs. These results
are similar to those reported by Behre et al. (1990), who investigated the
pharmacokinetics of repeated administration of 250 mg testosterone oenanthate in
hypogonadal men.
Plasma free testosterone was measured by ultrafiltration, and pre-treatment
concentrations of 200 - 300 nmol/1, i.e. approximately 2% of total testosterone, were
obtained. This is in good agreement with previous reports. Other methods for the
determination of free testosterone, and indeed of other hormones which are
predominantly bound to plasma proteins (for example thyroxine as well as other
steroids), have major drawbacks, including the need for a large volume of sample,
dilution effects, and prolonged time course for the determination (Hammond, Nisker,
Jones and Siiteri, 1980; Ekins, 1990). Centrifugal ultrafiltration was developed by
Hammond et al. (1980), using a dialysis membrane across which the free steroid
equilibrates, but that method involved the use of a second isotope ([14C]glucose) with
subsequent calculation of the [3H] testosterone / [14C]glucose ratio as the glucose will
equilibrate across the membrane unimpeded, acting as a marker for the movement of the
labelled steroid. This method was refined following the development of protein-
retaining membranes such as that used here, which allowed a rapid determination to be
carried out at physiological temperatures without dilution of the sample (and thus
disturbance of binding equilibriums), although both methods give very similar results
(Green and Yucis, 1982; Vlahos, MacMahon, Sgoutas, Bowers, Thompson and
Trawick, 1982). This method is currently thought to provide the best available
approximation to the physiological concentration of the free steroid (Ekins, 1990).
There is general agreement as to the methodology to determine the concentration of
non-SHBG bound testosterone, the ammonium sulphate method used here was
developed by O'Connor et al. (1973), who found that after precipitation of plasma
proteins with 50% ammonium sulphate, albumin was the only protein remaining in
solution. The addition of tracer concentrations of [3H]testosterone to plasma in both
methods gives a result as a percentage of total testosterone present in the sample: direct
assay of total testosterone by RIA in the original plasma sample then allows the
calculation of the plasma concentration of free and non-SHBG bound testosterone. It is
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also possible to measure testosterone in the ultrafiltrate by RIA, thus avoiding the use
of a radiolabeled tracer, but the small volume of ultrafiltrate obtained and the low
concentration of testosterone present requires an assay of increased sensitivity to that
normally used for the measurement of total testosterone in plasma.
The use of these methods in this study has allowed the description of the
pharmacokinetic profile of plasma bioavailable testosterone following the administration
of testosterone in normal men. Comparison with the profiles obtained for total plasma
testosterone shows that the rises in free and non-SHBG bound testosterone were
greater than those of total testosterone, with concentrations approximately 5 fold higher
than baseline 24 hours after the first injection (Figures 3.3 and 3.4). This compares to
3 fold rises in total testosterone. This difference is more marked after 16 weeks of
treatment: trough concentrations of total testosterone were approximately double
baseline values, but concentrations of free and non-SHBG bound testosterone were
nearly 5 times those at baseline (and similar to those found 24 hours after the first
injection), and there was a further doubling 24 hours after injection. At that time
concentrations were therefore approximately 10 times those at baseline.
Therefore measurement of total testosterone alone considerably underestimates
changes in plasma concentrations of bioactive testosterone under the conditions of these
studies, and thus the increase in androgen load and stimulus to the tissues. This applies
to both free and non-SHBG bound testosterone as these two parameters showed very
similar changes.
The changes in plasma concentrations of free and non-SHBG bound testosterone
expressed as a percentage of total testosterone (Figures 3.5 and 3.6) differ from when
expressed as true concentrations, in that both the percentage free and non-SHBG bound
testosterone on day 7 following the 1st injection are significantly greater than at baseline
in both groups. One explanation for this discrepancy is that the results when expressed
as concentrations depend on the values obtained from two different assays, i.e. the total
testosterone RIA and the free or non-SHBG bound testosterone assay. Both of the
latter two give results as percentages, and thus conversion to concentrations will
compound assay variability. Indeed, inspection of the results illustrated in Figures 3.3
and 3.4 show that free and non-SHBG bound testosterone concentrations are higher on
day 7, but that this only reached statistical significance in the oligozoospermic group
free testosterone results. These results therefore show that there are increases in
bioavailable testosterone at a time when total plasma testosterone concentration is
similar to baseline, and may be a result of the rapid fall in SHBG concentration
following testosterone administration, which is maximal at 7 days (Hampl, Stdrka,
Lachman, Snajdrovd and Kalvachovd, 1992).
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At no point were differences found in plasma concentration of free or non-SHBG
bound testosterone between men becoming azoospermic and those remaining
oligozoospermic, in support of the finding that there were no differences in total
testosterone between the two groups. Further confirmation of this result was provided
by the direct measurement of SHBG in plasma. These results also confirmed the
findings of previous studies that androgen administration causes a fall in plasma
concentrations of SHBG (Plymate et al., 1983), but the SHBG concentrations of the
two groups of men were similar both at baseline and after 16 weeks of testosterone
treatment (Figure 3.7). It therefore appears that these two groups of men do not differ
in the pharmacokinetics or pharmacodynamics of administered testosterone, and that the
maintenance of spermatogenesis in some men cannot be explained by a higher
concentration of bioavailable testosterone.
The demonstration that the administration of this dose of testosterone causes a 5
fold elevation in trough concentrations and 10 fold elevation in peak concentrations of
bioavailable testosterone is of interest in the light of the finding by Morse et al. (1973)
that a similar dose of testosterone propionate caused a fall in intratesticular testosterone
concentrations to only double that found in plasma, which was itself approximately
double the physiological concentration. If the determination of intratesticular
concentration of testosterone in that study is accurate, it suggests that the magnitude of
the increase in bioavailable testosterone found here may be sufficient to influence the
intratesticular environment.
Testosterone is converted to oestradiol by the enzyme aromatase (Longcope et al.,
1969). The results in Figure 3.7 illustrate the time-course of changes in plasma
oestradiol concentration following injection of TE, and show that the changes in plasma
oestradiol concentration closely parallel those of testosterone. Thus there was a rapid
rise in plasma concentration of oestradiol following TE injection, and an accumulation
of oestradiol following repeated administration. There were no differences in plasma
oestradiol concentration between men becoming azoospermic and those remaining
oligozoospermic at any time-point investigated. This suggests that there is no
constitutive difference in aromatase activity between the two groups of men which
might underlie the maintenance of spermatogenesis in those remaining
oligozoospermic.
The evidence that FSH is involved in the maintenance of spermatogenesis was
discussed in Chapter 1: although it appears that FSH is required for initiation and
quantitative maintenance of spermatogenesis in primates and man, the absolute
requirement of FSH for spermatogenesis to proceed after puberty is uncertain. The
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results presented here show a rapid fall in the secretion of both LH and FSH to
undetectable concentrations in the first 4 weeks of testosterone treatment, with similar
rates of inhibition in men becoming azoospermic and those remaining oligozoospermic
(Figures 3.9 and 3.10). This contrasts with the dramatic discrepancy in rate of
inhibition of spermatogenesis between the two groups (Figure 2.2). There therefore
appears to be no evidence for a difference in the sensitivity of the hypothalamo-pituitary
axis to steroid negative feedback between the two groups ofmen which could underlie
the maintenance of spermatogenesis in the oligozoospermic group. Furthermore, these
results suggest that the greater incidence of azoospermia reported when a GnRH
antagonist was used to inhibit gonadotrophin secretion (Pavlou et al., 1991) is not the
result of the more rapid rate of decline of gonadotrophin secretion under those
conditions. The sensitivity of the assay method used in the present studies also allows
greater confidence that suppression of gonadotrophin secretion was complete.
A bioassay has not been used in these studies to further validate this finding.
Although in some situations changes in immunoactive FSH have been found without
concomitant changes in bioactive FSH, and vice versa, these changes in ratio have been
relatively slight (Urban et al., 1991; Beitins and Padmanabhan, 1991). The extreme
sensitivity of the immunoassay used here (0.06 IU/1) would require inordinate
dissociation of immuno-active from bioactive FSH, and it is therefore highly unlikely
that there is persistent FSH bioactivity during testosterone treatment in this study. This
is supported by the finding that 19-nortestosterone administration suppressed the
secretion of both immunoactive and bioactive FSH to below the limit of detection
(Jockenhovel et al., 1990).
The plasma concentration of LH was significantly reduced 24 hours after the first
injection of testosterone, whereas FSH was not significantly reduced until 48 hours
post-injection. Several factors will be of importance in determining the plasma
concentration of both gonadotrophins after administration of testosterone, in particular
the clearance rates of the gonadotrophins and continuing secretion. LH is cleared from
the circulation faster than FSH (Yen, Llerena, Little and Pearson, 1968; Yen, Llerena,
Pearson and Little, 1970; Santen and Bardin, 1973; Urban et al., 1988; 1991), but the
apparent half-lives calculated from the data here (50 hrs for LH and 78 hrs for FSH,
Figure 3.11) are much greater than those in the literature derived from the injection of
the hormone or following hypophysectomy. It therefore appears that there is
continuing secretion of both gonadotrophins from the pituitary after the injection of the
first dose of testosterone. The calculated apparent half life of FSH was longer than that
of LH, but the shape of the decline in FSH secretion was very similar to that of LH,
with the major difference being the delay before a decline in secretion is detected. If
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clearance of the gonadotrophins was the major determinant of the decline seen here, the
curve for FSH would be much flatter that that for LH: this is not seen, suggesting that
suppression of secretion is the major factor. Alternatively, a combination of the two
factors, i.e. greater secretion of LH compensating for its more rapid clearance, could
result in similarly shaped curves. This interpretation, however, is at variance with
observations on the greater sensitivity of LH than FSH to androgen feedback (Urban et
al., 1991), thus suggesting that continuing secretion is the more likely explanation. A
further factor is the effect of steroids on the rate of clearance of the gonadotrophins. A
decrease in FSH half-life during oestradiol infusion has been suggested based on
deconvolutional analysis (Urban et al., 1991).
In conclusion, these results demonstrate that there are no differences in total or
bioavailable testosterone concentration in plasma between men becoming azoospermic
and those remaining oligozoospermic on supraphysiological doses of testosterone, nor
is there a difference in hypothalamo-pituitary sensitivity to negative feedback inhibition
of gonadotrophin secretion. These results also confirm that androgen administration
causes a decrease in plasma SHBG concentration, and support the finding that the
clearance of FSH is slower than that of LH. The maintenance of spermatogenesis in
the group of men remaining oligozoospermic is therefore not due to a greater plasma
testosterone concentration stimulating spermatogenesis directly nor to continuing
gonadotrophin secretion, and in the subsequent Chapters of this Thesis the possibility
of increased 5aR activity resulting in an amplification of the androgen stimulus in men
remaining oligozoospermic is investigated.
Chapter 4
The Metabolic Clearance Rate of Testosterone, and the
Conversion Rate of Testosterone to Dihydrotestosterone
4.1 Introduction.
The steady state plasma concentration of steroids, as with all other biological
molecules, is determined by the balance between the rate of synthesis and secretion and
that of metabolism. Thus changes in the rate of metabolism are as important as changes
in synthesis in determining the plasma concentration of the steroid. A difference in rate
of metabolism might account for the difference between men becoming azoospermic
and those remaining oligozoospermic, and this hypothesis has been investigated here.
There are several possibilities for the metabolism of testosterone: as described in
Chapter 1, it can be reduced to DHT, or aromatised to oestradiol. These reactions
however constitute only a very small fraction of the metabolism of testosterone, and the
great majority is rapidly cleared from the blood by the liver. As a result, it has a half
life of only 12 minutes.
The metabolic clearance rate (MCR) of a substance is that volume of blood from
which the substance is completely and irreversibly removed per unit of time (Tait,
1963), and is expressed in units of litres per day. This can be determined by two
methods: in one, a bolus of radiolabelled hormone in tracer quantities is injected, and its
elimination is followed by multiple blood sampling thereafter. This allows the
calculation of the various exponentials representing the compartments in which the
hormone is distributed. The second method involves the constant infusion of the tracer
until a steady state is reached, at which time comparison of the rate of infusion and the
steady state concentration of the tracer allows calculation of the MCR (Baird et al.,
1969; Horton 1978). These techniques were of particular importance before the
development of assay methods able to quantify the nanogram quantities of steroids in
biological fluids, but still have not been superceded as methods to determine MCR
values.
In the previous Chapter it was demonstrated that the plasma concentrations of total
and bioavailable testosterone (as both free and non-SHBG bound fractions) do not
differ between the groups of men becoming azoospermic and those remaining
oligozoospermic as a result of supraphysiological concentrations of testosterone. Nor
was there a difference between the two groups of men in the plasma concentration of
SHBG either before or after 16 weeks of treatment, although a fall in SHBG
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concentration was seen with testosterone treatment in both groups. In the present
experimental protocol, the exogenous administration of testosterone replaces
endogenous synthesis, but the effect of this on the MCR of testosterone (MCRT) in
normal men is unknown. MCRT was therefore determined before and after 16 weeks
of testosterone treatment, and both the effect of prolonged supraphysiological
concentrations of testosterone and differences between the two groups of men were
investigated.
The conversion rate of testosterone to DHT (CRT"DHT) is the most direct measure
of in vivo 5aR activity, and can be determined using the same methodology as that
used for the measurement ofMCRT. It has thus been demonstrated that conversion of
testosterone accounts for at least 70% of plasma DHT in the male (Ito and Horton,
1971; Mahoudeau, Bardin and Lipsett, 1971). The conversion of testosterone to DHT
is reduced in men with 5aR deficiency (Peterson et al., 1977), and occurs exclusively
in the extrasplanchnic circulation (Ishimaru et al., 1978). In the experiments described
in this Chapter, CRT~DHT was determined and compared between men becoming
azoospermic and those remaining oligozoospermic on supraphysiological doses of
testosterone, both before treatment was started and after 16 weeks of treatment
4.2 Materials and methods.
4.2.1 [3H]Testosterone infusion.
[^HjTestosterone ([l,2,6,7-3H]testosterone, 70 pCi/mmol, Amersham), was purified
as described in Chapter 3. 90(iCi was dried down, redissolved in 4ml ethanol, and
made up to 50 ml with sterile normal saline in a 50ml silanised glass syringe. A 20
gauge iv cannula (Venlon, Viggio, Sweden) was inserted into a forearm vein, and a 10
ml blood sample taken. The cannula was then connected to the syringe using
polyolefin-coated tubing (106 cm length, 270|il volume; MiniMed Technologies,
Sylmar, California): this is designed to minimise adsorption of drugs to the wall of the
tubing. A Harvard infusion pump was used, previously calibrated to deliver 20 ml per
hour when connected to the syringes and tubing used.
At time zero, 10ml was injected as a bolus, and the infusion was started after 30
min. Subjects remained semiprone during the infusion, and were given light
refreshments. Blood was collected from the contralateral antecubital fossa at 150 min,
and the infusion stopped. Plasma was separated and stored at -20°C. Radioactivity in
duplicate 50fil aliquots of infusate was determined by LSC to allow calculation of total
infused [^H], In preliminary experiments, plasma was taken at time 120 min and
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extracted as below to establish that these conditions were sufficient to allow equilibrium
of the infused [^H] testosterone.
4.2.2 Extraction, separation and quantification.
Plasma (5 ml) was extracted with 5 volumes of diethyl ether (AnalaR, BDH) for 7 min
by continuous vortexing, and the organic phase decanted after freezing the aqueous
layer in methylated spirits / solid C02- After drying down, the residue was redissolved
in 50pl of 50% acetonitrile containing 100 ng/ml testosterone and 1 mg/ml DHT, and
injected onto a high performance liquid chromatography (HPLC) column (5 ODS-2,
Spherisorb) using a 20|il injection loop and controlled by a BioRad HPLC-
minicomputor interface. The column was eluted with isocratic 50% aqueous
acetonitrile at lml/min. 1 min fractions were collected, and the radioactivity determined
by LSC with lOmin counting as described in Chapter 2. UV absorption at a
wavelength of 254 nM was also recorded to monitor the elution of the unlabelled
standards.
Recovery was determined by the addition of 2500cpm of [4-i4C] testosterone
(Amersham, 50 mCi/mmol) and 1500cpm of [4-i4C]DHT (New England Nuclear, 50
mCi/mmol) to the tubes in which the extraction was carried out. These tracers were
dried down, and plasma was equilibrated in the tubes for 20 min before extraction.
[14C] in the HPLC fractions was then used to calculate recovery (45-60%).
Results were calculated from the LSC results using the formulae:
[3H] testosterone / day infused
[%] testosterone/1 plasma
/-inT-DHT [H]DHT /1 plasma x 100CR = r
PH] testosterone /1 plasma
where MCRT represents the metabolic clearance rate of testosterone, and CRT~DHT
represents the conversion rate of testosterone to DHT. This convention is also used
below to describe the conversion ratio of precursor to product of other steroids.
4.2.3 Thin layer chromatography.
To compare the results obtained with the HPLC method described above with those
obtainable by thin layer chromatography (TLC), the methodology used widely in the
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past for separation of steroids, some samples were randomly selected for reanalysis by
this method.
Samples were extracted as above, including the addition of [14C]labelled tracers.
The extracts were then redissolved in 100|il diethyl ether, and spotted onto silicagel 60
TLC plates (Merck Ltd). The plates were then run in chloroform:diethyl ether (95:5),
dried, and cut into areas after visualisation of standards run in parallel by UV
absorption (testosterone and androstenedione) or after spraying with 10% sulphuric
acid in methanol and heating (DHT and androstanediol). Radioactivity was determined
by LSC, and results calculated as above.
4.2.4 Statistical analysis.
All results in this Chapter were analysed using Student's t test, on paired and unpaired
results as appropriate.
4.3 Results.
Steroids in low concentration can be absorbed to plastic and glass, and therefore the
infusion system used silanised glassware, tubing coated with polyolefin and teflon-
coated intravenous tubing. The tubing used has a coating designed to minimise
absorption of drugs. That dose of radioactivity actually being infused into the subject
was confirmed by comparing the radioactivity in a sample of infusate with that in the
syringe, samples being taken from the syringe before the infusion was started and at the
end. This data was obtained from trial experiments carried out before any infusions
into the subjects were carried out. The radioactivity in the syringe after 2 hours was
96.6 ± 1.1% of that in the syringe at the beginning of the experiment, and that in fluid
from the end of the tubing was 98.1 ± 1.4% of that in the syringe initially, and 100.5 ±
2.3% after 2 hours (mean ± sem of 8 determinations). There were no significant
differences between the amounts of radioactivity in the syringe and tubing at the
beginning of the experiment and in either the syringe or in the tubing after 2 hours, and
there was therefore no evidence for any significant absorption of [3H] testosterone by
either syringe or tubing.
The HPLC system used was similar to that used by Bonsall, Rees and Michael
(1989) to investigate the metabolism of [3H] testosterone in monkey brain after injection
of the radioisotope. The retention times of testosterone and dihydrotestosterone were
8.6 and 15.8 minutes respectively, demonstrating good separation. Other steroids
tested were oestradiol (retention time 7.5 min), androstenedione (10.8 min) and
androstanediol ( 11.8 min). An example of the HPLC profiles of the [3H]testosterone
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and of the [14C] labelled standards is shown in Figure 4.1, to illustrate the degree of
separation obtained.
MCRt was calculated as described in Methods, and the results are shown in Figure
4.2. At baseline, MCRT in the azoospermic group was 1120 ± 60 1/day, and 1020 ±
90 1/day in the oligozoospermic group. After 16 weeks of testosterone treatment,
MCRt had significantly increased to 1300 ± 100 1/day in the azoospermic group
(p<0.02), and to 1280 ± 100 1/day in the oligozoospermic group (p<0.02). In 5 men
blood samples were taken at 100 minutes (ie after 70 minutes of infusion) to establish
that equilibrium conditions had been reached. In this group MCRT was 1120 ± 120
1/day at 120 minutes, and 1090 ±160 1/day after 150 minutes, ie at the end of the
infusion.
The blood production rate (Pb) of testosterone is shown in Figure 4.3, calculated
using values for plasma testosterone concentration taken from Chapter 3. Before
treatment, Pb was 6.6 ±0.3 mg/day in the azoospermic group, and 6.9 ± 0.6 mg/day in
the oligozoospermic group. These values were not significantly different. During
testosterone treatment, production of endogenous testosterone is assumed to be greatly
reduced secondary to inhibition of LH secretion (as shown in Chapter 3), and the
plasma concentration of testosterone reflects absorption of the administered dose. The
value for Pb calculated is therefore an "apparent" rather than a real value. Figure 4.3
shows that apparent Pb increased in both groups of men, to 13.5 ±0.7 mg/day in the
azoospermic group and to 13.7 ± 0.9 mg/day in the oligozoospermic group (p<0.001
for both groups). Data from Chapter 3 was used to calculate the mean plasma
concentration of testosterone over a week, by extrapolation between the data points
shown in Figure 3.2 and this value was then used to recalculate mean Pb over a week.
By this method, mean plasma testosterone concentrations were 49.5 ± 3.4 nmol/1 in the
azoospermic group and 55.2 ± 4.0 nmol/1 in the oligozoospermic group. Calculation of
average Pb thus gives a result of 17.6 ±1.2 mg/day in the azoospermic group and of
20.9 ± 2.5 mg/day in the oligozoospermic group (values not significantly different),
compared to the administered dose of 140mg/week of free unesterified testosterone,
equivalent to 20 mg/day.
Results of the determination of CRT~DHT are shown in Figure 4.4. CRT"DHT was
3.39 ± 0.20% in the azoospermic group and 3.18 ± 0.25% in the oligozoospermic
group pretreatment. After 16 weeks of testosterone treatment, CRT~DHT in the
azoospermic group was unchanged (3.12 ± 0.25%), but in the oligozoospermic group
CrT-DHT was increased to 4.00 ± 0.35% (p<0.05). CRT~DHT of the oligozoospermic


















(a) HPLC profile of purified [ H]testosterone used for
infusion.
(b) HPLC profile of [14C] testosterone and [ C]DHT




Effect of testosterone on MCR in those men who
became azoospermic and those remaining
oligozoospermic.
Open columns, baseline
Hatched columns, after 16 weeks testosterone
treatment.
* p<0.05 vs baseline in both cases.



















Blood production rate of testosterone at baseline in
those men who became azoospermic and those who
remained oligozoospermic.




The effect of testosterone administration on CR
in men becoming azoospermic and those remaining
oligozoospermic.
Open columns, baseline.
Hatched columns, after 16 weeks of testosterone
treatment.
* p<0.05 vs baseline
Mean ± sem, n=18, azoospermic group
n=15, oligozoospermic group.
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To validate the method further, 5 samples were analysed by TLC using the method
ofMowszowicz and Bardin (1977) to estimate MCRT and CRT"DHT , and in addition
the conversion of testosterone to androstenedione and androstanediol. The steroids
were well separated, with Rf values of 0.18 for androstanediol, 0.28 for testosterone,
0.34 for DHT, and 0.49 for androstenedione. Thus testosterone and DHT were not as
well separated as by HPLC. This method gave values for MCRT of 1240 ± 901/day,
compared to 1050 ± 90 1/day for the same samples by HPLC. CRT"DHT was 4.80 ±
0.38% by TLC, and 4.20 ± 0.56% by HPLC. In both cases the values obtained by
TLC were not significantly different from those obtained by HPLC.
CRT"Androstenedione was 5 4 + 12%, and CRT"Androstanedio1 was 1.9 ± 0.4% in these
samples.
4.4 Discussion.
The metabolic clearance rate of steroids is determined by one of two methods. The
most widely used, and that used here, is the constant infusion method in which a
constant intravenous infusion of the radiolabeled steroid is given (sometimes after an
initial loading dose to reduce the duration of infusion required) until a steady state is
reached. The second is the bolus method, in which a single bolus of labelled steroid is
given, and the amount remaining in the blood at times thereafter is determined (Baird et
al„ 1969; Horton, 1978).
The principle of the infusion method is that the infused steroid is in tracer quantity,
and therefore equilibrates with the endogenous steroid in the circulation. It is then
metabolised at the same rate as the endogenous steroid, and comparison of the quantity
of steroid infused with that measured in the blood after equilibrium is reached allows
calculation of MCR. This method does not distinguish between hepatic and extra-
hepatic metabolism: these components can be separated by determining the gradient of
steroid across the splanchnic circulation but this requires invasive methodology,
including the catheterisation of the central veins, and cannot therefore be performed on
healthy volunteers whereas the standard method requires only peripheral venous
access.
Two further values can be determined from these experiments: the conversion ratio
(CR) of the infused steroid (ie the precursor) to a metabolite, and the blood production
rate (Pb)- CR is usually expressed as a percentage of radioactivity converted from the
precursor to the metabolite, and Pb is the product of the MCR and the plasma
concentration of the steroid, giving the production in mg/day.
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The values for MCRT obtained from plasma samples taken at 120 min were similar
to those at 150 min. This suggests that the infusion had reached equilibrium, an
essential prerequisite for the validity of the method (Baird et al., 1969). The results for
MCRt are similar to those reported in the literature (Lipsett , Wilson, Kirschner,
Korenman, Fischman, Sarfaty and Bardin, 1966; Southren, Gordon, Tochimoto,
Pinzon, Lane and Stypulkowski, 1967; Ito and Horton, 1971). These results were
further validated by comparison to those obtained using TLC. The retention times of
androstenedione and androstanediol under these conditions for HPLC were 10.8 and
11.4 min respectively. Thus, with the 1 min fractions collected in these experiments,
androstenedione and androstanediol were not sufficiently clearly separated from
testosterone to allow CRT~Androstenedione and CRT~Androstanedio1 to be accurately
determined. Determinations of CRT~Androstenedione and CRT"Androstanedio1 were
obtained in a few experiments by TLC, and the results (5.4% and 1.9% respectively)
were in good agreement with those previously reported (3.4% for CRT"Androstenedione,
and 1.3% for CRT~Androstanedio1 ; Longcope et al., 1969; Mahoudeau et al., 1971)
This suggests that any error in the calculation ofMCRT from incorporation of the other
androgens would be very small.
Testosterone administration increased MCRT by approximately 20% (Figure 4.2).
Testosterone has been previously reported to increase MCRT in women (Southren et
al.. 1967), but this effect has not been previously reported in normal men. MCRT is
thought to be dependent on the non-SHBG bound testosterone in the blood. Thus
MCRt is decreased in conditions such as thyrotoxicosis and hepatic cirrhosis when the
plasma concentration of SHBG is increased (Gordon et al., 1969; Baker, Burger, de
Kretser, Dulmanis, Hudson, O'Connor, Paulson, Purcell and Seah, 1976), and
increased in obesity, in which SHBG is reduced (Kirschner, Samojlik and Silber,
1983). Under the conditions of this study, plasma testosterone concentrations were
increased, but the non-SHBG bound testosterone was increased by a greater amount as
a result of the reduction in SHBG (Chapter 3). The increase in MCRT was similar to
the fall in SHBG (approximately 30%), in contrast to the rise in total testosterone of
approximately 100% and of 400% in free and non-SHBG bound testosterone, which
supports the hypothesis that MCRT is determined largely by the concentration of
SHBG (Vermuelen, Verdonck, van der Straeten and Orie, 1969).
There were no differences in MCRT between the azoospermic and oligozoospermic
groups, before or during testosterone administration. This result, together with the
results presented in Chapter 3 of the measurement of concentrations of free and non-
SHBG bound testosterone and of SHBG itself, suggest that the basis of the differences
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between these two groups is not in the pharmacokinetics or pharmacodynamics of
testosterone.
Calculation of values for Pb (Figure 4.3) confirmed that 6-7 mg of testosterone is
produced by the adult male per day (Horton 1978). There was no difference between
the azoospermic and oligozoospermic groups. During testosterone administration,
endogenous production of testosterone is reduced, and absorption from the site of
injection replaces it. A value for "apparent" Pg can be calculated, representing this.
The results shown in Figure 4.3 show that apparent Pb is increased to 13.5 ± 0.7
mg/day in the azoospermic group, and to 13.7 ± 0.9 mg/day in the oligozoospermic
group. Over one week the apparent production of testosterone is therefore
approximately 50 mg, compared to 140 mg of free testosterone administered. Pb,
however, is dependent on the concentration of testosterone for its calculation, and the
infusion experiments were carried out 7 days after the last testosterone injection had
been given, when the next was due. The concentration of circulating testosterone was
therefore at its nadir, and the data in Chapter 3 show that at this time plasma
testosterone concentrations are approximately half those found on the two days
following injection. If it is assumed that MCRT does not vary over the week (which
may not be the case as the concentration of testosterone varies so greatly), then Pb can
be recalculated using the values for plasma testosterone shown in Chapter 3 with
extrapolation between the data points to give mean values for plasma testosterone.
Calculation of average Pb by this method gives a result of 17.6 ± 1.2 mg/day in the
azoospermic group and of 20.9 ± 2.5 mg/day in the oligozoospermic group. The
apparent production per week is therefore approximately 123 mg in the azoospermic
group, and 146 mg in the oligozoospermic group, in much closer agreement to the
administered dose of 140 mg. These results do not allow any speculation as to whether
there is any continuing secretion of testosterone under these experimental conditions,
despite the good agreement between calculated apparent Pb and known administered
dose, particularly as it is not known whether MCRT varies as the plasma concentration
of testosterone varies but do support the contention that endogenous secretion of
testosterone is greatly suppressed.
CRT-DHT was 3.39% jn the azoospermic group and 3.18% in the oligozoospermic
group at baseline, values which were not significantly different (Figure 4.4). Values
obtained by HPLC were similar to those obtained by TLC in a trial experiment, and are
similar to those previously reported (Ito and Horton 1971; Saez , Forest, Morera and
Bertrand, 1972; Horton, 1978). This is a measure of the peripheral conversion of
testosterone to DHT, as this is not thought to occur in the splanchnic circulation despite
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the presence of the enzyme 5aR in the liver (Ishimaru et al., 1978). It only measures
the conversion of testosterone to DHT which is then released back into the circulation,
and does not reflect any further metabolism of DHT at the site of action, for example
conversion to androstanediol or glucuronidation (Moghissi, Ablan and Horton, 1984).
If further metabolism at the site of action is important, then the value for CRT"DHT as
estimated by this method will give an underestimate of the true 5aR activity of the
body. Despite the direct nature of this method, it can therefore only be regarded as an
index of peripheral 5aR activity.
After 16 weeks of testosterone administration, CRT_DHT had increased
significantly in the oligozoospermic group but was unchanged in the azoospermic
group (Figure 4.4). This implies that the activity of 5aR was increased by testosterone
treatment in the oligozoospermic group but not in the azoospermic group. This
increased activity would tend to increase tissue concentrations ofDHT and thus amplify
the androgen stimulus. In the skin, it has been shown that 5aR activity is androgen
dependent: this has been demonstrated in vivo (Mauvais-Jarvis, Bercovici, Crepy and
Gauthier, 1970; Kuttenn, Mowszowicz and Mauvais-Jarvis, 1980), and in vitro
(Kuttenn and Mauvais-Jarvis, 1975; Mowszowicz, Melanitou, Kirchhoffer and
Mauvais-Jarvis, 1983), and individuals with androgen insensitivity have a secondary
deficiency of 5aR (Kuttenn et al., 1979; Imperato-McGinley et al., 1982). Thus men
remaining oligozoospermic may have a greater androgen stimulus at the level of the
tissues than those becoming azoospermic, without any differences in plasma
testosterone, as was shown in Chapter 3. The finding that the two groups of men had
the same CRT~DHT in the pretreatment experiments implies that under normal
physiological conditions, peripheral 5aR activity is similar in the two groups, and thus
any screening method to try to identify which men would become azoospermic and
which would remain oligozoospermic would fail to distinguish between them.
In conclusion, the results presented so far demonstrate that there is no difference in the
pharmacokinetics or pharmacodynamics of testosterone in these two groups of men.
There is, however, evidence that the conversion of testosterone to the more potent
androgen DHT is increased in the men remaining oligozoospermic, reflecting enhanced
activity of the enzyme 5aR in that group. In the next Chapter, plasma concentrations




Dihydrotestosterone and Androstanediol Glucuronide
5.1 Introduction.
In this Chapter androgen metabolism in acne and hirsutism, the common disorders
involving the pilosebaceous unit (PSU), will be reviewed, as the study of these
conditions has provided the majority of our knowledge of the metabolism of androgens
in the skin. The skin is the largest androgen-dependent organ in the body, and the
object of this discussion is to determine which androgens in plasma most accurately
reflect the concentration of 5aR activity in the PSU and would therefore be most
appropriate index to investigate possible differences in peripheral androgen metabolism
in men receiving supraphysiological doses of testosterone. While the prostate is also an
important androgen-dependent organ, there is little data availabe regarding the
contribution of prostatic metabolism to plasma androgen concentrations.
Although hirsutism and acne are both conditions of the PSU, they affect different
populations: thus hirsutism is a condition exclusively affecting women, whereas acne
affect both sexes. Although males are more commonly affected, it has been suggested
that if the study is rigorous enough, some degree of acne can be detected in almost all
Caucasians at some point during puberty (Rosenfield, 1986). These sex differences
may therefore introduce discrepancies in comparing the two conditions relating more to
gender rather than to the condition itself. However itwill become apparent that despite
this possible cause for confusion, there is considerable similarity in androgen
metabolism in the two conditions.
5.1.1 Androgen metabolism in hirsutism.
The bulk of the endocrinological literature on androgen metabolism by the skin
concerns hirsutism. Early studies to investigate whether hirsutism was a
hyperandrogenic condition yielded largely negative results. Thus plasma testosterone
concentrations were only mildly elevated, as were urinary androgens (Lloyd,
Lobotsky, Segre, Kobayashi, Taymor and Bath, 1966) and plasma androstenedione
(Kuttenn, Mowszowicz, Schaison and Mauvais-Jarvis, 1977). Androstenedione is the
major source of DHT in women (Ito and Horton, 1971, Mahoudeau et al., 1971) and
this has also been demonstrated in the skin in vitro (Silva, Gentzschein and
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Lobo,1987). Androstenedione is converted to DHT via 5a-androstanedione rather
than testosterone (Stanczyk, Matteri, Kaufman, Gentzschein and Lobo, 1990). The
origin of plasma DHT is therefore different in the two sexes. These minor increases in
circulating concentrations of androgens were more marked in women with polycystic
ovarian syndrome (PCOS), and it is now thought that PCOS is the underlying
condition in over 90% of hirsute women (Kirschner , Zucker and Jespersen, 1976,
Conway and Jacobs, 1990). There was, however, a greater increase in free
testosterone concentration (Rosenfield, 1971), and this population of women have
lower SHBG concentrations (Vermuelen et al., 1969, Cunningham and McKenna,
1988). In all these parameters, however there is considerable overlap with normal non-
hirsute women, and these results therefore suggest that if there is an increased supply
of androgen to the skin, it is relatively minor.
An alternative possibility is that there is an increased utilisation of androgen. In
support of this, an increase in both MCRT (Bardin and Lipsett, 1967) and CRT~DHT
(Mahoudeau et al., 1971) have been reported in hirsute women, as has an increased
plasma concentration of DHT. This slight elevation of plasma DHT (also reported by
Kuttenn et al., 1977) has not been widely confirmed (Lobo, Goebelsmann and
Horton,1983). In vitro studies, however, have demonstrated a dramatic increase in
5aR activity of skin homogenates from hirsute women (Thomas and Oake, 1974;
Kuttenn et al., 1977; Mowszowicz, et al., 1983; Serafini, Ablan and Lobo, 1985), and
there is evidence that the rate of hair growth correlates with plasma androstenedione and
DHT concentrations (Ebling, Randall and Sawers, 1984).
DHT is further metabolised to androstanediol (Adiol), which can be measured in the
urine. Although hirsute women were found to have slightly elevated plasma
concentrations of DHT in some studies but not others, the urinary excretion of Adiol
was greatly increased (Kuttenn et al., 1977), as was the plasma concentration of
androstanediol glucuronide (AdiolG) (Horton, Hawks and Lobo, 1982; Paulson,
Serafini, Catalino and Lobo, 1986). Women with PCOS and hirsutism have been
reported to have markedly elevated concentrations of AdiolG, whereas those with
PCOS but not hirsutism did not (Lobo et al., 1983). Again, others have been unable to
confirm these findings (Scanlon, Whorwood, Franks, Reed and James, 1988), but in
that study there was a very wide variation in AdiolG concentrations in the hirsute
women studied. A comparison of AdiolG concentrations with the plasma
concentrations of androgen precursors in mildly hirsute women found evidence of
increased conversion of precursors to AdiolG, but there was considerable overlap of
AdiolG concentrations with normal controls (Giagulli, Giorgino and Vermuelen,
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1991). Furthermore, clinical cure (following treatment with cyproterone acetate and
ethinyl oestradiol) did not correlate with changes in AdiolG concentration; a reduction
in AdiolG concentration occurred in all women treated, but only half showed a clinical
improvement.
Androsterone glucuronide is also a product of DHT metabolism, and its plasma
concentration is increased in hirsutism (Scanlon,Whorwood, Reed, Franks and James,
1987; Thomson, Horton and Rittmaster, 1990) but has been subject to less
investigation. This metabolite has recently been suggested to be preferentially increased
in women with acne but not hirsutism, in contrast to AdiolG which was elevated in
both conditions (Carmina, Stanczyk, Matteri and Lobo, 1991).
The increased concentrations of these metabolites may reflect both the increased
supply of androstenedione and the increased conversion rate in the tissues. One
possible conclusion that can be drawn from these studies is that the increased local
conversion of precursor androgens to DHT is of major importance in the pathogenesis
of hirsutism. Indeed, the ratio of a/p steroid metabolites in urine, interpreted as
reflecting hepatic 5aR activity, was increased in women with PCOS (Stewart,
Shackleton Beastall and Edwards, 1990), and these authors concluded that increased
5ocR activity in liver and skin is the major underlying abnormality in this condition.
The androgen receptor has not been widely studied in hirsutism, but in one study
no abnormality was detected (Eil, Cutler and Loriaux, 1985).
5.1.2 Androgen metabolism in acne
Similar hormonal processes have been implicated in the development of acne, although
there is less data, and the other pathological factors involved in the aetiology of acne
complicate interpretation. Thus bacterial infection of the blocked duct of the sebaceous
gland is of major importance (Pochi, 1990), in addition to the increased secretion of
sebum (Pochi and Strauss, 1964; Cunliffe and Shuster, 1969).
There are reports of testosterone concentrations being normal or elevated in patients
with acne, and of SHBG being reduced (Marynick, Chakmakjian, McCaffree and
Herndon, 1983; Lawrence, Katz, Robinson, Newman, McGarrigle, Shaw and
Lachelin, 1981). 5aR activity in skin has been shown to be raised (Sansone and
Reisner, 1971, Hay and Hodgkins, 1974), and in facial skin the enzyme is
concentrated in the sebaceous glands (Hay and Hodgkins, 1978). An important study
(Lookingbill, Horton, Demers, Egan, Marks and Santen, 1985) showed that in a group
of young women with mild to moderate acne (only one of whom had any degree of
hirsutism), plasma total and free testosterone and androstenedione were normal, whilst
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plasma DHT was elevated to a mean of double that of controls and plasma AdiolG was
nearly 3 times that of controls. The conclusion drawn was that precursor androgens
were normal, but that "tissue" androgens, the result of local 5a-reduction, were
elevated. In a similar study, the same authors investigated the correlation between
AdiolG and acne and chest hair in men (Lookingbill, Egan, Santen and Demers, 1988),
and found that there were correlations between the serum concentration of the
metabolite and both skin markers. There was also a good correlation between AdiolG
and non-SHBG bound testosterone but not with total testosterone. One important
caveat to the interpretation of these data suggesting that increased 5aR is involved in
the pathophysiology of acne is that the increase in enzyme activity may be because of
proliferation or hyperplasia of the sebaceous glands rather than be causal.
5.1.3 Ethnic differences in clinical and biochemical markers of 5a-
reductase.
Lookingbill's group have more recently investigated differences in androgen
metabolism between Caucasian and Chinese subjects (Lookingbill, Demers, Wang,
Leung, Rittmaster and Santen, 1991). They found that Caucasian men had hairier chests
and more acne than Chinese men, and thus clinical evidence for a greater androgen
stimulus to the PSU. Biochemical studies showed that plasma concentrations of total
and bioavailable (non-SHBG bound) testosterone were the same in the two groups, but
that concentrations of dehydroepiandrosterone sulphate (DHAS) and androstenedione
were higher in Caucasian men. Concentrations of the 5a-reduced androgens AdiolG
and androstenedione glucuronide were, however markedly higher in the Caucasians,
both in men and women, to approximately double the concentrations found in Chinese
subjects. The plasma concentration of DHT was similar in the two groups of men, but
higher in the Caucasian than in the Chinese women. These biochemical results provide
indirect evidence that there is a racial difference in 5aR activity in both sexes, and
provide a possible explanation for the differences in hair growth and the incidence of
acne. It may be said that the higher 5a-reduced androgens in Caucasian than Chinese
men is because of the increased mass of hair follicles, but because 5a-reduced
androgens are also increased in Caucasian women compared to Chinese women despite
similar Ferriman Galway scores (very low in both groups), it is unlikely that the
markedly higher 5a-reduced metabolite concentrations in Caucasian women are due to
a greater mass of hair follicles. This make genetic and ethnic differences in androgen
metabolism more likely. As yet, there are no studies comparing androgen metabolic
clearance rate and CRT~DHT or 5aR activity in skin biopsies in Caucasian versus
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Chinese men, which might provide more direct evidence for a lower activity of this
enzyme in Chinese men and women.
A recent study has investigated serum AdiolG and androsterone glucuronide
concentrations (as indices of 5aR activity) in Japanese men compared to Caucasian and
black US men (Ross, Bernstein, Lobo, Shimizu, Stanczyk, Pike and Henderson,
1992). Concentrations of both 5aR markers were higher in the two US populations,
but there were no differences serum testosterone concentrations. These results were
discussed with respect to the much lower incidence of prostatic carcinoma in Japanese
than American men. However, although the two US groups had similar AdiolG
concentrations, the incidence of prostatic carcinoma is considerably higher in blacks.
These studies are of particular interest to the present investigation, in view of the
striking differences in the incidence of azoospermia between Chinese and Caucasian
men with testosterone treatment (World Health Organisation, 1990), with over 90%
azoospermia being achieved in the Chinese centres in this study, compared to 50-70%
in the Caucasian centres. An incidence of 100% azoospermia has also been reported in
a group of Indonesian men receiving a combination of progestogen and testosterone as
a contraceptive (Pangkahila, 1991).
5.1.4 The skin as a source of circulating androgens
There is therefore a body of evidence showing that there is increased 5aR activity in
both hirsutism and acne, in Caucasians compared to Chinese and Japanese, and that
AdiolG may be a good plasma marker for this. What is the evidence for the skin being
the origin of this metabolite, and that its concentration reflects 5aR activity? This was
first suggested by Mauvais-Jarvis et al. (1970), who found that there was greater
conversion of radiolabeled testosterone to AdiolG when it was applied to the skin
rather than given intravenously. An extrasplanchnic source of AdiolG was supported
by infusion studies in men (Morimoto, Edmiston , Hawks and Horton, 1981; Moghissi
et al., 1984), and the results were compatible with the major pathway of metabolism
being testosterone to DHT to AdiolG, with DHT glucuronide being a possible
intermediate. These studies also revealed that plasma Adiol was derived from a
different pool from its glucuronide (Moghissi et al., 1984). Some 75% of plasma
Adiol is derived from DHT (Kinouchi and Horton, 1974), but the reason for the
apparently different metabolic involvements of Adiol and AdiolG are unknown. There
may also be a contribution by adrenal androgens to AdiolG, as there is a correlation
between plasma DHA and AdiolG concentrations in castrated men (Bdlanger, Brochu
and Cliche, 1986), and AdiolG concentrations rise at adrenarche in boys (Brochu and
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Bdlanger, 1987). Urinary excretion of AdiolG was found to rise to very high levels
after prolonged adrenal stimulation in normal men, and men having undergone
adrenalectomy for Cushing's disease were found to have lower urinary AdiolG
excretion than normal men (Deslypere, Sayed, Punjabi, Verdonck and Vermeulen,
1982). It therefore appears that urinary AdiolG has a combined splanchnic and
extrasplanchnic origin.
Direct production of AdiolG in rat prostate but not liver was reported by Chung and
Coffey (1977), but it was not until 1987 that human skin was shown to be capable of
converting testosterone and DHT to AdiolG (Lobo, Paul, Gentzschein, Serafini,
Catalino, Paulson and Horton, 1987). The rate of conversion was higher in men than
women, paralleling differences in plasma concentrations (Mauvais-Jarvis et al., 1970).
Mauvais-Jarvis et al. (1970) also reported that AdiolG was found in reduced
concentration in the plasma of subjects with testicular feminisation. Similar findings
have been reported in subjects with 5aR deficiency (Horton, Imperato-McGinley and
Peterson, 1984). While the latter result provides further evidence that AdiolG reflects
5aR activity, the former is less easy to explain as the major defect in that condition is
believed to lie with the androgen receptor rather than the enzyme. However the activity
of the enzyme in homogenates of pubic skin from subjects with testicular feminisation
was undetectable, whereas it was normal in genital skin (Northcutt et al., 1969;
Kuttenn et al., 1979). This may reflect the importance of activation of the androgen
receptor in determining the concentration of activity of 5aR (vide supra, Section
1.6.2), with the very low or absent 5aR activity in skin from subjects with testicular
feminisation being a secondary effect
Further evidence for the validity of serum AdiolG as a marker of 5ocR activity in
skin was provided by the demonstration of a very good correlation between the two
using genital skin biopsies (Paulson et al., 1986), in a study of 4 groups of subject:
premenopausal and postmenopausal women, hirsute premenopausal women, and men.
On the basis of these results it has been proposed that in skin, 5aR converts
testosterone to DHT, which is then converted by the enzyme 3a-hydroxysteroid
dehydrogenase to Adiol, an inactive metabolite, which is further conjugated to the polar
compound AdiolG and released into the circulation (Lookingbill et al., 1985). The
circulating concentration of AdiolG therefore appears to be a useful marker of 5aR
activity in peripheral tissues, to which the skin and in particular the PSU may be a
major contributor. Infusion of testosterone into normal men causes a prompt rise in
serum AdiolG concentrations, of a similar magnitude to the rise in testosterone
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concentrations (Reed, Whorwood, Scanlon, Beranek, Poison, Franks and James,
1986).
The importance of the plasma concentration of DHT is less clear. Whilst being the
primary product of 5aR in skin as in other androgen-dependant tissues, the above
discussion demonstrates that elevated plasma concentrations are only demonstrated in
some studies of disorders of the PSU, and the elevations are usually slight when
detected. One possibility is that DHT is rapidly metabolised to Adiol at the site of
action, and indeed plasma concentrations of AdiolG are considerably higher than those
ofDHT and are similar to those of testosterone (Moghissi et al., 1984; Lookingbill et
al., 1991). DHT may therefore be predominantly a local paracrine amplifier of
androgen action. However it is clear that the bulk of plasma DHT derives from
5a-reduction of testosterone in men, and in view of the differences in origin of DHT in
men and women, it is unclear to what extent the studies on androgen metabolism in
women discussed above are relevant to the male. In the current study the plasma
concentrations of both DHT and AdiolG were therefore determined to investigate
whether this would provide further evidence as to whether men remaining
oligozoospermic when administered supraphysiological doses of testosterone have a
higher level of peripheral 5ocR activity than those becoming azoospermia
5.2 Methods.
5.2.1 DHT assay.
The concentration of DHT in plasma was determined by RIA, using [3H]testosterone /
dihydrotestosterone assay system kits supplied by Amersham International pic. The
technique used enables the separate measurement of DHT from testosterone in this
assay by the chemical oxidation of the double bond in testosterone, which causes it to
lose immunoreactivity without affecting DHT. DHT can then be determined, despite
the antibody used showing 50% crossreactivity for DHT compared to testosterone.
Reagents supplied were [3H]DHT ( 5a-dihydro[l,2,4,5,6,7-3H]testosterone),
4|iCi (148kBq) in ethanol; oxidation reagent (KMn04 in water); anti-testosterone
antiserum and charcoal precipitating reagent. Assay buffer consisted of 6.06g AnalaR
Tris, 1.49g AnalaR EDTA, disodium salt, and lg gelatin per litre, pH 8.0.
500(il of plasma made up to 1ml with assay buffer was extracted twice into 3ml of
ether. The extracts were combined and dried under nitrogen, and reconstituted in 1ml
of buffer. 500p.l of water was added, followed by 50|il of oxidation reagent. The
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samples were vortexed and reacted for 20 min., before being extracted twice as before
with 3ml ether. The extracts were dried down, and reconstituted in 1ml assay buffer.
To 200|il duplicate aliquots of sample or standard (range 25-800 pg/tube) 200|il of
[3H]DHT was added, then 200|il of antiserum. Non-specific binding determinations
consisted of 400|il buffer and tracer, and Bo of 200pl of buffer, tracer, and antiserum.
The tubes were vortexed, and incubated at room temperature for 1 hr. 200pl of
charcoal reagent was then added, the tubes vortexed and allowed to stand for 10 min
before being centrifuged at 3000 rpm for 30 min. [3H] in 500|il aliquots of supernatant
was then determined by LSC, and results calculated using the AssayZap. Quality
control samples were included, and recoveries were determined in parallel samples.
Assay sensitivity (lowest standard concentration, corrected for recovery) was
approximately 1.1 nmol/1, when 500fil of sample was extracted. Intraassay CV was
7.5%, interassay CV 9.9%, and mean recovery was 74%. The efficiency of the
oxidation stage was checked in view of the high concentrations of testosterone in the
plasma of the men in this study, and found to be complete in plasma spiked with a
concentration of 100 nmol/1 testosterone.
Recovery was also confirmed by spiking plasma samples with known quantities of
DHT: mean recovery was 103 ± 6% over the range 50-800 pg DHT added.
5.2.2 Androstanediol Glucuronide assay.
The concentration of AdiolG in serum was determined by RIA using a kit supplied by
DSL Inc (Texas, USA) which uses an antibody directed against 3a-androstanediol 17-
glucuronide-7-hemisuccinate and which has been shown to give values in good
agreement with previous laborious chromatographic methods (Samojlik and Kirschner,
1990). This antibody has 10.7% cross reactivity with unconjugated Adiol, 5.9% with
Adiol-3-glucuronide (which contributes approximately 20% to total serum AdiolG;
Thomson, Rittmaster, Rodriguez, Moore and Rao, 1991) and <2% with testosterone
glucuronide and DHT glucuronide.
Standards were supplied in over the range 0.5-100 ng/ml plus a zero standard.
Non-specific binding was estimated using 200|il of zero standard in the absence of
antiserum. 100(il of standard or sample were assayed in duplicate. A high (10.5
ng/ml) and low (2.5 ng/ml) quality control sample were included with the kit. 500|il
of 125I-AdiolG was added to each tube, followed by 100p.l of AdiolG antiserum.
Tubes were vortexed, and incubated at room temperature for 3 hrs. 1ml of goat anti-
rabbit globulin with polyethylene glycol precipitating reagent was then added, the tubes
vortexed, and incubated at room temperature for a further 15 min before being
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centrifuged at 1500g for 20 min. The supernatant was decanted, and radioactivity in
the pellet counted in a gamma counter. Results were calculated using AssayZap.
Quality control samples gave results within the range quoted by the manufacturer, and
over 3 assays the interassay CV was 6.4% and the intraassay CV was 6.1% at 10
ng/ml. The sensitivity of the assay was 0.5 nmol/1.
The assay was validated by assessing linearity of serial dilution of serum samples
and seminal plasma samples (for Chapter 7 results), and recovery was investigated by
spiking serum and seminal plasma with AdiolG standards in the range 0.5 to 30 ng/ml.
The results of these checks are shown in Figure 5.1, showing linearity of dilution and
complete recovery of standard with both sample types. Mean recovery was 103% in
serum and 105% in seminal plasma (n=8 in both cases).
5.2.3 Statistical analysis.
Results in this Chapter were analysed using Student's t test, on paired and unpaired
results as appropriate, or the Mann-Whitney U test on non-parametric data.
5.3 Results.
5.3.1 Dihydrotestosterone.
Plasma concentrations of DHT were determined at baseline before testosterone
treatment was started, and after 16 weeks of treatment at the time the next injection was
due. Baseline concentrations of DHT were 2.51 ± 0.19 nmol/1 in the azoospermic
group, and 2.64 ± 0.30 nmol/1 in the oligozoospermic group (Figure 5.2a). The
concentrations of DHT were significantly increased in both groups after 16 weeks of
testosterone treatment, to 3.08 ± 0.20 nmol/1 in the azoospermic group (p<0.01), and
to 4.08 ± 0.35 nmol/1 in the oligozoospermic group (p<0.001). The concentrations of
DHT were similar at baseline, but after 16 weeks, the concentrations in the
oligozoospermic group were significantly greater than in the azoospermic group
(p<0.02). The plasma concentrations of DHT in the two groups after 16 weeks of
testosterone treatment expressed as a percentage of baseline are shown in Figure 5.2b,
illustrating the greater increase in the oligozoospermic group at that time, to 166 ± 16%
of baseline compared to 133 ± 11% in the azoospermic group (p<0.05).
Plasma DHT concentrations were compared to values for CRT~DHT reported in
Chapter 4 (Figure 5.3). There was no significant correlation between plasma DHT
concentrations and CRT"DHT before treatment (r=0.27, for all men; r=0.24,













(a) Recovery of AdiolG from spiked samples of serum
and seminal plasma. Known concentrations of AdiolG
were added to lOOpl of serum or seminal plasma.
(b) Linearity of dilution of serum and seminal plasma.
Open symbols, serum.












Effect of testosterone treatment on plasma DHT
concentration in those men becoming azoospermic
and those remaining oligozoospermic.
(a) Open columns, baseline.
Hatched columns, after 16 weeks testosterone
treatment.
(b) Increase in DHT after testosterone treatment,
results expressed as percentage of baseline
concentration.
a: p<0.05 vs baseline
b: p<0.01 vs baseline
c: p<0.05 vs Azoospermic group
































Correlation between plasma concentration of DHT, and CR in
those men becoming azoospermic and those remaining
oligozoospermic.
(a) Baseline
(b) After 16 weeks of testosterone treatment.
Open symbols, Azoospermic group.
Filled symbols, Oligozoospermic group.
Correlation coefficients:
(a) All men, r= 0.27, p>0.05
(b) All men, r=0.64, p<0.001
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weeks treatment, the correlation coefficient for the whole group was 0.64, p<0.001,
and there was a significant correlation between these two parameters at that time in the
oligozoospermic group (r=0.67, p<0.01) but not in the azoospermic group (r=0.40,
p>0.05), although the correlation in that group was greater than at baseline. The
treatment-induced changes in plasma DHT concentration and CRT"DHT were also
compared (Figure 5.4), after calculating the values after 16 weeks testosterone
treatment as a percentage of baseline values for each set of data. The correlation
coefficient for the whole group of men was 0.47 (p<0.01), and Figure 5.4 also shows
the distribution of the results according to the azoospermic/oligozoospermic criterion.
This Figure demonstrates that there is a significant correlation between increases in
CR.T-DHT and plasma DHT with testosterone treatment, and also illustrates that there is
a degree of separation between the two groups of men. It thus amplifies the results
presented in Figures 4.4 and 5.2, showing the greater increase in both CRT"DHT and
DHT in the oligozoospermic group of men.
The correlation between plasma testosterone and DHT was also determined using
plasma testosterone concentrations measures in Chapter 3. The correlation was
significant in both groups at baseline (r=0.54 in the azoospermic group, p<0.05;
r=0.77 in the oligozoospermic group, p<0.01), but not after 16 weeks of treatment
(r=0.09 in the azoospermic group; r=0.08 in the oligozoospermic group).
5.3.2 Androstanediol Glucuronide.
AdiolG concentrations in serum were measured at the same time points as DHT, i.e.
before testosterone treatment was started, and after 16 weeks of treatment. There was
no difference in baseline AdiolG concentrations between men who subsequently
became azoospermic (20.1 ± 3.0 nmol/1), and those who remained oligozoospermic
(18.2 ± 2.3 nmol/1). Testosterone treatment caused a significant increase in AdiolG
concentrations in both groups (Figure 5.5), to 31.0 ± 4.8 nmol/1 (p<0.01) in the
azoospermic group and to 40.3 ±7.1 nmol/1 in the oligozoospermic group (p<0.001).
The difference between the values of the oligozoospermic group and the azoospermic
group after 16 weeks of testosterone treatment did not reach statistical significance, but
when the results were recalculated to give the concentration after 16 weeks as a
percentage of baseline, this revealed that testosterone treatment caused a greater increase
in AdiolG in the oligozoospermic group than in the azoospermic group (111 ± 16%
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Figure 5.4
Correlation between increase in plasma concentration of DHT and
increase in CRT"DHT after 16 weeks treatment, in those men
becoming azoospermic and those remaining oligozoospermic.
In both cases, data points are values after 16 weeks testosterone
treatment as a percentage of value at baseline.
Open symbols, Azoospermic group.
Filled symbols, Oligozoospermic group.
Correlation coefficient:































Effect of testosterone on serum AdiolG concentrations in
those men becoming azoospermic and those remaining
oligozoospermic.
(a) Open columns, baseline
Hatched columns, after 16 weeks testosterone treatment.
(b) Increase in AdiolG after testosterone treatment, results
expressed as percentage of baseline concentration.
* p<0.05 vs Azoospermic group
** p<0.01 vs baseline
*** p<0.001 vs baseline.
Mean ± sem, n=18, azoospermic group;
n=15, oligozoospermic group.
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There was no significant correlation between serum AdiolG and plasma DHT
concentrations in either group, either at baseline or after 16 weeks testosterone
treatment (r=0.34 and 0.05 in the azoospermic group, r=0.16 and 0.25 in the
oligozoospermic group, baseline and after 16 weeks testosterone treatment
respectively). However when the results after 16 weeks treatment were recalculated as
percentages of baseline concentrations, there was found to be a significant correlation
between the increases in DHT and AdiolG concentrations in the oligozoospermic group
(r=0.58, p<0.05) but not in the azoospermic group (r=0.1, p>0.05). This is shown in




The results in Figure 5.2 show that administration of supraphysiological doses of
testosterone causes an increase in plasma DHT at 16 weeks of approximately 40%.
This increase is thus considerably lower than the change in plasma testosterone
concentrations, which are increased by approximately 100% at this time (Table 3.1).
Schulte-Beerblihl and Nieschlag (1980) reported similar increases in plasma DHT
following a single injection of testosterone oenanthate, but their study did not involve
repeated administration. An increase in plasma DHT was also reported following
infusion of testosterone (Reed et al„ 1986), with an increase within 40 min of starting
the infusion. There are no previous data on the plasma concentrations of DHT
following repeated administration of testosterone to normal men.
It is accepted that in men most of the DHT in the circulation results from the
peripheral 5a-reduction of testosterone (Ito and Horton, 1971, Ishimara et al., 1978).
The smaller increase in plasma DHT than testosterone therefore suggests a low rate of
conversion of testosterone to DHT in the periphery, ie a low 5aR activity. In Chapter
1, the literature reporting changes in 5aR activity after hypophysectomy or testosterone
treatment was discussed. 5aR activity is increased by androgens and decreased by
hypophysectomy in the androgen-dependent organs (skin, prostate, and epididymis),
but the opposite is true of 5aR in the liver and adrenal cortex. It is not always clear
from those studies whether the effect of hypophysectomy is mediated by a decrease in
testosterone or other hormones (including a direct effect of the gonadotropins). Under
the conditions of the current study, testosterone treatment causes an increase in plasma
testosterone, and a decline in gonadotrophin secretion to undetectable concentrations.
DHT, % of baseline
Figure 5.6
Correlation between increases in AdiolG and DHT
concentrations after 16 weeks of testosterone treatment,
results expressed as percentage of baseline
concentrations.
Open symbols, Azoospermic group.
Filled symbols, Oligozoospermic group.
Correlation coefficient:
All men r=0.33, p>0.05.
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5aR in the skin (and prostate) might therefore be expected to be increased, with an
increased production of DHT relative to the concentration of testosterone, and thus a
greater increase in DHT than testosterone. The small increase in plasma DHT observed
therefore requires an explanation.
One possibility is that DHT in plasma does not reflect 5aR activity directly, but is
the result of a "leak" of the hormone from within the cell in which it is produced, while
most of the DHT thus produced is further metabolised, eg to Adiol; DHT thus has a
paracrine rather than an endocrine role. This is consistent with the finding that
finasteride treatment causes a much greater inhibition of prostatic tissue DHT
concentrations than plasma DHT (McConnell et al., 1992), as well as the results
discussed in the Introduction to this Chapter, which suggest that AdiolG is a better
index of hyperandrogenic status (eg in hirsutism) than is DHT. If increased 5aR
activity is coupled with increased metabolism ofDHT, then increasing the concentration
of the substrate, testosterone, will preponderantly increase the concentration of AdiolG
in the circulation, even though tissue concentrations of DHT may also be raised. Any
leak of DHT might also be increased, but to a smaller extent. Thus the circulating
concentration of DHT is a poor index of 5aR activity.
After 16 weeks of testosterone treatment, the plasma concentration of DHT in the
oligozoospermic group was significantly greater than in the azoospermic group (Figure
5.2). As the plasma concentration of testosterone was not different between the two
groups (Chapter 3), this result suggests that the 5aR activity of the oligozoospermic
group was greater than that of the azoospermic group, and supports the finding of a
selective increase in CRT"DHT in the oligozoospermic group after 16 weeks of
testosterone treatment (Chapter 4). An alternate explanation is that the metabolism of
DHT was increased to a greater extent in the azoospermic group: no data are available
on this point, but the demonstration in Chapter 4 that MCRT was the same in the two
groups, and increased to the same extent with testosterone treatment argues against it.
There was also a significant correlation between plasma DHT and CRT"DHT results
(Figure 5.3), but only after 16 weeks of treatment. This was confirmed by comparing
changes in CRT~DHT and DHT concentration as a result of testosterone treatment
(Figure 5.4), showing a significant correlation between the two measures of 5aR
activity. The experimental protocol for the determination of CRT"DHT requires the
release of [3H]DHT into the circulation after reduction of infused [3H]testosterone, and
as discussed in Chapter 4, any further metabolism of the [3H]DHT produced will tend
to reduce the value for CRT"DHT. It is thus at best only an index of tissue 5aR activity,
but the correlation with plasma DHT is consistent with the suggestion that under
conditions of (exogenously-administered) supraphysiological testosterone
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concentrations, plasma DHT is more closely related to 5aR than under physiological
conditions.
Information on the relationship between plasma testosterone and DHT is also
obtained by determining correlations between them directly. The correlation between
plasma testosterone and DHT was significant in both groups at baseline as reported by
others (Rittmaster et al., 1989), but not after 16 weeks of treatment. This result
suggests that under physiological conditions, the amount of DHT in the circulation is
related to the amount of testosterone, i.e. that the concentration of product is related to
the concentration of precursor. During testosterone treatment, this relationship no
longer appears to be present: the large increase in plasma testosterone has perhaps
"swamped" the 5aR. This would also explain the smaller increase in plasma DHT than
testosterone.
5.4.2 Androstanediol Glucuronide.
Baseline concentrations of AdiolG were similar to those reported by others using
chromatographic/hydrolytic methods (Morimoto et al., 1981; Lookingbill et al., 1988),
although the results reported by Lookingbill et al. (1991) are considerably higher (mean
AdiolG in normal Caucasian men 35 nmol/1 in that study, compared to 11 nmol/1 in
Lookingbill et al. 1988). The results presented here are very similar to those reported
in a study comparing the assay kit used here with a chromatographic method (Samojlik
and Kirschner, 1990).
Testosterone treatment caused a significant increase in AdiolG concentrations in
both groups of men after 16 weeks of treatment. Although the concentration of AdiolG
in the oligozoospermic group was higher than in the azoospermic group after 16 weeks
of treatment (40.3 ± 7.1 nmol/1 vs 31.0 ± 4.8 nmol/1), this did not reach statistical
significance. The increase in AdiolG with treatment was however significantly greater
in the oligozoospermic group when the treatment concentration is expressed as a
percentage increase (111% vs 69%, p<0.05, Figure 5.5). These results therefore
support the hypothesis that there is an increased 5aR activity in men remaining
oligozoospermic.
Comparison of Figures 5.2 and 5.5 shows that the increase in AdiolG is greater
than the increase in DHT, and is similar in magnitude to the increase in plasma
testosterone described in Chapter 3. This is consistent with DHT being further
metabolised to AdiolG before being released into the circulation, and both supports the
hypothesis that AdiolG is a better marker of hyperandrogenism than DHT and provides
a further explanation for the lesser rise in plasma DHT concentrations observed. While
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the lack of direct correlation between AdiolG and DHT concentrations found here
confirms the previous report of a lack of correlation between DHT and AdiolG (or
androsterone glucuronide) concentrations (Rittmaster et al., 1989), further analysis of
the data with recalculation to show changes after testosterone treatment showed that
there was a significant correlation between increases in DHT and AdiolG concentrations
with testosterone treatment in the oligozoospermic group (Figure 5.6). This
demonstrates the importance ofmeasuring dynamic changes in steroid concentrations in
the investigation of relationships between them, and provides further support for the
hypothesis that there is a difference in 5aR activity between those men who became
azoospermic and those remaining oligozoospermic, but that this difference is only
unmasked during testosterone treatment
The regulation of 5aR was discussed in Chapter 1.6, where the evidence which
suggests that 5aR in the skin and prostate is androgen-dependent was presented. The
hypothesis of this Thesis is that men remaining oligozoospermic on supraphysiological
doses of testosterone have a higher 5aR than those remaining azoospermic, resulting in
more testosterone being converted to DHT thus providing a greater androgen stimulus
systemically and also presumably in the testis. This may be sufficient to maintain a low
rate of spermatogenesis. If this is correct, then the rate of decline of sperm density
might inversely correlate with measures of 5aR. This was investigated by subdivision
of the oligozoospermic group into those who exhibited a rapid decline in sperm density
to less than 0.1 xl06/ml but remained oligozoospermic ("rapid" group), and those who
showed a slower decline and maintained a greater sperm density ("slow" group).
Examination of the data revealed 6 men from the oligozoospermic group who all had a
sperm density of <0.1 xl06/ml after 16 weeks of testosterone treatment. The mean
sperm density of the remaining "slow" oligozoospermic group (n=9) at 16 weeks was
4.2 ±1.7 xl06/ml, and that of the azoospermic group was <0.1 xl06/ml (13 of that
group had already become azoospermic at that time). The sperm densities of these 3
groups during testosterone treatment are shown in Figure 5.7. DHT and AdiolG
results were presented in the same groups, and these results (normalised to baseline)
are shown in Figure 5.8. This shows a progressive rise in the testosterone-induced
increase in the circulating concentrations of both hormones with the degree of
maintenance of spermatogenesis, such that the increases in concentration of both
hormones was greatest in the more resistant oligozoospermic group and lowest in those
who rapidly achieved azoospermia. Those men whose sperm density declined rapidly
but in whose ejaculates spermatozooa remained detectable formed an intermediate
Weeks of testosterone treatment
Figure 5.7
Effect of testosterone treatment on sperm density,
subjects divided into 3 groups.
□ Azoospermic group, n=18
a "Rapid" oligozoospermic group, n=6



















Plasma concentrations of DHT and AdiolG after 16 weeks of
testosterone treatment expressed as a percentage of baseline
concentration, subjects divided into 3 groups.
Open columns, azoospermic group.
Hatched columns, "rapid" oligozoospermic group.
Filled columns, "slow" oligozoospermic group.
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group. These results did not reach statistical significance due to the small numbers in
each group.
The results presented in this Chapter thus demonstrate increases in circulating DHT and
AdiolG concentrations with testosterone administration. The increases in both
hormones were greater in the group of men remaining oligozoospermic than in those
becoming azoospermia and there also appeared to be a correlation between degree of
maintenance of spermatogenesis and increases in DHT and AdiolG. There were also
corelations between testosterone-induced changes in the three measures of 5aR activity
(CRT_DHT , DHT and AdiolG), particularly in the oligozoospermic group of men.
These results therefore support the results presented in Chapter 4, suggesting that there
is increased activity of the enzyme 5aR in those men who remain oligozoospermic, and
that this may underlie the maintenance of spermatogenesis in these men. This is further
investigated in the following two Chapters, in which androgen concentrations in
seminal plasma, and steroid precursors of testosterone metabolism in urine and plasma
are measured. In Chapter 8, the effect of testosterone administration on sebum
secretion is reported, to investigate whether increased 5aR activity in those men
remaining oligozoospermic can be demonstrated at the level of an end-organ response.
Chapter 6
Androgens in Seminal Plasma.
Introduction.
In the preceding Chapters, results have been presented of measurements of the
concentration of testosterone, DHT and AdiolG in blood before and after 16 weeks of
testosterone treatment, and these results have been interpreted in terms of the activity of
the enzyme 5aR. The concentrations of DHT and AdiolG are believed to reflect
peripheral conversion of testosterone. Interpretation of these data in relation to the
degree of inhibition of spermatogenesis by supraphysiological concentrations of
testosterone is difficult, as testicular and peripheral androgen metabolism may differ
considerably. An alternate, and perhaps closer, approach to the investigation of
testicular steroidogenesis may be by the measurement of androgens in seminal plasma.
The development of specific and sensitive RIAs has allowed the analysis of
steroids in seminal plasma in addition to their study in blood plasma, with improved
accuracy compared to previously available methods such as bioassay (Raboch,
Gregorovd and Rezdbek, 1963) and fluorimetry (Diczfalusy, 1954). Such earlier
methods are now recognised to have often given very erroneous values. However,
Purvis, Landgren, Cekan and Diczfalusy (1975) demonstrated the presence and
concentration of several steroids in seminal plasma by RIA, including testosterone,
DHT, pregnenolone, androsterone and oestradiol, in both normal and infertile men.
These results showed that the concentration of testosterone in seminal plasma is much
lower than in blood, whereas the concentration of DHT in seminal plasma is
approximately double that of testosterone (compared to being 10% of the concentration
of testosterone in blood plasma). These results have since been confirmed by others
(Biswas, Ferguson, Stedronska, Baffoe, Mansfield and Kosbab, 1978; Purvis,
Calandra, Sander and Hansson, 1978; Le Lannou, Massart, Chambon, Nicol and
Allannic, 1980; Hudson, Hayes, Crawford and McKay, 1983).
Seminal plasma is composed of the secretions of the male sex accessory glands, the
prostate and seminal vesicles, as well as fluid from the testis and epididymis. Evidence
for the relative contributions of these tissues to the concentrations of steroids in seminal
plasma has been obtained from the study of men after vasectomy, and from direct assay
of steroids in the tissues. DHT is found in much greater concentration in the
epididymis than in the testis, but whereas testosterone is found predominantly in the
testis, the concentration of testosterone in the epididymis is still 3 fold greater than that
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of DHT (Purvis et al., 1978). These authors also demonstrated the absence of a
concentration gradient for either androgen along the human epididymis, in contrast to
the gradient (decreasing from the Caput towards the Cauda) found in several species
including the rat, rabbit and bull, a gradient which parallels that of ABP (Aafjes and
Vreeburg, 1972; Guerrero, Ritzdn, Hansson, Purvis and French, 1975; Pujol, Bayard,
Louvet and Boulard, 1976).
The epididymis contains 5aR, with an activity approximately half that of the
prostate in the human (Gloyna and Wilson, 1969), and in the epididymis as in the
prostate, the activity of the enzyme is androgen-dependent (Viger and Robaire, 1991).
Epididymal DHT is therefore likely to be produced locally from testosterone, and the
concentration of DHT in the epididymis is 10 fold higher than in seminal plasma
(Purvis et al., 1975; 1978).
The operation of vasectomy physically prevents the passage of spermatozoa and
fluid from the testis and epididymis, and thus provides a useful model for the
investigation of the relative contributions of the testis/epididymis and the accessory
glands to the components of seminal plasma. The concentration of DHT in seminal
plasma after vasectomy is reduced to 20-40% of normal, but that of testosterone is
unchanged or only slightly reduced (Le Lannou et al., 1980; Ying, Hedman, de la
Torre, Jensen, Pedersen and Diczfalusy, 1983; Hudson et al., 1983). Measurement of
steroids in split ejaculates also supports a differential contribution, as DHT is found
predominantly in the first fraction (mostly consisting of prostatic and
testicular/epididymal fluid), whereas testosterone is found equally in that fraction and
the second, mostly from the seminal vesicles (Cohen, Delafontaine and Grenier,
1978). There have also been similar reports of selectively reduced concentrations of
DHT but not testosterone in seminal plasma of men who are azoospermia of both
obstructive and non-obstructive aetiologies (Purvis et al., 1975; Schoenfeld, Amelar,
Dubin and Numeroff, 1978; Biswas et al., 1978; Le Lannou et al., 1980).
These findings therefore suggest thatmost DHT in seminal plasma derives from the
testis/epididymis rather than the accessory glands, and in particular from the conversion
of testosterone to DHT in the epididymis, whereas testosterone in seminal plasma is
derived in more equal measure from the testis/epididymis and accessory glands. The
relative concentrations of testosterone in the epididymis and seminal plasma suggest
that testicular/epididymal fluid makes up only a small proportion (no more that l/50th)
of seminal plasma, which is supported by the lack of effect of vasectomy on the volume
of the ejaculate. The estimation of DHT in seminal plasma may thus be a marker for
epididymal 5ocR activity.
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This has been investigated in this Chapter. If the analysis of the results of the
preceding Chapters are correct, the concentration of DHT in seminal plasma would be
expected to be increased in men remaining oligozoospermic on supraphysiological
doses of testosterone to a greater extent than in those men becoming azoospermia A
complication of this is that the testosterone substrate for epididymal 5aR may be
derived mostly from direct testicular secretion, rather than via the peripheral circulation.
It may therefore be reduced under the conditions of these studies. Comparison with
changes in seminal plasma testosterone concentrations, which may predominantly
reflect accessory gland concentrations, may provide some insight to this.
Adiol has been detected in the human epididymis (Purvis et al., 1978), although at
concentrations close to the sensitivity of the assay used (approximately 5 ng/ml,
compared to 20 ng/ml in serum). AdiolG has been reported in seminal plasma
(Paulson, Bernstein, Marrs and Lobo, 1986), at a concentration 25% that in serum, i.e.
several fold greater than the concentration of testosterone in seminal plasma. The
concentrations of conjugated steroids are very high in seminal plasma, with for example
the concentrations of sulphated testosterone and dihydrotestosterone being
approximately 5 times that of the free steroid (Purvis et al., 1975). Serum
concentrations of AdiolG are elevated by supraphysiological testosterone treatment
(Chapter 5), and the effect of supraphysiological testosterone treatment on
concentrations in seminal plasma are reported here.
6.2 Methods.
Semen samples were centrifuged at 2000g for 5 min to give a preparation of seminal
plasma, which was stored at -20°C until assay. Subjects were asked to abstain from
ejaculation for at least 2 days previously.
Testosterone, DHT and AdiolG were determined in seminal plasma samples at
baseline and after 16 weeks of treatment. Radioimmunoassays were as described in
Chapter 4 for testosterone, and in Chapter 5 for DHT and AdiolG.
For the testosterone assay, 100(il of sample in duplicate was assayed, compared to
50fil for plasma. This was because of the lower concentration of testosterone in
seminal plasma. The antibody used shows 30% cross-reactivity with DHT (Corker and
Davidson, 1978). Results presented here are not corrected for this.
Validation of the AdiolG assay for use with seminal plasma samples was carried out
by testing for linearity of dilution and for recovery after spiking of seminal plasma with
authentic AdiolG. Results of these experiments are shown together with results of
similar experiments using serum in Figure 5.1.
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6.3 Results.
The concentrations of testosterone in seminal plasma at baseline and after 16 weeks of
testosterone treatment are shown in Figure 6.1. Testosterone treatment increased
seminal plasma testosterone concentrations in both groups of men, from 1.31 ± 0.13
nmol/1 to 2.55 + 0.47 nmol/1 in the azoospermic group (p<0.02), and from 1.25 ± 0.21
nmol/1 to 2.58 ± 0.46 nmol/1 in the oligozoospermic group (p<0.01). The mean
increase was thus 94% in the azoospermic group and 106% in the oligozoospermic
group, and similar to the increase in peripheral plasma concentrations reported in
Chapter 3.
There was no significant effect of testosterone administration on seminal plasma
DHT concentrations in the azoospermic group, which were 2.18 ± 0.31 nmol/1 at
baseline, and 2.54 ± 0.27 nmol/1 after 16 weeks of testosterone treatment. In the
oligozoospermic group, however, DHT was increased from 2.12 ± 0.29 to 2.94 ±
0.33 nmol/1 (p<0.05). These results are shown in Figure 6.2.
The effect of testosterone administration on seminal plasma concentrations of
AdiolG was similar to the effect on testosterone. In the azoospermic group, AdiolG
concentrations were increased from 5.1 ± 1.5 to 9.3 ± 2.3 nmol/1 (p<0.005), and in the
oligozoospermic group from 6.0 ± 3.0 to 11.1 ± 3.1 nmol/1 (p<0.001) (Figure 6.3).
6.4 Discussion.
Baseline seminal concentrations of testosterone (=1.3 nmol/1) are much lower than
concentrations in peripheral plasma, as previously described, although the
concentrations reported here may be an overestimate due to cross-reactivity of the
antiserum with DHT (present in much greater concentration relative to testosterone in
seminal plasma than in peripheral plasma). The concentration of testosterone in saliva
is also much lower than in plasma, but in that case it closely approximates to (and has
been claimed to be equivalent to) the concentration of free testosterone in plasma
(Fahmy, Read, Walker and Griffiths, 1982). The concentration of testosterone in
seminal plasma is intermediate to these two values, and also contrasts with the
concentrations of LH and FSH in seminal plasma, which are similar to those found in
plasma (Schoenfeld et al., 1978).
Testosterone administration caused an increase in seminal plasma concentrations of
testosterone in both groups of men, and the magnitude of the increase was similar to
that of testosterone in peripheral plasma. After 16 weeks of testosterone treatment,
testicular production of testosterone is assumed to be greatly reduced secondary to the




















The effect of testosterone treatment on seminal plasma
testosterone concentrations in those men becoming
azoospermic and those remaining oligozoospermic.
Open columns, baseline.
Hatched columns, after 16 weeks testosterone treatment.
* p<0.02
** p<0.01 vs baseline.
Mean ± sem, n=18, azoospermic group
n=15, oligozoospermic group.
Figure 6.2
The effect of testosterone treatment on the
concentration ofDHT in seminal plasma in
those men becoming azoospermic and those
remaining oligozospermic.
Open columns, baseline.
Hatched columns, after 16 weeks testosterone
treatment.
* p<0.05 vs baseline.
Mean ± sem, n=18, azoospermic group
n=15, oligozoospermic group.
Figure 6.3
The effect of testosterone treatment on the concentration
of AdiolG in seminal plasma in those men becoming
azoospermic and those remaining oligozoospermic.
Open columns, baseline.
Hatched columns, after 16 weeks testosterone treatment.
* p<0.005
** p<0.001 vs baseline.
Mean ± sem, n=18, azoospermic group
n=15, oligozoospermic group.
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of testosterone in seminal plasma reflects the systemic rather than the intratesticular
concentration of testosterone. This is supported by the only small fall in seminal
plasma testosterone concentration following vasectomy (Ying et al., 1983; Hudson et
al., 1983).
The concentration of DHT in seminal plasma is reported to be similar to that in
peripheral plasma (Purvis et al., 1975), and appears to be largely of
testicular/epididymal origin. Thus it is reduced after vasectomy and in obstructive
azoospermia to approximately 25% of normal (Le Lannou, 1980; Ying et al., 1983;
Hudson et al., 1983). Baseline concentrations of DHT reported here are similar to
those in previous reports, and are similar to the values obtained in peripheral plasma in
Chapter 5. After 16 weeks of testosterone treatment, the concentration of DHT in
seminal plasma was not significantly altered in the azoospermic group, but was
increased in the oligozoospermic group (Figure 6.2). The lack of effect in the
azoospermic group may be due to the combination of two opposing influences: an
increased peripheral concentration tending to increase seminal plasma DHT
concentrations, and a reduced supply from the testis/epididymis secondary to reduced
testicular production of testosterone and thus less conversion to DHT within the
epididymis. In contrast, the increase in seminal plasma DHT concentrations in the
oligozoospermic group may reflect both the higher peripheral plasma concentration than
in the azoospermic group, and increased 5aR activity in the epididymis, converting a
greater proportion of the available testosterone. This result is therefore consistent with
the hypothesis that the maintenance of spermatogenesis is associated with increased
5aR activity. This conclusion must, however, be cautious in view of the mixed origin
ofDHT in seminal plasma.
The baseline concentration of AdiolG in seminal plasma was 5.5 nmol/1, which is
approximately 25% of that in serum (Chapter 5). There is only one previous report of
AdiolG in seminal plasma, and the concentration found in that study was 161 ng/dl, i.e.
3.4 nmol/1. (Paulson et al., 1986). Testosterone treatment caused an increase in the
concentration of AdiolG in seminal plasma in both groups of men, and to a similar
degree (Figure 6.3). In both groups, the concentration of AdiolG was increased by
approximately 80%. The magnitude of this increase is therefore similar to that of
testosterone, and greater than the change in concentration of DHT. It therefore appears
that both testosterone and AdiolG are found in seminal plasma in considerably lower
concentrations than in blood, and in both fluids show large increases with testosterone
treatment. In contrast DHT is present in similar amounts in seminal plasma and the
increases in DHT are much smaller, and in fact there was no change in seminal plasma
DHT concentration in the azoospermic group.
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The origin of AdiolG in seminal plasma is unknown. In the only previous report of
its presence, in a study of the steroid content of seminal plasma of men with idiopathic
oligospermia (Paulson et al., 1986), there was no difference in seminal plasma AdiolG
concentration between normal men and those with idiopathic oligospermia, although the
latter had lower seminal plasma testosterone and DHT concentrations. The results
presented here suggest that seminal plasma AdiolG concentration is related to
testosterone concentration, but not DHT concentration. Pathways of androgen
metabolism in the accessory glands appear to be similar to those elsewhere in the body,
and have been extensively investigated in the prostate in particular (Krieg and Tunn,
1990). The small or non-existent changes in DHT observed here are therefore
compatible with the DHT in seminal plasma being mostly from a different source to the
testosterone and AdiolG, as suggested above. Any influence of the selective increase in
seminal plasma DHT concentrations on AdiolG concentrations in the oligozoospermic
group would be difficult to detect under such circumstances.
In conclusion, the selective increase in DHT concentration in seminal plasma in those
men remaining oligozoospermic during testosterone treatment is compatible with the
hypothesis that there is increased 5aR activity in this group, but the lack of clear
evidence as to the relative contributions of various organs to androgens in seminal
plasma complicates interpretation.
Chapter 7
Plasma Steroids and Urinary Metabolites: Effects of
Testosterone, and the Interaction between Gonadal and
Adrenal Androgen Secretion.
7.1 Introduction.
In previous Chapters of this Thesis, results of the investigation of the possible role of
the enzyme 5aR in the maintenance of spermatogenesis in those men who remain
oligozoospermic on supraphysiological doses of testosterone have been presented. In
particular, this has involved the determination of the conversion rate of testosterone to
DHT, and plasma concentrations of DHT and AdiolG, i.e.products of 5areduction of
testosterone. In this Chapter, the plasma concentrations of precursor steroids and
urinary excretion of steroid metabolites are investigated.
The liver contains the enzymes 5aR and 5pR, which result in the formation of the
17-ketosteroids androsterone (A) and aetiocholanolone (E) respectively, which can be
measured in the urine. In congenital 5aR deficiency, the urinary excretion of A is
reduced relative to that of E, such that the E/A ratio is greatly elevated, from
approximately unity in normal men to a mean of 5 in men with 5aR deficiency,
whereas it is normal in men with testicular feminisation (Peterson et al., 1977). This
enzyme pair also converts Cortisol to the 5ocR / 5[5R metabolites allo-tetrahydocortisol
(aTHF) and tetrahydrocortisol (THF), and the determination of these corticosteroid
metabolites in urine has proved useful in the early diagnosis of 5aR deficiency in
infancy when A and E are excreted in insufficient quantity for detection (Imperato-
McGinley et al., 1986). In particular, the ratios of these metabolites (i.e. E/A and
THF/aTHF) provides an index of hepatic 5aR activity.
Treatment of men with the 5aR inhibitor, finasteride, alters urinary excretion of
androgens, resulting in an E/A ratio similar to that of men with 5aR deficiency
(Vermuelen et al., 1989; Imperato-McGinley et al., 1990). Finasteride therefore
appears to inhibit hepatic as well as peripheral 5aR. If men who remain
oligozoospermic on supraphysiological doses of testosterone as used in this study have
a greater 5aR activity than those who become azoospermia then this may be reflected
in the pattern of urinary androgen excretion as well as in plasma androgen
concentrations, with increased excretion of A relative to that of E, and with increased
excretion of aTHF relative to that of THF. Such differences, however, may not be
nearly as clear-cut as in men with congenital 5aR deficiency.
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Andersson, Bishop and Russell (1989), however, found that orchidectomy
increased 5aR activity and mRNA in the liver of rats, and similarly androgens (in
particular DHT) have been reported to inhibit 5aR in the rat adrenal cortex (And6 et al.,
1989; Canonaco, And6, Valenti, Tavolaro, Panno, Maggiolini and Dessi-Fulgheri,
1989; Lephart et al., 1991). Administration of testosterone may therefore decrease
hepatic and adrenal 5aR activity in men, resulting in increased E/A and THF/aTHF
ratios.
The measurement of THF, aTHF and of tetrahydrocortisone (THE) allows the
estimation of the activity of the enzyme lip-hydroxysteroid dehydrogenase
(1 lpOHSD). This enzyme converts Cortisol to the inactive metabolite cortisone, which
is excreted as THE in the urine, and the ratio of THE to the sum of THF and aTHF is
an index of its activity (Walker and Edwards, 1991). This enzyme is of particular
importance in the distal tubule of the kidney, "protecting" the mineralocorticoid receptor
from Cortisol (Fraser, 1990), but is also found in the testis (Phillips, Lakshmi and
Monder 1991) where its function is unknown.
The results of two further series of investigations are also presented here: the
plasma concentrations of precursors of testosterone synthesis, and the possible
contribution of adrenal secretion of androgens to the maintenance of spermatogenesis.
Androstenedione is the proximate precursor of testosterone in steroidogenesis and is
reversibly converted to testosterone by the enzyme 17(3-hydroxysteroid dehydrogenase,
both in the testis and peripherally, eg in the skin (Mowszowicz et al., 1983). 170H-
progesterone is a crucial intermediate, as it is the metabolite at which the synthetic
pathways for C19 and C21 steroids diverge, and its urinary metabolite is pregnanetriol.
Dehydroepiandrosterone-sulphate (DHAS) is the major adrenal androgen, and 11 (3-
hydroxy steroids have been proposed to be specifically of adrenal origin (Goldzieher,
Pena and Aivaliotis, 1978; Poison, Reed, Franks, Scanlon and James, 1988). These
steroids and their urinary metabolites were measured to investigate the possible
contribution of continuing androgen synthesis in the testis and adrenal to the
maintenance of spermatogenesis in those men remaining oligozoospermic on
supraphysiological doses of testosterone.
7.2 Methods.
Subjects collected 24 hr urine samples before testosterone treatment started and after 16
weeks of treatment. The second collection was made during the 24 hrs before the next
testosterone injection was due, and therefore reflects steroid excretion at a time when
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testosterone concentrations were at a nadir. The volume of each collection was
recorded, and aliquots were stored at -20°C until assay.
7.2.1 Urinary steroid measurements.
Urinary steroid profile analysis was performed by capillary column gas
chromatography after derivatisation of unconjugated steroids. This method allows the
determination of up to 30 steroid metabolites excreted as either free steroids or
conjugated to glucuronides or sulphates.
Steroid metabolites were extracted from 10 ml of urine by passage through a Sep-
Pak CI8 column and elution with methanol. The extract was dried down under
nitrogen, reconstituted in acetate buffer to which Helix Pomatia juice was added for
hydrolysis of steroid conjugates. Samples were incubated at 37°C for 36 hrs, steroids
extracted using Sep-Pak columns, and internal standards (5a-androstane-3a,17a-diol,
cholesterol butyrate and Stigmasterol) were then added. After washing with 8%
NaHC03, the samples were derivitised by incubation overnight with methoxyoxime
trimethylsilyl ether at 100°C. Excess derivatisation agent was removed by passage
down a Lipidex 5000 column. Steroid derivatives were separated using a model 438
gas chromatograph (Packer-Becker BV, Netherlands), fitted with a "Flexsyl" 25m x
0.32mm capillary column coated with OV-1 (Phase-Sep, Queensferry, Clywd) and
quantified by comparison with peak height of the internal standards.
7.2.2 Radioimmunoassays of andostenedione, 170H-Progesterone, and
dehydroepiandrosterone.
Androstenedione and 170H-progesterone were measured by established "in-house"
RIAs (Wallace and Wood, 1984; Thomson, Wallace and Cook, 1989). The 170H-
progesterone assay involved the use of microencapsulated antibody. DHAS was
measured directly by RIA using a commercial kit (Diagnostic Products Corporation).
7.3 Results.
7.3.1. Urinary excretion of androsterone and aetiocholanolone.
The excretion of both A and E was significantly increased by testosterone
administration in all men (Figure 7.1). Excretion of A was increased from 2.12 ± 0.35
mg/24 hrs to 3.49 ± 0.38 mg/24 hrs in the azoospermic group (p<0.005), and from





The effect of testosterone treatment on urinary excretion of
androsterone and aetiocholanolone in those men becoming
azoospermic and those remaining oligozoospermic.
Open columns, baseline.
Hatched columns, after 16 weeks of testosterone treatment.
* p<0.02
** p<0.005
*** p<0.001 all vs baseline.
Mean ± sem, n=18, azoospermic group
n=15, oligozoospermic group.
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(pcO.OOl). Excretion of E was increased from 2.00 ± 0.29 mg/24 hrs to 3.15 ± 0.39
mg/24 hrs in the azoospermic group (p<0.02), and from 1.86 ± 0.27 mg/24 hrs to
3.07 ± 0.40 mg/24 hrs in the oligozoospermic group (pcO.OOl). Calculation of the
E/A ratio (Figure 7.2) showed that there was a small but statistically significant
decrease in the ratio in the azoospermic group from 1.02 ± 0.08 to 0.93 ± 0.07
(p<0.01), but there was no change in the ratio in the oligozoospermic group (0.97 ±
0.08 to 0.99 ± 0.08).
There was a close correlation between A and E excretion both at baseline and after
16 weeks of testosterone treatment (Figure 7.3, a and b). The correlation coefficient
was 0.90 at baseline, and 0.84 after 16 weeks of testosterone treatment (pcO.OOl in
both cases), using results for all subjects.
7.3.2 Urinary excretion of Cortisol metabolites.
Three major urinary metabolites of Cortisol were measured: the 5ocR and 5pR pair
aTHF and THF, and THE. The excretion of all three metabolites was not significantly
affected in either group after 16 weeks of testosterone treatment (nor were there any
significant effects when the results were analysed as one group). Results are shown in
Table 7.1 and Figure 7.4. This shows that although the 24 hr excretion of the
metabolites appeared to be unchanged in both groups, there was a statistically
significant increase in the THF/aTHF ratio in the oligozoospermic group from 1.13 ±
0.14 to 1.30 ± 0.15 (p<0.005), but no change in that ratio in the azoospermic group
(1.27 ± 0.14 to 1.28 ± 0.12) (Figure 7.5).
Table 7.1
aTHF THF THE
Group Baseline Treatment Baseline Treatment Baseline Treatment
Azoospermic 2.01 2.02 2.20 2.41 3.82 3.95
±0.30 ±0.25 ±0.27 ±0.29 ±0.46 ±0.53
Oligo¬ 2.70 2.41 2.49 2.46 4.45 3.94
zoospermic ±0.51 ±0.53 ±0.29 ±0.28 ±0.47 ±0.56
24 hr urinary excretion of aTHF,THF and THE. All values mg/24 hrs, mean ± sem.
The THE/(THF+aTHF) ratio was also significantly reduced in the oligozoospermic
group after 16 weeks of testosterone treatment, from 0.94 ± 0.10 to 0.84 ± 0.06
Azoospermic Oligozoospermic
Figure 7.2.
Effect of testosterone on urinary E/A ratio in those
men becoming azoospermic and those remaining
oligooospermic.
Open columns, baseline.
Hatched columns, after 16 weeks testosterone
treatment.
* p<0.01 vs baseline.
Mean ± sem, n=18, azoospermic group
n=15, oligozoospermic group.
(a)
oJ i —i 1 1 1 1
0 2.0 4.0 6.0 8.0 10.0
Androsterone, mg/24 hrs
Figure 7.3.
Correlation between 24 hr urinary excretion of
Androsterone and Aetiocholanolone.
(a) Baseline.



























The effect of 16 weeks testosterone treatment on 24 hr
urinary excretion of the major metabolites of Cortisol,
aTHF, THF and THE, in those men becoming





Hatched columns, after 16 weeks testosterone treatment.





The effect of testosterone treatment on THF/aTHF ratio
in those men becoming azoospermic and those
remaining oligozoospermic.
Open columns, baseline.
hatched columns, after 16 weeks testosterone treatment.
* p<0.005 vs baseline
Mean ± sem, n=18, azoospermic group
n=15, oligozoospermic group.
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(p<0.05), but was unchanged in the azoospermic group (0.93 ± 0.05 to 0.90 ± 0.05)
(Figure 7.6).
The correlation between urinary excretion of aTHF and THF was determined. The
correlation coefficient was 0.82 (p<0.001) both at baseline and after 16 weeks of
testosterone treatment, using results for all subjects (Figure 7.7). Correlations were
also determined between C19 and C21 p/a ratios, i.e. between E/A and THF/aTHF
ratios (Figure 7.8). The correlation coefficient was 0.78 at baseline and 0.90 after 16
weeks of testosterone treatment.
7.3.3 Plasma concentration of 170H-progesterone and urinary excretion
of pregnanetriol.
Plasma concentrations of 170H-progesterone were reduced in both groups, from 4.6 ±
0.4 nmol/1 to 2.5 ± 0.2 nmol/1 in the azoospermic group (p<0.001), and from 5.4 ± 0.3
nmol/1 to 2.4 ± 0.2 nmol/1 in the oligozoospermic group (p<0.005) (Figure 7.9a) after
16 weeks of testosterone treatment
Pregnanetriol excretion was also significantly reduced in both groups after 16
weeks of testosterone treatment. In the azoospermic group, pregnanetriol excretion
was reduced from 0.95 ± 0.14 mg/24 hrs to 0.59 ± 0.11 mg/24 hrs (p<0.005), and in
the oligozoospermic group from 0.99 ±0.13 mg/24 hrs to 0.55 ±0.15 mg/24 hrs
(p<0.01) (Figure 7.9b).
7.3.4 Plasma concentration of androstenedione.
Plasma concentrations of androstenedione were significantly increased in both groups
after 16 weeks of testosterone treatment (Figure 7.10). In the azoospermic group,
plasma androstenedione was increased from 6.8 ± 0.5 nmol/1 to 9.3 ± 0.5 nmol/1
(p<0.001), and from 6.9 ± 0.5 nmol/1 to 8.5 ± 0.7 nmol/1 in the oligozoospermic group
(p<0.005).
7.3.5 Plasma concentration and urinary excretion of DHAS.
The plasma concentration ofDHAS was reduced by testosterone treatment, but only in
those men who became azoospermic (Figure 7.11a). Thus after 16 weeks of
testosterone treatment, plasma concentrations of DHAS were reduced from 11.5 ± 1.6
|imol/l to 9.4 ±1.0 [imol/1 (p<0.05) in the azoospermic group, whereas there was no
change in the plasma concentration of DHAS in the oligozoospermic group (9.1 ±1.3




















The effect of testosterone treatment on the urinary
ratio of THE/(aTHF + THF) in those men becoming
azoospermic and those remaining oligozoospermic.
Open columns, baseline
Hatched columns, after 16 weeks testosterone
treatment.
* p<0.05 vs baseline





Correlation between the urinary excretion of aTHF
and THF, the 5aR and 5pR metabolites of Cortisol.
Data from all men.
(a) At baseline
(b) After 16 weeks testosterone treatment.
Correlation coefficient r=0.82, p<0.001 in both cases.
Aetiocholanolone/Androsterone ratio
Figure 7.8
Correlation between (3/a ratios of CI9 and C21
steroids. Results from all men.
(a) Baseline
(b) After 16 weeks testosterone treatment.
Correlation coefficients
r= 0.78 (p<0.001) baseline







































The effect of testosterone treatment on plasma concentrations
of 17aOH-progesterone and the urinary excretion of





Hatched columns, after 16 weeks testosterone treatment.
* p<0.01
** p<0.005
*** pcO.OOl vs baseline.





Effect of testosterone on plasma concentrations of
androstenedione in those men becoming azoospermic
and those remaining oligozoospermic.
Open columns, baseline.
Hatched columns, after 16 weeks testosterone
treatment.
* p<0.005
** p<0.001 vs baseline.
Mean ± sem, n=18, azoospermic group
n=15, oligozoospermic group.
Chapter 7 94
DHAS in urine is hydrolysed to DHA prior to analysis by this methodology, and
the result thus obtained is the sum of DHAS and DHA. To distinguish between plasma
and urinary results, the convention of referring to the urinary results as DHA will be
followed.
The urinary excretion of DHA showed parallel changes. Thus it was significantly
decreased by testosterone treatment in the azoospermic group, from 0.91 ± 0.19 mg/24
hrs to 0.37 ± 0.10 mg/24 hrs (p<0.002), but excretion of DHA in the oligozoospermic
group was unchanged (0.85 ± 0.26 mg/24 hrs to 0.72 ± 0.30 mg/24 hrs). These
results are shown in Figure 7.11b. Urinary excretion of 160H-DHA was also
measured, and similar results were obtained. Excretion of 160H-DHA was 0.91 ±
0.14 mg/24 hrs in the azoospermic group at baseline, and 0.79 ± 0.15 mg/24 hrs after
16 weeks of testosterone treatment, and were 0.93 ± 0.20 mg/24 hrs in the
oligozoospermic group at baseline and 0.92 ± 0.30 mg/24 hrs after 16 weeks of
testosterone treatment. The decrease in the azoospermic group did not reach statistical
significance due to the wide individual variation, but the sum of DHA + 160H-DHA
was significantly reduced in this group, from 1.82 ± 0.31 mg/24 hrs to 1.15 ± 0.25
mg/24 hrs (p<0.05), while there was no change in the oligozoospermic group (1.78 ±
0.45 mg/24 hrs to 1.65 ± 0.53 mg/24 hrs).
Urinary excretion of llfi-hydroxy androsterone (lip-OHA) and llfl-hydroxy
aetiocholanolone (ll(3-OHE) was also measured (Figure 7.12). In the azoospermic
group, excretion of both metabolites was reduced, although that of 1lfl-OHA did not
reach statistical significance. Excretion of ll|3-OHA was reduced from 0.92 ± 0.15
mg/24 hrs to 0.72 ± 0.11 mg/24 hrs and of 11P-OHE from 0.37 ± 0.06 mg/24 hrs to
0.29 ± 0.04 mg/24 hrs (p=0.05). In the oligozoospermic group, neither metabolite
was significantly affected. 1 lp-OHA excretion was 1.04 ± 0.12 mg/24 hrs at baseline
and 0.91 ± 0.17 mg/24 hrs after 16 weeks of testosterone treatment, lip-OHE
excretion was 0.35 ± 0.05 mg/24 hrs and 0.34 ± 0.04 mg/24 hrs respectively.
7.4 Discussion.
There were no differences in the plasma concentration or urinary excretion of any of the
steroid metabolites reported in this Chapter between those men who became
azoospermic and those remaining oligozoospermic, either at baseline or after 16 weeks
of testosterone treatment. The absolute concentrations of these parameters cannot
therefore be used to distinguish between the groups, either before or during treatment.
There were, however, several differences between the two groups of men in the pattern
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the headings of effects on 5ot/p reductase metabolites, Cortisol metabolites, testosterone
precursors, and adrenal androgens.
7.4.1 5oc/(3 reductase metabolites
Androsterone and aetiocholanolone are 17-ketosteroids excreted by the liver after the
metabolism of testosterone by 5aR and 5(3R respectively . The increase in urinary
excretion of these two steroids (Figure 7.1) therefore reflects the increase in plasma
testosterone concentrations during testosterone treatment (Chapter 3), although
excretion of both A and E was increased by approximately 60% compared to increases
of over 100% in plasma testosterone. In contrast there was, as expected, no evidence
for an effect on the concentrations ofCortisol metabolites in urine (Figure 7.4), either in
the excretion of aTHF, THF or THE.
These results were further examined to investigate whether there was any evidence
for an effect of testosterone administration on the activity of hepatic 5ocR. The activity
of this enzyme in vivo is often expressed as a ratio of the products of 5(3R to 5aR,
i.e.E/A or THF/aTHF, as it has been shown that the same enzyme converts testosterone
to A as Cortisol to aTHF (Fisher et al„ 1978). This assumes that the two enzymes are
independently controlled, which is without experimental basis, but has provided useful
in the investigation of 5aR deficiency, the effects of finasteride on 5aR activity, and
steroid metabolism in PCOS (Peterson et al., 1977; Imperato-McGinley et al., 1990;
Stewart et al., 1990). In these studies, (3/oc ratios were found to be greatly elevated in
5aR deficiency or following finasteride administration, from approximately unity to
between 2 and 12 in 5aR deficiency (E/A) and to 25 (E/A) or as much as 150
(THF/aTHF) following finasteride administration (Imperato-McGinley et al., 1990). In
PCOS, the E/A ratio was 0.75 compared to 1.35 in controls, and the THF/aTHF ratio
was 1.10 compared to 1.64 in controls, and this increase in activity of 5aR has been
suggested to be the aetiological abnormality in this condition (Stewart et al., 1990).
Plasma androgen concentrations (androstenedione and testosterone) were 75% higher
in the PCOS group than in the control group (Stewart et al., 1990), whereas plasma
testosterone was unaffected by finasteride treatment but was approximately doubled in
the subjects with 5aR deficiency (Peterson et al., 1977; Imperato-McGinley et al.,
1990).
These comparisons suggest that finasteride causes a much greater inhibition of
hepatic 5aR than is present in subjects with autosomal recessive 5aR deficiency, and
may be a consequence of the normal expression of 5aR 1 in that condition (Andersson
et al., 1991). Finasteride has a much lower IC50 for 5aR 2 than 5aR 1 (Andersson et
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al., 1991), but this degree of selectivity in vitro may not be so clear in vivo, especially
at the higher doses used in the study of Imperato-McGinley et al. (1990).
In the present study, testosterone administration was found to cause a small but
statistically significant decrease in the E/A ratio in the azoospermic group, with no
effect in the oligozoospermic group (Figure 7.2). In contrast, there was a significant
increase in the THF/aTHF ratio in the oligozoospermic group but not in the
azoospermic group (Figure 7.5). The E/A ratio result therefore suggests increased 5aR
or decreased 5(3R activity in the azoospermic group during testosterone treatment, while
the THF/aTHF result suggests decreased 5ctR activity in the oligozoospermic group. It
therefore appears that testosterone administration has little overall effect on hepatic 5aR
activity in either group, particularly compared to the effect of 5aR deficiency or
finasteride administration.
Close correlations were found between the urinary excretion of 5aR and 5[lR pairs,
both before and after 16 weeks of testosterone treatment (Figure 7.3). Similar
correlations were found for both androgens and Cortisol metabolites (Figure 7.7), and
between p/a ratios of both classes of metabolite (Figure 7.8). These results suggest
that the same enzymes convert C19 and C21 steroids, as previously suggested (Fisher et
al., 1978), and that the same pool of precursor is metabolised by the two enzymes.
Orchidectomy has been reported to increase 5aR activity and mRNA in the liver
and adrenal of rats, and androgens have been shown to inhibit 5aR activity and reduce
the concentration of 5aR mRNA in the adrenal cortex (Andersson et al., 1989; And6 et
al., 1989; Canonaco et al, 1989; Lephart et al., 1991). These effects contrast with the
effects of androgens in the skin, prostate and epididymis (using human tissue), in
which an enhancing effect ofDHT on 5aR activity and mRNA concentrations has been
demonstrated (Chapter 1.6). A further contrast is evident in reports of urinary
excretion of androgens by men with testicular feminisation; this group of men were
found to have a normal urinary E/A ratio, in contrast to the very low concentration of
5aR activity in pubic skin in this condition (Peterson et al., 1977; Kuttenn et al.,
1979). It therefore appears that hepatic and adrenal 5aR may have different control
mechanisms to the enzyme elsewhere in the body, but extrapolation between species
may be misleading.
7.4.2 Other effects on Cortisol metabolites
The conversion of Cortisol to cortisone is a major route of inactivation of the
biologically active hormone, and is carried out by the enzyme ll(3-hydroxysteroid
dehydrogenase (1IPOHSD). This enzyme has a striking similarity of function to 5aR
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as a modulator of potency of steroid effect, in that it is believed to protect the distal
tubule of the kidney from the effects of Cortisol (Fraser, 1990; Walker and Edwards,
1991). The mineralocorticoid receptor has a similar affinity for aldosterone and
Cortisol, but as the latter is produced in 1000 times the amount and does not have the
biological effect of the mineralocorticoid, the kidney appears to be protected from it.
This is afforded by the conversion of Cortisol to cortisone (which has low affinity for
the mineralocorticoid receptor) by the enzyme 11POHSD, which occurs in a paracrine
manner within the tubule. Deficiency of this enzyme results in hypokalaemia and
hypertension but without mineralocorticoid excess. Cortisone is predominantly
excreted in the urine as tetrahydrocortisone (THE), and the activity of this enzyme can
be expressed as the ratio of THE to THF and aTHF, i.e. THE/(aTHF+THF). The
results presented here suggest that 11 pOHSD activity is reduced by testosterone
administration, but only in the oligozoospermic group, with no effect on the ratio in the
azoospermic group (Figure 7.6). As with the p/a ratios discussed above, this effect
was only small, but was statistically significant
Physiological modulation of 11POHSD activity is not established, although several
steroid hormones have been reported to affect it and it is inhibited by liquorice (Walker
and Edwards, 1991). Thus hepatic lipOHSD activity is higher in male than female
rats, it is reduced by orchidectomy, and is restored by testosterone administration (Lax,
Ghraf and Schriefers, 1978). 11POHSD is present in the rat testis; immunofluorescent
staining was undetectable in the foetal testis and before sexual maturation, but in the
adult the entire interstitial region showed dense staining (Phillips et al., 1989). These
authors proposed that 11POHSD serves to protect the adult testis from the effects of
corticosterone, as corticosteroids are known to inhibit testosterone synthesis (Bambino
and Hsueh, 1981). Men with Cushing's syndrome have reduced plasma
concentrations of testosterone and pathological changes in the testes (McKenna,
Lorber, Lacroix and Rabin, 1979).
No clear conclusion can be drawn from these preliminary findings, but the
demonstration of a difference between men remaining oligozoospermic and those
becoming azoospermic on supraphysiological doses of testosterone in the activity of an
enzyme which may be of importance in intratesticular steroidogenesis and which shows
some functional parallels with 5aR is noteworthy. The results presented here do not
provide any evidence as to the site of action of testosterone on 11 pOHSD activity.
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7.4.3 Effects on testosterone precursors
Plasma and urinary concentrations of two intermediates in steroid biosynthesis were
also determined, to investigate the effect of testosterone administration for a prolonged
period on steroid synthesis and whether there were detectable differences between men
becoming azoospermic and those remaining oligozoospermic.
170H-progesterone is a key intermediate in steroid biosynthesis, as it is the product
of 17a-hydroxylase on progesterone and the site at which corticosteroid and sex steroid
biosynthetic pathways diverge (Figure 1.1). As an intermediate of the A4 pathway in
the testis, it may not be of as great importance as the A5 intermediate
170H-pregnenolone, but it is found in spermatic vein blood in concentrations
approximately 40 fold greater than in peripheral plasma (Laatikainen, Laitinen and
Vihko, 1971; Hammond et al., 1977) and parallel increases in plasma testosterone and
170H-progesterone concentrations are seen after hCG injection and LH infusion in
men (Laatikainen et al., 1971; Forest, Lecog and Saez, 1979; Nankin, Lin, Murono,
Osterman and Troen, 1980). The blood production rate has been estimated to be 1.8
mg/24 hrs, with 90% secreted by the testes (Strott, Yoshimi and Lipsett, 1969). The
major urinary metabolite of 170H-progesterone is pregnanetriol.
Plasma concentrations of 170H-progesterone and 24 hr urinary excretion of
pregnanetriol were reduced after 16 weeks of testosterone treatment in both groups of
men (Figure 7.9), with a fall of approximately 45% in both plasma and urinary
steroids. These results suggest that the A4 pathway is suppressed by testosterone
treatment in all men, and confirms the result of Strott et al. (1969), who found that
androgen administration (40 mg fluoxymesterone for 3 days) reduced the plasma
concentration of 170H-progesterone by 90% in normal men. As the great majority of
plasma 170H-progesterone is derived from the testis, it is likely that this is secondary
to the suppression of LH secretion by testosterone (Chapter 3), although the rapidity of
effect reported by Strott et al. is difficult to reconcile with the time-course of the fall in
LH secretion reported here. It is not possible to make deductions as to the degree of
ongoing activity of testicular steroidogenesis on the basis of this result, as even on the
most simple assumption that the rate of secretion of intermediates reflects the
intracellular concentration, this will be affected by changes in both the rate of synthesis
of the intermediate and the rate of further metabolism, Thus if the rate of synthesis is
drastically reduced, an equal fall in the rate ofmetabolism will approximately maintain
the intracellular concentration. LH enhances the transcription of genes encoding
enzymes in the steroidogenic pathway, and a fall in the concentration of these enzymes
results from the absence of LH (Waterman and Simpson, 1989).
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Androstenedione is the proximate precursor of testosterone (Chapter 1.2), and is
secreted by the testis (Hammond et al., 1977) and adrenal cortex. In some patients,
plasma androstenedione concentrations were increased following orchidectomy, and in
this group (who also showed a lesser fall in plasma testosterone), the remaining plasma
concentrations of testosterone and androstenedione were suppressed by dexamethasone
(Sciarra, Sorcini, di Silverio and Gagliardi, 1973). In a second group of men whose
plasma testosterone concentrations fell more after orchidectomy, there was only a
small, transient increase in plasma androstenedione concentrations. Others have
reported a decrease in plasma androstenedione concentrations after orchidectomy
(Bdlanger, Dupont and Labrie, 1984). These studies were carried out on older men
being treated for prostatic carcinoma, and may thus not be comparable with healthy,
younger men. Nevertheless, these results show a smaller effect of orchidectomy on
plasma androstenedione concentrations than on plasma testosterone or 170H-
progesterone concentrations, and are therefore consistent with the adrenal being an
important source of androstenedione in men.
The fall in plasma 170H-progesterone and urinary pregnanetriol is thought to
reflect reduced testicular steroidogenesis, and it would appear reasonable to assume that
testicular androstenedione secretion would be similarly reduced. However, after 16
weeks of testosterone administration, plasma androstenedione concentrations were
increased in both groups of men, by approximately 35% (Figure 7.10). This increase
may reflect an increase in secretion from the adrenal, but perhaps a more likely
explanation is an increased conversion of administered testosterone to androstenedione
in the skin. The skin has 17P*hydroxysteroid dehydrogenase activity (Sansone-
Bezzano, Seeler, Cummings and Reisner, 1979) and contains a high concentration of
androstenedione (approximately 3 fold greater than that of testosterone, Toth and
Faredin, 1985). Perhaps clearer evidence for an effect of testosterone administration on
the secretion of androgens by the adrenal is discussed below, in the light of the effect of
testosterone treatment on the plasma concentration of DHAS and urinary excretion of
DHA and 1 lp-OHA and 1 lp-OHE.
The plasma concentration of androstenedione is also elevated by the administration
of finasteride in doses which caused an increase in plasma testosterone without changes
in plasma LH concentrations (Gormley et al., 1990). In rats, finasteride causes an
increase in intratesticular testosterone concentration (George et al., 1989). The increase
in plasma androstenedione with finasteride treatment may therefore reflect increased
back-conversion from testosterone both in the skin and testis.
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7.4.4 Effects on adrenal androgens
DHAS and DHA are secreted by the human testis, but only in small quantities (Gandy
and Peterson, 1968; Laatikainen et al., 1971; Nieschlag, Loriaux, Ruder, Zucker,
Kirschner and Lipsett, 1973; de la Torre, Hedman, Nordn and Sjoberg, 1986). This is
supported by the finding that orchidectomy does not affect plasma concentrations
(Gandy and Peterson, 1968, Parker, Lai, Wolk, Lifrak, Kim, Epstein, Hadley and
Miller, 1984; Bdlanger et al., 1984). In contrast, the gradient of DHA across the
adrenal is large (Nieschlag et al., 1973). DHAS is also secreted by the adrenal
(Nieschlag et al., 1973), but in small quantities; the very low metabolic clearance rate
(20 1/day) compensates for this, resulting in a large plasma pool (Baulieu, Corpdchot,
Dray, Emiliozzi, Lebeau, Mauvais-Jarvis and Robel, 1965). Thus most plasma DHAS
is thought to be secreted directly, with only approximately 15% arising from peripheral
conversion of DHA, whereas DHA has a very high rate of secretion and metabolic
clearance rate (18001/day, Horton and Tait, 1967), and the majority of circulating DHA
is thought to arise from conversion of DHAS.
Infusion of ACTH increases the secretion of DHA (Nieschlag et al., 1973;
Vermuelen and And6, 1978), and dexamethasone caused approximately 65%
suppression of plasma DHA concentrations (Nishida, Matsumara, Masaharu, Oyama
and Tenku, 1977). Synchronous secretion of DHA and Cortisol has been reported
(Rosenfield, Hellman, Roffwarg, Weitzman, Fukushima and Gallagher, 1971),
presumably in response to ACTH, but others have proposed that ACTH may have a
more long-term permissive effect on adrenal androgen secretion in physiological
conditions (Parker and Odell, 1980).
The existence of one or more additional adrenal androgen stimulatory factors has
been proposed to account for situations in which Cortisol secretion appears to be
dissociated from that of adrenal androgens (Grumbach, Richards, Conte and Kaplan,
1978; Parker and Odell, 1980), and Parker, Lifrak and Odell (1983) reported the
isolation of a glycoprotein of 60,000 daltons molecular weight from human pituitary
which stimulated the production ofDHA but not Cortisol from dog adrenal cells. The
situations in which adrenal androgen secretion is dissociated from that of Cortisol
include adrenarche, during fasting, and during recovery from adrenal suppression. The
term adrenarche refers to the rise in adrenal androgens which occurs before puberty,
and contributes to the development of pubic and axillary hair (Albright, 1947). At this
time there is increased secretion of DHA without increased secretion of Cortisol
(Hopper and Yen, 1975), and it is associated with the development of the zona
reticularis of the adrenal cortex (Dhom, 1973).
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Steroidogenesis and the response to ACTH are similar in cells from the zona
fasciculata and the zona reticularis in culture (Neville and O'Hare, 1979), which implies
that there is no fundamental difference in the properties of the two cell types. During
steroidogenesis, pregnenolone leaves the mitochondrion, and is then converted by the
enzyme 17a-hydroxylase to 17a-hydroxypregnenolone and then by Cn^o-lyase to
DHA. Alternatively, 3P-hydroxysteroid dehydrogenase can convert
17a-hydroxypregnenolone to 17a-hydroxyprogesterone, which is then converted to
Cortisol. ACTH induces increases in the activity of all these enzymes, but in the human
adrenal, 3|3-hydroxysteroid dehydrogenase activity is low (Hornsby and Aldern,
1984). It has therefore been suggested that discrepancies between adrenal androgen
and Cortisol secretion may result from changes in the activity of 3(3-hydroxysteroid
dehydrogenase, with a decrease in activity reducing the conversion of
17a-hydroxypregnenolone to 17a-hydroxyprogesterone and thus promoting the
synthesis of DHA relative to Cortisol (Adams, 1985).
An alternative possibility is that the regulatory site is the enzyme Cn^o-lyase. This
is suggested by the finding that, as the adrenal matures, there is increased supply of
17a-hydroxypregnenolone in response to ACTH stimulation , the percentage converted
to DHA increases, and there is less converted to the A4 pathway (Rich, Rosenfield,
Lucky, Helke and Otto, 1981). These findings suggest that there is an increase in
activity of Cn^o-tyase with maturation, with reduced activity of 3(3-hydroxysteroid
dehydrogenase. A reduction in activity ofCn^o-tyase has been suggested to underlie
the attenuation of ultradian and circadian rhythms of DHA secretion in postmenopausal
women, who showed a reduced pulse amplitude ofDHA secretion without any change
in pulse frequency, and a decrease in the acrophase amplitude compared to younger
cycling women, without any effect on Cortisol secretion (Liu, Laughlin, Fischer and
Yen, 1990).
These findings account for the dissociation between adrenal androgen and Cortisol
metabolism without the need for an adrenal androgen-stimulating hormone, although
Rich et al. (1981) suggest the existence of an "adrenarche factor", to bring about the
development of an ACTH-responsive zona reticularis.
Urinary excretion of DHA was reduced from 910 + 140 (tg/24 hrs to 370 ± 101
fig/24 hrs in the azoospermic group after 16 weeks of testosterone treatment, but there
was no effect in the oligozoospermic group (Figure 7.11). Urinary excretion of
160H-DHA was also selectively reduced in the azoospermic group, although individual
concentrations were very variable and the result did not reach statistical significance.
These changes were paralleled by changes in plasma concentrations of DHAS, also
selectively reduced in the azoospermic group, although the change was smaller. There
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was no change in the plasma concentration of DHAS in the oligozoospermic group
(Figure 7.11).
11J3-OHA and llfi-OHE are products of the enzyme ll^-hydroxylase. This
enzyme is thought to be selectively present in the adrenals: thus activity was
undetectable in the ovary, and castrated men had normal levels of plasma 11(5-
hydroxyandrostenedione (Goldzieher et al., 1978). Urinary excretion of both these
metabolites were reduced in the azoospermic group, although the reduction in excretion
of 11P-OHA did not reach statistical significance (Figure 7.12). There was no effect of
testosterone treatment on either metabolite in the oligozoospermic group. These results
therefore support the DHA and DHA results, and provide further evidence for a
selective effect of testosterone treatment on adrenal androgens.
The physiological importance of adrenal androgens is uncertain, particularly in
men. DHA is a weak androgen, but both DHA and DHAS can be converted to DHT
within the prostate in vivo and in vitro (Farnsworth, 1973; Harper, Pike, Peeling and
Griffiths, 1974). In castrated rats, infusion of DHA increases prostatic DHT
concentrations and prostatic size (Labrie, Bdlanger and Labrie, 1988). A stimulatory
effect on androgen-dependent prostatic gene expression has also been reported in
response to DHA infusion in the castrated rat, and this effect was antagonised by
flutamide (Labrie, Simard, Zhao, Belanger, Pelletier and Labrie, 1989). Castration has
a limited effect on prostatic DHT in man, causing only 70% reduction in tissue
concentrations (Geller, Albert, Loza, Geller, Stultzing and Vega, 1978), which
supports an important role for adrenal androgens as precursors. This is also supported
by the recent demonstration of a much more complete suppression of prostatic DHT
concentrations by finasteride (Geller, 1990, McConnell et al., 1992). Conversion of
androstenedione, DHA and DHAS to testosterone and DHT has also been demonstrated
in skin (Cameron, Baillie, Grant, Milnes and Thompson, 1966; Gomez and Hsia,
1968; Kaufman, Stanczyk, Matteri, Gentzschein, Delgado and Lobo, 1990), by which
these compounds may contribute to hair growth and sebum secretion (Pochi, Strauss
and Mescon, 1963). The adrenal androgens may therefore contribute to the androgenic
load throughout the body, and the two sites discussed here suggest the importance of
5ocR in their action.
Under the conditions of this study, intratesticular testosterone synthesis is
presumed to be suppressed secondary to the suppression of gonadotropin secretion.
The maintained supply of adrenal androgens may therefore contribute to the
maintenance of spermatogenesis in the oligozoospermic group, whereas the fall in
adrenal androgens in the azoospermic group may contribute to the complete
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suppression of spermatogenesis in these men. However, the high circulating
concentrations of administered testosterone is likely to be of greater importance as a
substrate for 5ctR than the weak adrenal androgens.
The selective effect of testosterone on adrenal androgen secretion is also of interest
in the light of the finding that the concentration of DHAS in plasma is lower in Chinese
men than in Caucasians (Lookingbill et al., 1991). The difference between plasma
concentrations reported in that study (9.5 pmol/1 in Caucasians vs. 6.5 pmol/1 in
Chinese) is very similar to the magnitude of the effect of testosterone in the
azoospermic group reported here, although Lookingbill et al. (1991) did not feel that
the differences in adrenal androgens could account for the larger differences in the
concentrations of 5a-reduced androgens which they found.
In the present study, no effects on the excretion of THF, aTHF or THE, the major
urinary metabolites of Cortisol, were found, suggesting a selective effect of testosterone
on adrenal androgen but not glucocorticoid secretion.
In summary, the results presented in this Chapter demonstrate that during testosterone
administration:
1. There is no significant change in hepatic 5aR activity, as reflected in the metabolism
of either C19 or C21 steroids
2. There is a selective reduction in the plasma concentration of DHAS and urinary
excretion of its major metabolite DHA in the azoospermic group, suggesting decreased
adrenal production. These weak androgens may contribute to the maintenance of
spermatogenesis in the oligozoospermic group.
3. Excretion of 170H-progesterone, an intermediate in testicular steroidogenesis, was
inhibited, whereas the plasma concentration of androstenedione was increased,
probably reflecting increased conversion of administered testosterone.
The administration of supraphysiological doses of testosterone therefore appears to
demonstrate an interaction between testosterone and adrenal androgen metabolism, and
to result in a condition in which there is dissociation of adrenal androgen and Cortisol
secretion. Whether this reflects alteration of enzyme activity in the adrenal, or the
secretion of an adrenal androgen-stimulating hormone from the pituitary remains to be
established, but the lack of differential sensitivity of the hypothalamo-pituitary axis to
the negative feedback effects of testosterone on gonadotropin secretion between the
men becoming azoospermic and those remaining oligozoospermic may indicate that the
site of action lies in the adrenal.
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The Effect of Testosterone on Sebum Excretion Rate
8.1 Introduction.
Sebum is the holocrine secretion of the sebaceous gland. These glands are widely
situated in the body but are absent from the palms and soles, with up to 900 glands/cm2
in areas such as the face (Benfenati and Brillanti,1939). They are usually associated
with hair follicles (thus making up the pilosebaceous unit, PSU), but can be found
alone at sites of transition between skin and mucous membrane, eg the Meibomian
glands of the eyelids.
Sebaceous glands throughout the body are similar in structure. There is a single or
collection of acini opening into the piliary duct, surrounded by a connective tissue
capsule, which also acts as a fibrous support. The lipid-producing cells are arranged
according to their degree of differentiation, with small cells which are relatively
undifferentiated peripherally. As the cells divide and mature, they accumulate lipid
which is produced by the smooth endoplasmic reticulum, and are progressively found
more centrally. These cells may be 100-fold larger than the peripheral cells (Tosti,
1974). Finally, the cells become necrotic, releasing the sebum into the duct and thence
to the skin approximately 7 days later. This mixture of lipids consists of triglycerides,
squalene, wax esters and a relatively low concentration of cholesterol (Greene,
Downing, Pochi and Strauss, 1970; Lewis and Hayward, 1971).
The pilosebaceous units are formed in the foetal skin at 2-4 months of age and are
active in utero, with a similar rate of sebum secretion in the first week of life as in the
adult (Agache, Blanc, Barrand and Laurent. 1980). The glands then involute and
remain quiescent until puberty, when there is an increase in size and activity, with
sebum secretion increasing approximately 5 fold in men (Pochi, Strauss and
Downing, 1979). The rate of secretion remains constant through adult male life, only
decreasing in old age (Plewig and Kligman, 1978). In women, the adult rate is 75% of
that of men, and declines after the age of 50 (Pochi and Strauss, 1974). This sex
difference (and post menopausal decline) clearly suggests a hormonal influence in the
control of sebum secretion.
Early studies suggested a stimulatory effect of testosterone on sebum secretion
(Hamilton, 1941; Jarrett, 1959), and the role of androgens was clearly demonstrated by
Strauss and Pochi (1961). These authors showed that the oral administration of
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methyltestosterone to prepubertal boys stimulated sebum secretion and increased the
size of the sebaceous glands, and they obtained similar results in eunuchs. However,
they failed to find any effect of testosterone administration in normal adult men
(Strauss, Kligman and Pochi, 1962). This was attributed to sebum secretion being
already maximally stimulated in adult men. An alternative explanation is that the
methodology used was insufficiently sensitive, as they later found that a dose of 300mg
testosterone propionate weekly produced a small increase in sebum secretion (Pochi
and Strauss, 1974). 200mg testosterone oenanthate i.m. by weekly injection for 10
weeks also increased sebum secretion slightly in 2 out of 3 elderly men (Smith and
Brunot, 1961).
More recently, it has been shown that anabolic steroids increase sebum secretion
and the size of sebaceous glands in athletes (Kirdly, Alen, Rahkila and
Horsmanheimo,1987; Kiraly, Collan and Aldn, 1987) although the mixture of steroids
taken and the variable self-administered doses makes quantification of the androgenic
stimulus difficult. There is also a considerable body of data from animal experiments
showing similar effects of androgen administration on sebum production (Ebling,
1974; Shuster and Thody, 1974).
There are two main processes in sebaceous glands which may be the site of action
of androgens. One is cell division, the other lipid synthesis. Both these appear to be
stimulated by testosterone (in animal experiments), but by separate mechanisms
(Ebling, 1957; Ebling and Skinner, 1967). Thus testosterone stimulates lipid synthesis
and the mitotic activity of the gland, and both effects are inhibited by the antiandrogen
cyproterone acetate. This contrasts with the inhibitory effect of oestradiol on lipid
production;. This effect was evident at doses which did not affect mitotic activity,
either basally or after simulation by testosterone (Ebling, 1973).
The mechanism of action of testosterone in the PSU appears to be similar to that at
other androgen target organs. Thus androgen receptors are found in skin, and pubic
and axillary hair are deficient in subjects with testicular feminisation (Keenan et al.,
1974). The skin is capable of metabolising testosterone, and DHT is a major product
(Gomez and Hsia, 1968). The skin therefore contains the enzyme 5aR (Wilson and
Walker, 1969; Northcutt et al., 1969; Voigt, Fernandez and Hsia, 1970). 5ocR activity
is very high in genital skin, which is capable of converting up to 80% of incubated
testosterone to 5a-reduced metabolites (Gomez and Hsia, 1968). Activity in non-
genital areas is low, and in sexual but not genital skin, eg the pubic area, is intermediate
but higher in men than women (Wilson and Walker, 1969). Similar regional
differences have been reported in experiments using cultured monolayers of fibroblasts
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(Wilson, 1975), which technique has allowed further characterisation of the enzyme in
skin.
5aR activity is therefore sex-dependent, and in both sexes is high in skin derived
from the urogenital ridge. Indeed, 5aR activity has been measured in human foetal
tissue, and was found to be high in the urogenital tubercle, fold and swelling, but very
low in non-genital skin (Siiteri and Wilson, 1974). This may explain the differences in
pubic hair growth at puberty between the sexes, and why males with a congenital
deficiency of the enzyme show female-type pubic hair growth (Peterson et al., 1977).
Micro-dissection techniques have allowed the demonstration that the majority of
5aR activity in the skin is found in the sweat and sebaceous glands, with minimal
activity in the epidermis (Hay and Hodgins, 1978; Takayashu, Wakimoto, Itami and
Sano, 1980), and the observation that adolescents with 5aR deficiency do not suffer
from acne suggests that DHT may be the major active androgen, although there are no
reports of sebum secretion rate in these individuals (Peterson et al., 1977).
Puberty in males is accompanied by an increase in 5aR activity in pubic skin
(Kuttenn and Mauvais-Jarvis, 1975), having been very low before puberty. In
contrast, activity in genital skin is high throughout childhood, and is the same as at
birth and after puberty. Similar results were obtained when males with
hypogonadotrophic hypogonadism were treated with hCG; in these subjects there was
an increase in 5aR activity in pubic skin before the clinical onset of puberty (Kuttenn
and Mauvais-Jarvis, 1975). In vitro studies using cultured fibroblasts have shown that
testosterone or DHT itself can increase the activity of 5ocR, an effect that is mediated by
the androgen receptor (Mowszowicz et al., 1983). These results suggest that the 5ocR
activity associated with the appearance of secondary sexual characteristics, including
the increase in sebum secretion, is androgen-dependent, and acts as an androgen
amplifier at and after puberty.
The rate of secretion of sebum is therefore androgen-dependent, and the PSU
contains the necessary metabolic pathways for the conversion of testosterone to
5a-reduced metabolites. There is evidence that DHT is, as elsewhere, the active
androgen, and that sebaceous gland 5aR activity is androgen-dependent. The rate of
secretion of sebum is therefore a possible marker of skin 5ocR activity, and one that has
not been previously explored: there are for example no studies on sebum secretion rate
in women with hirsutism. This study was therefore carried out to investigate whether
there are differences in the rate of secretion of sebum between those men becoming
azoospermic on supraphysiological doses of testosterone, and those remaining
oligozoospermic. Comparison with results presented elsewhere in this Thesis allows a
discussion of the usefulness of this approach as a marker of tissue 5aR activity.
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8.2 Method.
The method used was the gravimetric technique of Strauss and Pochi (1961), with
minor modifications. The basis of the method is that sebum is absorbed onto paper
from a delimited area of the skin over a defined period of time, extracted into ether,
dried and weighed.
8.2.1 Preparation.
Pads of 4 cigarette papers (Rizla brand, standard weight) were prepared, stapled at both
ends and the adhesive strip cut off. All pads were then washed in ether and dried
before use. After washing the pads were handled using clean tweezers only. 3 pads
for each of the 4 skin sites sampled were required per subject for each determination.
The mask used was made from Micropore tape, 4cm wide. A 5 cm2 hole from a
strip of tape 10 cm long was cut using a graph paper template. This was conveniently
done by first sticking the tape onto a thin sheet of clear plastic.
8.2.2 Method.
Measurements were carried out starting at 9am, and the temperature of the room was
maintained at 21-23°C. The areas measured were the forehead above the eye and the
upper back over the blade of the scapula. Both sides of the body were sampled to give
duplicate determinations. The skin was first wiped with a gauze swab, and the mask
applied. The first pad of papers was then attached, and held in place with thin strips of
Micropore tape at each end. A folded gauze swab was then applied as a pressure pad,
and held in place with a gauze bandage around the head or strips of wide Micropore
tape on the back.
After 15 min the first pad of papers was removed and discarded. A second pad was
applied, again for 15 min, and discarded. The final pad was then applied, and left in
place for 3 hours. At the end of the collection period, the sebum-loaded pads were
removed and the central area bearing the sebum was cut out. This was facilitated by
holding the pad up to the light, when the sebum area could be clearly seen.
The paper was transferred to foil gallipots which had been pre-weighed on a 5-
figure balance, and the sebum extracted into 20 ml ether for 10 min. The papers were
then transferred into glass beakers, and rewashed twice more in 10 ml ether. All
washings were combined in the foil gallipots, dried, and the gallipots reweighed.
Subtraction gave the quantity of sebum per sample, and determinations on the two sides
of the body were averaged. In each run, blanks were included consisting of pads
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prewashed as in the preparation stage but not applied to the skin, and the blank value
was subtracted from the sample value. Extraction blanks gave values of less than
lOOfig. Results are expressed as mg/3hrs/10cm2. This investigation was carried out
on 32 of the subjects: the other man declined to attend for such a relatively time-
consuming procedure.
The incidence of acne was assessed on both occasions, and was graded using an
adaptation of the scoring described by Lookingbill et al. (1978) into none, mild
(comedones with no or only a few inflammatory papules or pustules), and
moderate / severe.
Statistical significance was calculated using Student's t test for paired or unpaired
values except when results are expressed as percentage increase when the Wilcoxin
signed rank test was used.
8.3 Results.
To assess the reproducibility of the method, samples from the right and left of the body
were compared, before being combined to give the final value. The correlation between
left and right for forehead and upper back is shown in Figure 8.1. This gave a
correlation coefficient of r=0.91, p<0.001. These results are from the baseline
measurements: very similar results were obtained when the measurements were
repeated after 16 weeks of treatment.
The results of SER determinations are shown in Figure 8.2. Mean baseline SER
from forehead was 2.02 ± 0.02 mg/3 hrs/10cm2 in the men who became azoospermic,
and was 2.06 ± 0.22 mg/3 hrs/10cm2 in those who remained oligozoospermic. SER
was consistently less from upper back skin, being 0.78 ± 0.04 mg/3 hrs/10cm2 in the
azoospermic group and 0.77 ± 0.08 mg/3 hrs/10cm2in the oligozoospermic group.
This difference between forehead and back was highly significant for both groups
(p<0.001). There was thus no difference in SER at either anatomical site between the
two groups at baseline.
There was a significant correlation between SER measurements from forehead and
upper back at baseline (r=0.47, p<0.02, Figure 8.3). Further analysis revealed that a
statistically significant correlation was only found in those men who became
oligozoospermic on testosterone treatment (r=0.67, p<0.001 in the oligozoospermic
group; r=0.17 in the azoospermic group). During testosterone treatment there was no
significant correlation in either group, or when all subjects were analysed together.
After 16 weeks of testosterone treatment, many of the subjects reported a subjective
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Correlation between SER from left and right sides at
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Hatched columns, after 16 weeks testosterone treatment.
* p<0.05
** p<0.01 vs baseline.




SER, mg/10 cm2^ hrs, forehead
Figure 8.3
Correlation between SER of forehead and upper
back at baseline.
(a) All men.
(b) Oligozoospermic group only.
Figure 8.4
Increase in SER after 16 weeks of testosterone
treatment in those men becoming azoospermic and
those remaining oligozoospermic, expressed as a
percentage of baseline value.
Open columns, forehead
Hatched columns, upper back.
* p<0.02
** p<0.005, both vs forehead.
Mean ± sem, n=17, azoospermic group
n=15, oligozoospermic group.
Chapter 8 109
which showed a significant increase in both groups of men on both forehead and back
(Figure 8.2). In the azoospermic group, forehead SER had increased to 2.90 ± 0.31
mg/3 hrs/10cm2 (p<0.01 vs baseline), and from the upper back to 1.51 ± 0.15 mg/3
hrs/10cm2 (p<0.001 vs baseline). In the oligozoospermic group, forehead SER had
increased to 2.77 ± 0.15 mg/3 hrs/10cm2 (p<0.02 vs baseline), and from the upper
back to 1.58 ± 0.29 mg/3 hrs/10cm2 (p<0.01 vs baseline). There were again no
differences in SER between the two groups after 16 weeks of testosterone treatment
Results as percentage increase in each area for the two groups are shown in Figure
8.4. In the azoospermic group, SER was increased to 150± 13% of baseline rate from
the forehead, and to 203 ±31% from the back. In the oligozoospermic group, SER
was increased to 156 ± 11% and 206 ± 20% respectively. This demonstrates the
greater increase in SER from the upper back than forehead in both groups (p<0.005,
azoospermic group; p<0.02, oligozoospermic group).
The incidence and severity of acne at the time of the SER determinations is shown
in Table 8.1., together with the sebum excretion results recalculated according to acne
grading.
Table 8.1
Acne Grade None Mild Moderate/Severe
Baseline n= 29 2 0
Treatment n= 5 20 6
SER (+testosterone)
Head 3.50 ± 0.59 2.81 ±0.19 2.31 ± 0.37
Back 1.18 ± 0.08 1.63 ± 0.23 1.55 ± 0.12
SER (% of baseline)
Forehead 195 ±22% 140 ±9% 161 ±24%
Back 214 ±27% 195 ±19% 237 ± 34%
Effect of testosterone on acne scoring; values are numbers of men with each grade of
acne, before and after 16 weeks of testosterone treatment. The centre section of the
table gives SER results after 16 weeks testosterone treatment for the men grouped
according to acne score, in mg/3 hrs/10 cm2, and the lower section gives results
recalculated as SER after 16 weeks of testosterone treatment as a percentage of baseline
rate.
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These results revealed that men who developed acne tended to have a higher SER from
the back than those who remained free of acne, but this did not reach statistical
significance, nor did it reach significance when the two acne groups were combined.
The percentage increase in SER from the back was similar in the three groups. There
was no such trend in SER from the forehead.
8.4 Discussion.
The "Gravimetric" technique originally described by Strauss and Pochi (1961) has been
widely used in human studies, and most of what is known about the endocrine control
of the gland is based on studies in which it was used. More recent developments
include the Lipometre, which measures lipid secretion after absorption onto a ground
glass plate (Cunliffe, Kearney and Simpson, 1980), but this has been reported to give
erroneous results at high rates of sebum excretion (Chivot, Zeziola and Saurat, 1981).
Other developments include depletion of the follicular reservoir by application of
bentonite clay on polyester cloth over a period of 14 hours, followed by collection of
sebum onto clay discs for 3 hours and analysis of the lipid by thin layer
chromatography (Harris, Downing, Stewart and Strauss, 1983: Hughes and Cunliffe,
1989), and the analysis of the secretion of individual follicles (Nordstrom, Schmus,
McGinley and Leyden, 1986), The gravimetric method was therefore used because of
the body of information previously obtained using it, its relative ease, and
reproducibility.
Sebum secretion measured by this method is linear for at least 5 hours (Strauss and
Pochi, 1961) but is not sustained over a more prolonged period. This implies that a
pool of sebum which has already been secreted is being sampled: this pool is thought to
represent the sebum on the skin and in the duct of the gland (Downing, Stranieri and
Strauss, 1982). This method thus measures sebum excretion rate (SER), not sebum
production rate, and therefore reflects the activity of the sebaceous gland indirectly
(Shuster and Thody,1974).
There is a diurnal variation in SER which parallels that of testosterone, being higher
in the morning, but there is no seasonal variation (Burton, Cunliffe and Shuster, 1970).
SER is also temperature-dependent, which may reflect either increased liquefaction of
sebum and therefore greater flow from the duct or improved absorption by the papers at
higher temperatures rather than increased activity of the gland (Cunliffe, Burton and
Shuster, 1970). In this study all measurements were therefore carried out in the
morning starting at 9 am, and the temperature of the room was controlled at 21-23°C.
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Baseline values for SER of the forehead and back are in good agreement with those
in the literature determined by this and other methods (Shuster and Thody, 1974;
Cunliffe et al., 1980), and the lower SER of the skin of the back is as previously
described (Greene et al., 1970). The degree of correlation between determinations
from left and right side of the body is also similar to that previously reported (Simpson,
1987), although that study used the photometric method, and the subjects (including
both men and women) had acne. Simpson (1987) also found a high correlation
between SER of forehead and back. The results reported here suggest that in men
without acne the correlation is lower, and was only significant at baseline in those men
who subsequently became oligozoospermic on testosterone treatment. There was no
correlation in either group after 16 weeks of testosterone treatment The significance of
this observation is unclear. It may reflect the wider range of SER found by Simpson
(1987) as that population was less homogeneous than the population of normal men
without acne studied here, or may be a function of Simpson's population all having
acne. However, the lack of correlation found here suggests that in normal skin local
factors might be important in determining the SER at a particular anatomical site, rather
than a more systemic influence such as the concentration of a hormone such as
testosterone in the blood.
Testosterone administration caused a significant increase in SER from both forehead
and upper back. The magnitude of the increase is similar to that reported with anabolic
steroid abuse in athletes (Kirdly et al., 1987a), who found an increase in SER of
forehead skin to approximately 150% of baseline after 2 weeks of self-medication, with
no further change up to 12 weeks. The subjects in that group had all abused steroids in
the past, but had remained free of all hormonal preparations for at least 12 weeks before
the baseline measurement
The increase in SER of upper back was significantly greater than that of forehead,
with an increase to 200% of baseline for back vs. 150% for forehead (Figures 8.2 and
8.4). Using surface microscopy, it has been revealed that there are approximately 4
times as many follicular openings in the forehead as in the skin of the back, but only 2-
3 times the sebum production (Cunliffe, Perera, Thackray, Williams, Forster and
Williams, 1976). This suggests that under basal conditions the SER per gland is higher
in the back, which might reflect an increased sensitivity to stimulatory factors of
sebaceous glands in that region. Such a greater sensitivity might underlie the larger
effect of testosterone treatment on the SER of the back.
The increase in SER in response to testosterone treatment shown in Figure 8.2 is
considerably greater than that reported by Pochi and Strauss (1974). In their initial
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studies, they were unable to detect any effect of testosterone administration to adult
men, although an effect on adolescents was clear (Strauss et al., 1962). They only
studied a small group of subjects, however, and used low doses of testosterone. It
therefore appears that failure to demonstrate the effect of testosterone on SER in adult
men in previous studies is due to experimental design rather than a true lack of effect.
The present results suggest that the sebaceous glands are not under maximal
stimulation under physiological conditions and their activity can be considerably
increased, by as much as a factor of two in some areas.
These results therefore suggest either that the rate of sebum secretion is not
primarily dependent on 5aR activity, or that this method is not sufficiently sensitive to
detect small differences in the activity of that enzyme between groups. The evidence
presented in the Introduction to this Chapter and to Chapter 5 strongly suggests that
DHT is the active androgen in the skin, and that the activity of 5aR is therefore crucial
to the degree of androgenic stimulation of the PSU. If the interpretation of the results
presented in Chapters 4 and 5 is correct, namely that those men remaining
oligozoospermic have a higher 5aR activity during testosterone treatment than those
becoming azoospermia then this suggests that sebum secretion is not closely related to
5aR activity under these conditions. Other more important effects may include the
concentration of testosterone itself (and it is noteworthy that the increases in SER are
similar to the increases in plasma testosterone concentration, and greater than the
increases in plasma DHT concentration), and the increase in plasma oestradiol. It may
be that an interaction of stimulatory androgenic and inhibitory oestrogenic effects has
prevented the clear expression of any difference in 5aR activity. Local controlling
mechanisms may also have influenced this result: as discussed above, it appears that
PSU activity is partially dependent on anatomical location.
The second major possibility is that the method is insufficiently accurate or precise
to detect small differences in SER. While repeated measurement of SER from the same
individual was not possible with the design of this trial, measurements were taken from
both left and right sides of the forehead and back. The results in Figure 8.1 show the
degree of correlation obtained from left and right sides. These values are not true
duplicates, as different sites are being sampled, and the correlation obtained reflects the
precision of the method. Determination of the accuracy of the method would require
validation against an external "gold standard". This was not possible, and indeed there
is no definitive method of measuring SER. A further point is that SER is an indirect
measure of the true rate of sebum secretion by the gland, although there is a correlation
between surface lipid and both gland size and mitotic activity (Ebling, 1973).
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There are therefore a number of possible reasons why differences in SER were not
detected between those men becoming azoospermic and those remaining
oligozoospermic on testosterone treatment, and it appears that SER may not be a marker
of PSU 5aR activity under these conditions. In situations in which there are greater
differences in 5aR activity, for example in men with congenital 5aR deficiency or after
finasteride administration, SER may reflect the biochemical abnormality. These
experiments have not been carried out.
Patients with acne have seborrhoea which persists even after resolution of the
condition, and the degree of acne correlates with SER (Cunliffe and Shuster, 1969): a
rate of sebum excretion of double normal is associated with moderate to severe acne.
None of the subjects in this study had a history of acne requiring medical treatment, and
the incidence and severity of acne at the time of the SER determinations is shown in
Table 8.1. These results suggest that those men who developed acne had an increased
SER from the back after 16 weeks testosterone treatment, although this did not reach
statistical significance. Acne is a recognised side effect of androgen administration, and
in a previous study of testosterone as a male contraceptive 9 out of 271 men withdrew
from the trial because of it (World Health Organisation, 1990). In an earlier trial, 69%
of the subjects reported acne or increased oiliness of the skin (Swerdloff et al., 1978).
These results underline the importance of increased sebum secretion in the pathogenesis
of acne (Cunliffe and Shuster, 1969).
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Conclusions and Hypothesis
The administration of supraphysiological doses of testosterone to normal men,
sufficient to cause more than a 100% increase in trough plasma concentrations of
testosterone, was shown to cause a fall in sperm density in all men in this study. 55%
of these men achieved azoospermia within 20 weeks of testosterone treatment. The
remainder maintained a low rate of spermatogenesis, with sperm densities of less than
5 x 106/ml, and although 5 achieved azoospermia after more prolonged treatment, this
took more than one year in some cases.
The primary objective of the studies described in this Thesis was to investigate the
basis for this observed heterogeneity of spermatogenic response to testosterone
administration, and in particular to test the hypothesis that the maintenance of
spermatogenesis under these conditions is caused by an increased activity of the
enzyme 5a-reductase, 5aR, which converts testosterone to the more potent androgen
dihydrotestosterone.
The administration of this dose of testosterone caused a rapid and complete
suppression of gonadotrophin secretion in all men. The removal of LH stimulation of
the Leydig cells is presumed to cause a fall in testicular steroidogenesis, and this is
supported by the demonstration of parallel falls in both the plasma concentration of
170H-progesterone and the urinary excretion of pregnanetriol. Further evidence for
the degree of suppression of steroidogenesis under similar conditions in humans is
provided by the work of Strott et al. (1969), who showed a fall of 90% in the plasma
concentration of 170H-progesterone in men treated with a synthetic androgen, and by
the demonstration that intratesticular testosterone concentrations were reduced to 5% of
pretreatment values (such that the intratesticular concentrations of testosterone were
only double those in peripheral plasma) by treatment with testosterone propionate
(Morse et al., 1973).
It therefore appears that under the conditions of the present trial, the major
differences in the intratesticular environment from the physiological state are that:
1. There is no gonadotrophin stimulation of Leydig and Sertoli cells.
2. Steroidogenesis is reduced, but the intratesticular concentration of testosterone is
still higher than that in peripheral plasma. The intratesticular concentration is therefore
probably little influenced by the wide fluctuations in plasma concentration of
testosterone with the weekly injection schedule used.
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3. The rate of spermatogenesis falls rapidly to zero in 55% ofmen, with the remaining
men having a rate of spermatogenesis of less than 5% of normal (on the basis of sperm
density in the ejaculate).
The main hypothesis of this Thesis is that the maintenance of spermatogenesis in the
oligozoospermic group of testosterone-treated men is the result of higher 5aR activity
in these men. What evidence has been produced to substantiate this?
This conclusion can be considered in two parts:
I What is the evidence that 5aR may be of importance in the regulation of
spermatogenesis, in the human or any other species?
II What is the evidence for a difference in 5aR activity between men becoming
azoospermic and those remaining oligozoospermic?
Subsidiary points include whether such a difference is present under physiological
conditions, or only under the conditions of this trial, and the mechanism of such
differences.
Evidence for the presence of 5ocR in the rat and human testis is presented in Chapter 1.
In brief, 5aR activity is higher in immature than adult rat testicular tissue, and the onset
of meiosis within the seminiferous tubules is associated with an increase in 5ocR
activity with a decline subsequently (Rivarola et al., 1975; Nayfeh et al., 1975). A
similar pattern is present in the human. Although the level of activity is lower than in
the rat (Payne et al., 1973; Rivarola et al., 1973, 1975; Nayfeh et al., 1975), this is
also true for the rate of testosterone synthesis. In both species, 5ocR activity is
predominantly localised to the seminiferous tubules rather than the interstitial tissues, in
itself circumstantial evidence for a paracrine role in the regulation of spermatogenesis
rather than an endocrine role related to the secretion of steroids from the testis. This
maturational change in enzyme activity suggests that 5ocR may act as an amplifier of
androgen action at the time of puberty, as indeed it acts in other androgen-dependent
organs throughout life, from the in utero development of the external genitalia to the
prostatic hyperplasia of old age. In the mature adult testis, it appears that the high local
concentration of testosterone produced by the Leydig cells is sufficient to maintain
spermatogenesis, and this is associated with a fall in 5aR activity. The period of
elevated 5aR activity at the onset of spermatogenesis also corresponds to the period
during which the secretion of both LH and FSH has yet to achieve the adult pattern,
and therefore amplification of the effect of the lower concentrations of testosterone may
be required: this is supported by the observation that, in the rat, hypophysectomy
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caused a rapid fall in testicular 5aR activity, which could then be increased by
gonadotrophin administration (Nayfeh et al., 1975).
There are two pieces of experimental evidence which suggest that 5aR may be of
functional importance in the regulation of spermatogenesis under conditions in which
the intratesticular concentration of testosterone is low. The first is provided by the
demonstration by Ahmad et al. (1973) that intratesticular implants containing DHT
could maintain spermatogenesis in the ipsilateral but not the contralateral testis in
hypophysectomized rats. There therefore appears to be no absolute requirement for
testosterone itself, as indeed would be expected from the finding that there is only one
androgen receptor which binds both testosterone and DHT. The second, perhaps more
important but not so clearly interpretable piece of evidence is the study by Nicholson,
Guldenaar, Boer and Pickering (1991), who inserted oxytocin implants into the testes
of normal rats. This caused a marked fall in both intratesticular and peripheral
concentrations of testosterone after 21 days, but spermatogenesis was maintained. The
plasma concentration of LH was not affected, whereas the plasma concentration of
FSH was reduced. Measurement of intratesticular and peripheral concentrations of
DHT, however, showed that concentrations of that steroid were elevated. This result is
compatible with an inhibition of steroidogenesis by oxytocin (Adashi et al., 1984), but
with increased 5a-reduction of testosterone to DHT resulting in sufficient androgen
stimulus for the maintenance of spermatogenesis. A direct effect of oxytocin on 5otR is
also possible, and these results require confirmation and elaboration to elucidate the
mechanisms involved.
These studies therefore provide preliminary evidence that 5aR may be of
importance in the maintenance of spermatogenesis in the presence of low intratesticular
testosterone concentrations. The demonstration that 5aR inhibition by finasteride does
not affect spermatogenesis (George et al., 1989) does not contradict this hypothesis, as
finasteride administration is associated with an increase in intratesticular testosterone
concentrations, in the presence of normal plasma gonadotrophin concentrations.
Indeed, this supports the hypothesis that 5aR is only important when concentrations of
testosterone are low. The increase in intratesticular testosterone concentration with
finasteride administration is compatible with a negative feedback pathway in which
DHT, or some factor dependent on DHT, is involved in the local regulation of
testosterone synthesis.
Evidence for Part II above is provided by the results presented in this Thesis. The
results in Chapter 3 demonstrate that there are no differences in plasma concentrations
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of both total and bio-available testosterone, or in the sensitivity of the hypothalamo-
pituitary axis to the rate or degree of steroid suppression of gonadotropin secretion
between men becoming azoospermic and those remaining oligospermic. Thus the rate
of decline of gonadotrophin stimulation of the testes does not appear to be of
importance in determining whether azoospermia is achieved. Furthermore, plasma
oestradiol concentrations did not differ between the two groups ofmen, nor did MCRT.
In contrast, it was found that testosterone administration caused an increase in
crt-dht in the oligozoospermic group, without any change in the azoospermic group.
This increase was associated with a greater elevation of the plasma concentrations of the
5a-reduced androgens DHT and AdiolG during testosterone treatment. These results
suggest that there is increased 5aR activity in men remaining oligozoospermic. This
difference is not apparent under physiological conditions, but is induced by
administration of supraphysiological doses of testosterone.
The activity of 5aR in the liver was measured by quantification of the urinary
excretion of C19 and C21 steroid metabolites. No consistent effect of testosterone
treatment was demonstrated on the ratio of a: (3 metabolites. This may reflect the results
of animal experiments, which have shown that hepatic 5aR activity is increased
following hypophysectomy in male rats, but testosterone administration has little
inhibitory effect. The mechanisms of control of hepatic 5aR therefore appear to differ
from those in androgen-dependent tissues such as the prostate and skin, where 5ocR is
increased by androgens.
Sebum excretion rate was measured as an index of tissue 5aR activity, and
although a clear increase was found in both groups ofmen, there were no differences in
SER between those men becoming azoospermic and those remaining oligozoospermic
either at baseline or after 16 weeks of testosterone treatment. SER therefore appears to
reflect the hyperandrogenaemia caused by the administration of supraphysiological
doses of testosterone but no differentiation on the basis of 5aR activity was possible.
This may reflect the limitations of the method, or may imply that the increase in plasma
testosterone concentrations is of greater importance in terms of tissue response in the
PSU than any difference in 5aR activity. As with the lack of effect of finasteride on
spermatogenesis, this is compatible with 5ocR activity being of greater importance
under circumstances in which tissue testosterone concentrations are low.
These results therefore support the hypothesis that an increase in 5aR activity is
associated with the maintenance of spermatogenesis during treatment with
supraphysiological doses of testosterone. A causal relationship can only be postulated,
and further proof must await the direct measurement of 5aR in the testis or of
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intratesticular concentrations of DHT or other 5a-reduced steroids under these
conditions.
An interaction between testicular and adrenal steroidogenesis was suggested by the
results presented in Chapter 7. Testosterone treatment caused a selective fall in DHAS
production in those men who became azoospermic (with a trend towards a fall in the
plasma concentrations of other adrenal steroids), without any effect in those remaining
oligozoospermic. There was no effect on urinary excretion of Cortisol metabolites in
either group. Plasma androstenedione concentrations were elevated in both groups,
and the production of 170H-progesterone was reduced in both.
The results presented here are not easily explicable in terms of current
understanding of the mechanisms of control of adrenal androgen secretion, but they do
demonstrate a state in which there is dissociation between adrenal secretion of
androgens and Cortisol. They also allow speculation as to the possible role of these
weak androgens (in particular DHA and its sulphate) in the maintenance of
spermatogenesis in those men remaining oligozoospermic. Thus the maintained plasma
concentration of DHAS may contribute to the supply of androgens to the seminiferous
tubules. These steroids are thought to provide an important supply of tissue androgens
in the prostate, as castration for the treatment of carcinoma of the prostate does not
sufficiently lower prostatic androgens, and current therapies involve the concurrent
administration of an anti-androgen. In this respect, it is of great interest that finasteride
causes a more pronounced fall in prostatic DHT than does castration (McConnell et al.,
1992). This implies that adrenal androgens are a physiological source of precursor for
conversion to DHT by 5ocR within the prostate, as originally suggested by Harper et al.
(1974), and that the tissue concentrations of DHT (and thus the magnitude of the
androgen stimulus to the genome) is more directly determined by 5ocR activity than by
the concentration of the precursor, testosterone, in plasma.
The recent studies by Lookingbill et al. (1991) on ethnic variation in androgen
metabolism reveal close parallels with the results presented here. These authors
investigated differences in androgen metabolism between Caucasian and Chinese men
and women, as the former show clinical evidence of higher 5aR activity: thus
Caucasian men have more body hair and a higher incidence of acne, and the incidence of
prostatic hyperplasia is much greater in Caucasian populations. Biochemical evidence
was provided by the demonstration that Caucasian men had higher plasma
concentrations of AdiolG (but not DHT), and Caucasian women had higher plasma
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concentrations of both 5oc-reduced steroids. Higher plasma concentrations of AdiolG
and androsterone glucuronide have also been reported in both black and Caucasian
Americans compared to Japanese men (Ross et al., 1992). These ethnic differences
were interpreted as suggesting greater 5aR activity in Caucasians than Chinese, and it is
possible that this biochemical difference underlies the higher incidence of azoospermia
in Chinese men than Caucasians treated with the same dose of testosterone as used in
this study (World Health Organisation, 1990). Ofmore fundamental importance is the
suggestion by Ross et al., (1992) that the higher 5aR activity in both Caucasian and
black American men, suggested by the increased plasma concentrations of these two
steroids, may have a role in producing the 3 fold higher incidence of prostatic
carcinoma in these populations.
Caucasian men also had higher plasma concentrations of DHAS than Chinese men
in Lookingbill's study, which also parallels the finding of a suppression of plasma
DHAS concentrations in those men becoming azoospermic in the present study. While
the significance of this result is not clear, it underlines the possible role of adrenal
androgens as precursors for tissue 5aR.
In summary, these results suggest that the maintenance of spermatogenesis in a
subgroup of men during treatment with supraphysiological doses of testosterone is
associated with an increased activity of the enzyme 5aR. This is proposed to result in
the production of sufficient DHT and other 5a-reduced androgens for the maintenance
of a low rate of spermatogenesis in the seminiferous tubules, despite the greatly
reduced local concentration of testosterone and in the absence of gonadotrophin
stimulus. Adrenal androgens may have a supplementary role in this process.
The relative importance of the two isoenzymes of 5ocR, in the testis as elsewhere in
the body, remains to be determined. Although there will be great toxicological
problems to be overcome (especially the teratogenic effect on the developing male
foetus of such drugs, which may be absorbed by the female genital tract from seminal
plasma) the recent clinical availability of potent inhibitors of 5aR such as finasteride
("Proscar", Merck) provides a new therapeutic option to be explored in the
development of safe, effective, reversible and convenient hormonal methods of male
contraception.
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